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1. Nu door het gebruik van ultrasensitieve thyreoglobuline (Tg) bepalingen bij veel patienten 
lage maar nog juist aantoonbare concentraties worden aangetoond, moeten nieuwe 
'evidence-based' Tg afkapwaardes voor aanvullend onderzoek worden vastgesteld om 
overbodige diagnostiek bij deze patienten te voorkomen. (dit proefschrift) 
2. Landelijke harmonisatie van thyreoglobuline bepalingen is broodnodig om resultaten van 
diagnostiek en behandeling beter te kunnen vergelijken. (dit proefschrift) 
3. De recovery methode is een elegante wijze om in sera met thyreoglobuline antistoffen 
te bepalen of er daadwerkelijk sprake is van interferentie in de Tg meting en verdient 
hernieuwde aandacht. (dit proefschrift) 
4. De beperkte diagnostische opbrengt, de hoge kosten en de negatieve invloed op kwaliteit 
van leven maken <lat er geen plaats is voor routinematig gebruik van de door recombinant 
humaan TSH gestimuleerde Tg meting in de lange termijn follow-up van patienten met 
gedifferentieerd schildkliercarcinoom. (dit proefschrift) 
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5. Zorgen over schildklierkanker persisteren bij patienten met een aantoonbaar recombinant 
humaan TSH gestimuleerd Tg, ondanks <lat er bij aanvullend onderzoek geen aanwijzingen 
zijn gevonden voor een recidief. (dit proefschrift) 
6. Embolisatietherapie bij botmetastasen van gedifferentieerd schildkliercarcinoom 
vermindert pijn en neurologische symptomen. (dit proefschrift) 
7. Patienten die ziektevrij zijn na behandeling voor gedifferentieerd schildkliercarcinoom 
hebben een normale residuele levensverwachting, echter de mediane levensverwachting 
van patienten met persisterende ziekte is gereduceerd tot 60%. 
(T.P. Links et al, Endocrine-related cancer 2005;12:273-280) 
8. Met een beter inzicht in de resultaten van nacontrole in de oncologie wordt valse hoop 
voorkomen en onnodige medicalisering tegengegaan. (Gezondheidsraad. Nacontrole in de 
oncologie. Doelen onderscheiden, inhoud onderbouwen. Den Haag: Gezondheidsraad, 2007) 
9. Zorg is een kwestie van mentaliteit en beschaving. Niet de marktwerking maar solidariteit 
dient het leidend beginsel in de zorg te zijn. (bisschop Muskens) 
10. Voor het beheersen van de geneeskunst moet je eerst de kunst kunnen afkijken, de 
meester-gezelrelatie moet daarom de basis blijven van de opleiding tot medisch specialist. 
11. Landbouwgrond omzetten in natuurgebied is een contradictio in terminis. 
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INTRODUCTION AND AIM OF THE THESIS 
CHAPTER 1 
INTRODUCTION 
Differentiated thyroid cancer (DTC) develops from thyroid follicular cells. It is the most 
common form of thyroid cancer, accounting for about 90% of all cases, and includes both 
papillary and follicular thyroid carcinomas (including Hiirthle cell) (1). DTC is an uncom­
mon tumor, as it affects approximately 24,826 individuals annually in Europe. It is 2-4 times 
more frequent in females than in males (2,3). Although it is a rare disease, the incidence of 
thyroid cancer has increased faster than that of any other malignancy in recent years (4). 
This is mainly due to the increased use of medical technology, including neck ultrasound 
and fine needle aspiration cytology. The known high prevalence of clinically occult tumors 
at autopsy (5,6) indeed suggests that increased diagnostic scrutiny has caused an apparent 
increase in incidence of cancer rather than a real increase (7). The overall prognosis of thy­
roid cancer is favorable with reported IO-years survival rates of 80-95% (8,9). 
Initial treatment of differentiated thyroid cancer consists of total thyroidectomy (with 
lymph node dissection when indicated) and ablation therapy with radioactive iodine (I-131). 
Patients with residual and/or metastatic disease are usually treated by cyclic treatments with 
1-131 until complete remission is reached. Suppressive therapy with thyroid hormone is then 
initiated in order to prevent symptomatic hypothyroidism and to diminish the risk of recur­
rent disease. Growth of follicular cell-derived cancers cells depends on TSH: suppression 
of endogenous TSH is thought to deprive these cells of an important growth-promoting 
influence. 
After a remission has been reached long-term follow-up is initiated. The primary objec­
tive in the follow-up is to detect and localize recurrent disease as early as possible. Recur­
rence of DTC occurs in up to 20% of patients (8,9,10). Most recurrences are detected during 
the early years of follow-up, but may be found even after several decades (11). Therefore 
lifelong follow-up of DTC patients is required. Traditionally, the cornerstone of follow-up is 
the measurement of serum thyroglobulin (Tg). Tg is produced only by thyroid follicular cells 
and provides the physical backbone for thyroid hormone synthesis (12). The tissue-specific 
origin of Tg biosynthesis has led to its widespread use as a tumor marker for DTC. To mea­
sure Tg, optimal biochemical assays with high precision and accuracy are essential. The 
detection limit of Tg assays is critical for the early detection of small amounts of Tg and to 
follow a change in Tg concentration. Recently, increasingly sensitive Tg assays have become 
available, but their actual clinical benefit needs to be ascertained. 
The diagnostic accuracy of Tg measurement is hampered by interference from Tg anti­
bodies (TgAb). TgAb may cause falsely high or low Tg values depending on the type of anti­
body and the type of Tg method used. Falsely low values may lead to late diagnosis of recur­
rence and a delay in necessary treatment. Alternatively, a falsely elevated Tg level can lead to 
an incorrect diagnosis of tumor recurrence, subsequent unnecessary scans or treatment and 
cause patient anxiety. Unfortunately, no currently available Tg method is guaranteed free of 
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TgAb interference (13). Detecting TgAb interference is technically challenging. Quantitative ( 
TgAb measurement, Tg recovery testing and intermethod comparison of Tg assays (radio­
immunoassay / immunometric assay discordance) are available methods for assessing TgAb 
interference. But all these techniques suffer from shortcomings in technical performance or 
availability. Since approximately 25% of DTC patients have TgAb detected in their serum 
(13,14) further development of reliable methods for detecting TgAb interference is crucial. 
Optimal sensitivity of Tg measurement can be reached when the measurement is per­
formed after thyroid hormone withdrawal to elevate TSH level. This will cause a significant 
increase of Tg, which can then be more readily detected biochemically. Administration of 
recombinant human TSH (rhTSH) has proven to be an effective alternative to thyroid hor­
mone withdrawal. It also stimulates the release of Tg by thyroid remnants and metastatic 
lesions of differentiated thyroid carcinoma, but does so without inducing the side effects of 
hypothyroidism due to thyroid hormone withdrawal, which are often poorly tolerated by 
patients (15,16). The rhTSH procedure consists of an intramuscular injection on day 1 and 
day 2, Tg levels are subsequently measured on day 5. 
In the first year follow-up after initial therapy, most centers apply (rh)TSH stimulated 
Tg measurement, diagnostic I-131 whole body scan (WBS) and neck ultrasound to evaluate 
treatment response. When these methods show no abnormalities, patients are considered in 
complete remission. Although variation in methods during the first year is modest, the opti­
mal management ofDTC patients in the long-term follow-up phase (after reaching complete 
remission) is unclear. Uncertainty exists particularly about the appropriate method of Tg 
measurement. Some authors consider Tg measurement during thyroid hormone suppres­
sion therapy (Tg-on) sufficient for detection of recurrences in low-risk patients (17,18,19). 
Others favour periodic rhTSH stimulated Tg measurement (20,21), arguing that residual 
tumor may exist in patients with an undetectable Tg-on. Previous studies evaluating rhTSH 
stimulated Tg measurement in the follow-up of DTC included a heterogeneous group of 
patients in different phases of follow-up, and were often retrospective (22,23). Moreover, 
the potential contribution of the recently introduced highly sensitive Tg assays was not ad­
dressed. It is likely that these sensitive Tg assays increase the clinical utility of Tg-on mea­
surement, reducing the need for measuring Tg after the expensive injection of rhTSH. How­
ever, we lack a prospective study during long-term follow-up in which the diagnostic yield of 
rhTSH stimulated Tg measurement is compared with Tg-on measurement with a sensitive 
Tg assay. Additionally, the influence of rhTSH stimulated Tg measurement (and the possible 
subsequent diagnostic tests) on quality of life has never been studied. Moreover, the rhTSH 
procedure and eventual subsequent diagnostic tests are expensive and the cost-effectiveness 
still has to be established. 
Although the majority of patients with DTC have an excellent prognosis, patients with 
distant metastases (7% at initial diagnosis) are known to have a markedly reduced survival 
rate of 34% at 10 years (24). About 3 to 5% of patients with DTC develop bone metastases 
11 
CHAPTER 1 
(24,25,26). Bone metastases are less frequent than pulmonary metastases but carry a far 
worse prognosis (24,26). When bone metastasis have been demonstrated, both improvement 
of survival and palliation are the treatment goals. Therapeutic options include radioiodine 
therapy, surgical removal, external radiotherapy and possibly treatment with radio-labeled 
octreotide. Additionally, in 1980 selective embolization therapy (SET) for bone metastasis of 
DTC has been described for the first time (27). A few studies have been published, showing 
a rapid relief of pain and neurological symptoms after SET (28,29). Since the available data 
on SET concern small study populations, ongoing evaluation of this treatment modality, 
including its effect on survival, is needed. 
AIM OF THE THESIS 
In this thesis we evaluate the follow-up and treatment of patients with differentiated thyroid 
carcinoma. We investigated the clinical utility of monitoring methods used in the long-term 
follow-up of patients with differentiated thyroid carcinoma, with the emphasis on different 
aspects of serum thyroglobulin measurement. Additionally, we evaluated the effect of a spe­
cific treatment modality, selective embolization therapy, for patients with bone metastases 
from differentiated thyroid carcinoma. The specific aims of this thesis are: 
1. Thyroglobulin (Tg) and thyroglobulin antibodies (TgAb) 
a. To investigate the analytical and clinical performance of a new automated immuno­
chemiluminometric assay for Tg in patients in follow-up for differentiated thyroid 
carcinoma (chapter 2). 
b. To assess the clinical utility of recovery testing in detecting interference in serum 
Tg measurement in patients with differentiated thyroid carcinoma (chapter 3). The 
Tg Recovery assay is compared with quantitative TgAb testing and the methodolog­
ical benchmark for TgAb interference, radioimmunoassay / immunometric assay 
discordance, in relation to the clinical status of the patient. 
2. Recombinant human TSH (rhTSH) stimulated thyroglobulin measurement 
12 
a. To investigate the diagnostic yield of a sensitive Tg assay and rhTSH stimulated Tg 
measurement in the detection of a possible recurrence in the long-term follow-up of 
differentiated thyroid carcinoma (chapter 4). 
b. To investigate quality of life, and the impact of the use of rhTSH stimulated Tg 
measurement and eventual subsequent diagnostic tests on quality oflife, in patients 
in long-term follow-up for differentiated thyroid carcinoma (chapter 5). 
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c. To investigate the cost-effectiveness of rhTSH stimulated Tg measurement in the 
long-term follow-up of differentiated thyroid carcinoma (chapter 6) These three 
aims were addressed in a prospective study in patients who were in long-term 
follow-up for differentiated thyroid carcinoma, and who on clinical grounds were 
considered to be disease-free. 
3. Embolization of bone metastases 
a. To assess the effect of selective embolization therapy on symptoms and serum 
thyroglobulin in patients with bone metastases from differentiated thyroid carci­
noma. Additionally, we investigated if selective embolization therapy has influence 
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CHAPTER 2 
ABSTRACT 
Background: Thyroglobulin (Tg) measurements are important in the follow-up of patients 
with differentiated thyroid carcinoma (DTC). We evaluated the analytical and clinical per­
formance of a new automated immunochemiluminometric assay for Tg (Tg-ICMA; Nichols 
Advantage Tg; Nichols Institute Diagnostics). 
Methods: We used the Tg-ICMA to measure Tg concentration in serum samples from 110 
Tg antibody-negative DTC patients undergoing thyroid-hormone suppression therapy. Dis­
ease state at the time of measurement was assessed on the basis of routine follow-up data. We 
compared the clinical performance of this assay with the routinely used immunoradiomet­
ric assay (Tg-IRMA, ELSA-hTG; CIS Bio International). 
Results: The detection limit and functional sensitivity of the Tg-ICMA, based on direct cali­
bration to CRM-457, were 0.05 and 0.6 µg /L, respectively. No Tg-IRMA-positive cases were 
missed by the Tg-ICMA. Tg was measurable by Tg-ICMA (0.6-8.6 µg/L) but undetectable by 
Tg-IRMA (< 1.5 µg/L) in 12 patients (11%). Clinical data showed evidence of disease in 4 of 
12 patients (33%). 
Conclusion: The Tg-ICMA is a sensitive and reproducible assay for identifying patients in 
follow-up for DTC with evidence of disease, but uncertainty remains with regard to inter­
preting findings of measurable serum Tg in patients with no evidence of disease. Follow-up 
data are required to determine the predictive value of these isolated Tg results. New con­
cepts, i.e., serial Tg measurements and risk stratification of patients, need to be tested to 
confirm the applicability of this assay for clinical practice. 
INTRODUCTION 
High-quality thyroglobulin (Tg) assays are needed because of the fundamental role of Tg 
measurements in the postoperative monitoring of patients with differentiated thyroid car­
cinoma (DTC). Tg is a very large and heterogeneous glycoprotein that serves as the prohor­
mone for thyroid hormone synthesis. Tg is used as a tumor marker because thyroid cells are 
the only source of Tg in the human body (1). Thus, the presence of Tg after total thyroidec­
tomy and ablative 1-131 therapy indicates persistence or recurrence ofDTC. In particular, in­
creasing serum Tg concentrations are an early and reliable indicator of recurrent disease (2). 
Several Tg assays have been developed, but these assays are prone to methodologic 
problems, such as differences in standardization, suboptimal assay sensitivity and interas­
say precision, hook effects and interference attributable to Tg antibodies (TgAb) (2). A lack of 
standardisation can lead to difficulties with intermethod comparison ofTg results. Tg meth­
ods can also be too insensitive for monitoring DTC patients for disease recurrence. Poor 
interassay precision can make it impossible to reliably detect small changes in tumor size. 
18 
EVA LUATION OF AN IMMUNOCHEMILUMINOMETRIC THYROGLOBULIN ASSAY 
Furthermore, the hook effect in sera with very high Tg concentrations can lead to falsely 
low Tg values. Interference by TgAb leads to over- or underestimation of Tg concentrations, 
depending on the method used (2,3). No current Tg method is devoid of TgAb interference 
in every patient (4). 
Recently, fully automated chemiluminescence assays for Tg have been developed that 
use monoclonal antibodies specific for human Tg. These assays combine high sensitivity 
with short turnaround times (5,6). We evaluated the analytical and clinical performance of 
a new automated immunochemiluminometric assay for Tg (Tg-ICMA). 
MATERIAL AND METHODS 
Patients 
Since 1978, the Department of Endocrinology of the University Medical Centre Groningen 
has treated and followed about 600 patients with DTC. The present study included all 131 
consecutive patients who visited our outpatient clinic for follow-up during the period of May 
to September 2003. 
All patients (mean (SD) age, 54 (17) years; 22% male; median follow-up 8 years (inter­
quartile range, 2-18 years) see Table 1) previously underwent treatment with total thyroidec­
tomy and lymph node dissection, if indicated, followed by 1-131 treatment for ablation and, 
if necessary, for treatment of persistent or recurrent disease, when 1-131 uptake persisted (as 
earlier described by Haveman et al. (7)). Initial tumor staging was performed according to 
the postoperative tumor node metastasis (TNM) classification (8). 
At follow-up visits, patients underwent neck palpation and serum Tg and TgAb mea­
surements during thyroid hormone suppression therapy, and further imaging, such as ul­
trasound or magnetic resonance imaging of the neck and mediastinum, when there was 
clinical suspicion of disease recurrence. 
All patients received thyroid hormone suppression therapy at the time of sampling. 
Samples from small group op patients were assayed during initial treatment phase, after 
radioiodine ablation therapy or subsequent radioiodine therapy. 
Tg and TgAb concentrations were measured with standard and additional methods as 
described below. Patients positive for TgAb (n= 17), as measured in one or both quantitative 
TgAb assays, were excluded because of possible interference in the Tg assay. Four patients 
had to be excluded because of incomplete laboratory test results. Serum results from the 
remaining 110 patients were used for further analysis. 
Disease state at the time of measurement was assessed on the basis of routine follow-up 
data. "No evidence of disease" was defined as absence for at least 1 year of clinically detect­
able disease and of Tg detection by the routinely used Tg-IRMA during thyroid hormone 
treatment. In case of Tg measurement within 1 year after radioiodine therapy, no evidence 
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of disease was defined as a negative diagnostic or posttherapy 1-131 whole-body scan or 
undetectable Tg after discontinuation of thyroid hormone treatment. Patient characteristics 
are shown in Table 1. 
Table 1 .  Clinical characteristics of studied patients 
Patients included 
All patients• for analysis b 
Clinical characteristics (n=131) (n=llO) 
Male -no. 29 22 
Female -no. 102 88 
Mean (SD) age -years 54 (17)  55 (17) 
Histology -no. 
Papillary 85 71 
Follicular 39 32 
Hiirthle cell 7 7 
TNMd -no. 
TO 3 
Tl-T3 94 78 
T4 20 18 
Tx 14 13 
NO 84 69 
Nl 42 34 
Nx 7 7 
MO 118 97 
Ml 12 12 
Mx 1 1 
Age at initial diagnosis • -years 40 (32-54) 41 (32-54) 
Follow-up• -years 8(2-18) 6(2-19) 
Disease free period• -years 8 (2-18) 9(2-19) 
Disease state at time of Tg 
measurement -no. 
No evidence of disease 95 81 
Evidence of disease 36 29 
• All patients enrolled at the start of the study. 
b TgAb negative patients with complete laboratory results. 
c Patients with detectable Tg in the ICMA and undetectable Tg in the IRMA. 
d Postoperative TNM-classification (8). 
• Median (interquartile range). 
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Tg assays 
The established ELSA-hTG (CIS Bio International) Tg-IRMA is a solid-phase 2-site IRMA 
that uses two monoclonal antibodies, one coated on a solid phase and one labeled with 1-125 
and used as a tracer. Functional sensitivity (defined as the lowest concentration with an inter­
assay CV $ 20%), was 1.5 µg/1. Inter-assay imprecision was 8% and 6.9% at 5 and 223 µg/L, 
respectively. The Tg-IRMA was not calibrated against the CRM-457 reference preparation. 
The Nichols Advantage® Tg-ICMA (Nichols Institute Diagnostics) is a fully automated 
2-step chemiluminometric sandwich immunoassay that uses 3 monoclonal antibodies: 2 are 
biotinylated and used for capture, and the third antibody is labeled with acridinium ester for 
emitted-light quantification. Throughput is up to 80 samples/h with a time to first result of 
51 minutes. The Tg-ICMA was calibrated against the CRM-457 reference preparation. The 
limit of detection was determined by reading the +3 SD response from 10 replicate mea­
surements of the zero calibrator from the stored master curve on 2 different occasions. We 
determined functional sensitivity (defined as the lowest serum Tg concentration for which 
the interassay imprecision (CV) did not exceed 20%) and between-run reproducibility by 
measuring human DTC serum pools with Tg concentrations of 0.66, 16 and 146 µg/L in 35 
runs over a 7-month period with calibration on a weekly basis using 2 different lots of re­
agents. We tested interference by heterophilic antibodies (HAMAs) by remeasuring Tg after 
incubating 500 µL of serum sample in heterophilic blocking tubes (HBTs: Scantibodies) at 
room temperature for 1 h. 
We used a third Tg assay for method comparison in a limited number of patient sera 
samples. This radioimmunoassay (Tg-RIA), with a functional sensitivity of 1 µg/L, was re­
ported to have minimal interference from TgAb (4) and was developed by the University of 
Southern California Endocrine Services Laboratory (Los Angeles, CA). 
Thyroglobulin antibody assays 
Two different quantitative assays were used for TgAb detection. The Nichols Advantage TgAb 
assay (Nichols Institute Diagnostics) with a cut-off value for TgAb positivity of 2 mIU/L, and 
the AxSYM TgAb assay (Abbott Laboratories) with a cut-off value for TgAb positivity of 45 
mlU/1. Both TgAb assays are referenced to the WHO TgAb First International Reference 
Preparation (WHO 65/93). 
Thyrotropin assay 
Serum thyrotropin (TSH) concentrations were measured by a time-resolved immunofluoro­




Analytical performance of the Tg-ICMA 
The detection limit of the Tg-ICMA assay was 0.05 µg/L. For human DTC serum pools, Tg­
ICMA inter-assay imprecision over a 7-month period was 19% at 0.66 µg/L, 5.5% at 16 µg/L 
and 12% at 146 µg/L. The functional sensitivity, defined as the lowest concentration of serum 
Tg for which the interassay CV did not exceed 20%, was set at 0.6 µg/L, based on the CV of 
19% for the mean concentration of the low serum pool (0.66 µg/L). 
We used Passing and Bablok regression analysis to compare DTC sera with measur­
able Tg in both the Tg-ICMA and Tg-IRMA, as shown in Figure 1. The regression analysis 
yielded the following equation: Tg-ICMA=l.87 (95% confidence interval, 1.69-1.96) x Tg­
IRMA +3.01 (1.00-5.19); r = 0.992 (n=40). A limited number of TgAb-negative sera (n=8) 
with Tg concentrations ranging of 2-70 µg/L according to the Tg-ICMA assay were also 
tested by Tg-RIA; Passing and Bablok regression yielded the following equation: Tg-ICMA 
= 1.78 (1.71-1.87) x Tg-RIA +0.72 (0.16-1.240); r = 0,999). The Tg-RIA has been standard­
ized against the CRM-457 reference preparation. A marked difference in results for the 
Tg-ICMA and Tg-IRMA/Tg-RIA methods was likely related to differences in monoclonal 
epitope specificity. 
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F igure 1 .  Passing & Bablak regression analysis comparing the established Tg-IRMA (AJ and Tg-RIA (BJ with 
the Tg-ICMA. 
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Comparison of results obtained with the different Tg methods for TgAb-negative sera. A total of 
40 serum samples from 22 patients with measurable Tg in both the Tg-ICMA and Tg-IRMA were 
used. (AJ, serum Tg concentrations measured by Tg-IRMA and Tg-ICMA (n=40J. (BJ, serum 
Tg concentrations measured by Tg-RIA and Tg-ICMA (n=B). The dashed lines represent 95% 
confidence intervals. The gray line indicates lines of unity. 
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Clinical performance of the Tg-IRMA and Tg-ICMA 
We compared results obtained with both Tg assays and divided them into concordant and 
discordant results. Concordant results were Tg concentrations detectable in both assays (Tg­
IRMA � 1.5 µg/L and Tg-ICMA � 0.6 µg/L) or Tg concentrations undetectable in both assays 
(Tg-IRMA < 1.5 µg/L and Tg-ICMA < 0.6 µg/L). Results were considered discordant when 
Tg concentrations were detectable in one assay and undetectable in the other assay. Disease 
state and Tg results were correlated (Table 2). 
Table 2. Results of Tg assays divided into concordant and discordant results, related 
with disease state at time of measurement. 
Tg assay results 
Concordant results 
Tg undetectable by IRMA and ICMA 
Tg detectable by IRMA and ICMA 
Discordant results 
Tg detectable only by ICMA 





•TgAb-negative patients with complete laboratory results. 
Concordant Tg results 










Concordant results from both Tg assays were obtained for 98 patients. In 76 sera, no Tg was 
measurable by either the Tg-IRMA (< 1.5 µg/L) or the Tg-ICMA (< 0.6 µg/L), and in 22 sera 
Tg was measurable by both Tg assays, with Tg concentrations of 3.3-136000 µg/L in the Tg­
IRMA and 9.2 to > 125000 µg/L in the Tg-ICMA. 
Clinical data showed that of 76 patients with undetectable Tg results for both assays, 69 
had no evidence of disease whereas 7 had evidence of disease at the time of measurement, 
and all 22 patients with detectable Tg results in both Tg assays had evidence of disease at the 
time of measurement. 
Discordant Tg results 
Discordant results were obtained in 12 patients (11 %). In all of these patients, Tg was mea­
surable by the Tg-ICMA (� 0.6 µg/L) but not by the Tg-IRMA (< 1.5 µg/L). The median (SD) 
Tg results obtained with the Tg-ICMA were 1.9 (2.2) µg/L (range 0.65-8.6 µg/L). The clinical 
characteristics of the 12 patients with discordant Tg results are shown in Table 1. Eight of 
these 12 patients had no clinical evidence of disease, whereas 4 (33%), with Tg concentra­
tions ranging from 1.5 to 4.7 µg/L, had clinical evidence of disease, based on nuclear or 
radiologic imaging, at the time of measurement. The clinical characteristics and disease 
states of these 4 patients are shown in Table 3. As shown in Table 3, 1 of these 4 patients was 
assessed as having "clinical evidence of disease" during the initial treatment phase. 
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In 1 case we observed a marked discrepancy in serum Tg concentration measured by 
both Tg methods: serum Tg was 8.6 µg/L by the Tg-ICMA and < 1.5 µg/L by the Tg-IRMA. 
Because Tg was not detected (< 1.0 µg/L) by the Tg-RIA, we incubated the serum in HBTs 
to determine whether the increased Tg result for the Tg-ICMA assay was attributable to 
interference from heterophilic antibodies. The Tg concentration decreased to 1.2 µg/L after 
incubation in HBTs, indicating interference by heterophilic antibodies. 
Table 3. Clinical data of patients with detectable Tg only by ICMA assay and clinical 
evidence of disease. 
Follow-up Tg-ICMA Tg-IRMA 
Patient A�e/Sex• Histolofil: TNMb <rears) �g/L µ�/L Disease state c 
1. 39/F Pap d T4NlM0 4 1.5 <1.5 Persistent d isease; detectable 
Tg (IRMA) during 
withdrawal; negative last 
posttherapy scan; 
suspicious pre-/paratracheal 
neck foci on MRI 
2. 55/M Fol T0NlM0 8 4.67 <1.5 Repeatedly marginally 
detectable Tg concentrations 
(IRMA) previous years; no 
identifiable disease remnant 
3. 33/F Pap T2NlM0 0 2.8 <1.5 Initial treatment phase; 
abnormal neck uptake on 
postablat ion WBS. 
4. 41/M Pap T2NlM0 2.7 <1 .5  Persistent disease; suspicious 
paratracheal mass on MRI 
• Age in years. 
hPostoperat ive TNM classification (8) .  
c Disease state at time of Tg measurement. 
d Pap, papillary; Fol, follicular; MRI, magnet ic resonance imaging; WB S, whole-body scan. 
DISCUSSION 
In this study the analytical performance of the new ICMA was characterized by high sensi­
tivity with a detection limit of 0.05 µg/L and a functional sensitivity of 0.6 µg/L. Additional 
benefits of this ICMA were its full automation, nonradioactive design, high reproducibility, 
and short time to result. Clinical performance showed that for 12 of the 110 DTC patients 
(11 %), 4 (33%) of whom had clinical evidence of disease at the time of measurement, Tg was 
detected by ICMA but not by IRMA. 
In the postoperative follow-up of DTC patients, the main objective is the identification 
of patients who have residual tumour or develop a recurrence. Serum Tg detection in the fol­
low-up phase indicates the presence of residual healthy thyroid tissue or metastatic disease 
(9). Thus, important clinical decisions such as whether patients should undergo diagnostic 
or therapeutic procedures are based on the measurement of the serum Tg concentration in 
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individual patients (10), as is supported by the prominent place of the assay for (recombi­
nant) TSH-stimulated Tg concentration in follow-up protocols (11,12). 
The sensitivity of Tg measurements can be optimized by clinical and technical improve­
ments (13). Clinically, measurements of TSH stimulated Tg after thyroid hormone with­
drawal or exogenous TSH administration in patients with undetectable serum Tg during 
thyroid hormone suppression therapy is currently recommended for unmasking occult dis­
ease {12,14). Technically, the development of Tg assays with improved functional sensitivity 
enhances the value of Tg measurements. The Tg-ICMA meets the criterion proposed by an 
expert panel (11,12) that a Tg assay should have a functional sensitivity of at least 1 µg/L. 
Standardization or specificity differences can lead to between-method biases. The Tg­
ICMA and Tg-RIA are both standardized to CRM-457, whereas the Tg-IRMA is not. Tg­
IRMA results are approximately 20% lower when the Tg-IRMA standardization is compared 
with CRM-457 (manufacturer's information). The approximately 2- to 3-fold higher read­
ings obtained with the Tg-ICMA compared with both Tg-IRMA and Tg-RIA more likely 
reflect differences in the number and epitope specificities of the Tg monoclonal antibody re­
agents used by the manufacturers and differences between the nonserum calibrator matrices 
and patient sera (15). Accordingly, Spencer et al. (16) recently showed wide biases among 10 
tested immunometric methods and attributed this finding to differences in assay specifici­
ties for circulating Tg isoforms rather than differences in assay standardization. Despite the 
2- to 3-fold higher reading obtained with the Tg-ICMA, it has a far lower detection limit (0.6 
µg/L) than the Tg-IRMA (LS µg/L); thus, 4 additional patients with evidence of disease were 
identified by the Tg-ICMA but not the Tg-IRMA. 
The significance of the low Tg concentrations detectable by Tg-ICMA in the remaining 
8 patients in this study is unclear. Because detectable serum Tg in the follow-up phase has 
always been associated with the presence of residual healthy thyroid tissue or metastatic dis­
ease {9,17), these data could identify a population at high(er) risk for recurrence. Such find­
ings could enable risk stratification on the basis of Tg result and patient characteristics and 
the development of follow-up protocols more adapted to individual patients. On the other 
hand, lower specificity for the presence of recurrent thyroid cancer is a possible limitation 
of more sensitive Tg assays. Most of the 8 patients with Tg detectable by ICMA but no by 
IRMA and with no evidence of disease had undergone follow-up for years and had a mean 
disease-free period of 8 years. The present study had a cross-sectional design, and clinical 
evaluation was based on clinical history. Previous follow-up studies have shown that not all 
patients with detectable Tg will develop recurrent disease (18,19). Zophel et al. {20) observed 
that in 96% of DTC patients in remission with initial low Tg concentrations {0.03-0.8 µg/L 
by Tg ELISA), Tg concentrations were essentially unchanged during a 4-year observation 
period, and all of these group remained well. Of the 5 patients {4%) in whom Tg concentra­
tions increased, all but 1 had recurrence of DTC. 
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Interpretation of the low detectable Tg values obtained in our study is uncertain, but 
such findings may give rise to possibly unnecessary concern and even excessive diagnostics. 
Therefore, follow-up data of this Tg assay are required to interpret the finding of isolated Tg 
values and justify the performance of additional diagnostics in this group of patients. More­
over, because a change in serial Tg measurement during follow-up may be more informative 
for recurrence of disease than an absolute value ofTg in the lower range, prospective data for 
these patients could provide valuable information (20). 
Although sensitivity is optimized in this assay, 7 patients with evidence of disease had 
Tg concentrations below the functional sensitivity of the ICMA, suggesting that the sensitiv­
ity is suboptimal for managing patients with DTC (21). Moreover, Spencer et al. (16) recently 
showed that interference in Tg measurement by TgAb cannot be excluded when TgAb are 
not detectable. Tg was reported undetectable in euthyroid control subjects without evidence 
of TgAb. Consequently, "confidence in the specificity of a negative antibody report with an 
undetectable serum Tg becomes less secure" (21). Furthermore, TgAb assays vary consider­
ably in sensitivity and specificity, probably because of differences in assay specificities for the 
conformational epitopes characteristic of endogenous TgAb (16). Therefore, in our study, the 
7 patients with evidence of disease but undetectable Tg by ICMA may have serum TgAb that 
cannot be detected by the methods used. Similarly, Spencer et al. (16) reported poor con­
cordance of TgAb detection among 12 direct TgAb methods. In addition, tumor dediffer­
entiation can lead to an abscense of Tg synthesis or synthesis of Tg with altered biochemical 
features, obscuring recognition by the antibodies used in the Tg assay (22). Therefore, low or 
even undetectable Tg does not guarantee absence of recurrent or metastatic disease (22,23). 
Immunometric methods can also be subject to interference from heterophil antibodies 
(HAMAs), leading to inappropriately high serum Tg values (5,6). Recently, Preissner et al.(5) 
showed that HAMA interference is relatively prevalent (1.5%-3%) in a commonly used au­
tomated Tg assay and can lead to clinically significant artifacts. The Tg-ICMA assay appears 
to suffer from similar problems, as shown in the case reported here, despite the fact that the 
manufacturer has added mouse serum in the assay procedure as a precautionary measure. 
The possibility that HAMA interference played a role in the other discrepant cases in our 
study cannot be ruled out but is unlikely because the discrepancies in these cases can be ex­
plained by the difference in absolute readings between the Tg assays. However, interference 
from HAMAs should be considered if the Tg result does not fit the clinical picture. Further 
investigation, by repeated testing with a different Tg assay, testing serial dilutions or treat­
ment with additional blocking reagents, is advocated. 
In conclusion, the new ICMA is a robust and sensitive Tg assay that optimizes the iden­
tification of patients with disease activity during follow-up of DTC. Because Tg is detectable 
by the ICMA in some patients with no clinical evidence of disease, follow-up data of these 
patients are needed to demonstrate the applicability of this Tg assay in clinical practice. 
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ABSTRACT 
Background: Thyroglobulin (Tg) measurements are complicated by interference from Tg 
antibodies (TgAbs) or heterophilic antibodies (HAMAs). We used a new automated im­
munochemiluminometric assay (ICMA) with Tg recovery (TgR) on the Nichols Advantage® 
platform to reassess the clinical utility of recovery testing in detecting interference in serum 
Tg measurement in patients with differentiated thyroid carcinoma. 
Methods: We used 2 TgAb methods to detect Tg measurement interference with TgR and 
quantitative TgAb measurement in sera from 127 patients. In a limited number of samples, 
we used a radioimmunoassay (Tg-RIA) as comparison method because it appeared to be 
minimally affected by TgAb. 
Results: Prevalence of TgAbs was 13% (17 of 127) in either 1 or both TgAb assays. A com­
promised TgR (< 70%) corresponded with TgAb positivity in either TgAb assay for 10 of 11 
samples (91 %), whereas a normal TgR (� 70%) corresponded with TgAb negativity in both 
assays for 95 of 101 samples (94%). In 6 TgAb-positive sera with TgR within the reference in­
terval, there were no discrepancies between RIA and ICMA results. We obtained discordant 
RIA and ICMA results for 6 of9 TgAb-positive sera with decreased TgR. In 1 TgAb-negative 
sample, the Tg result was falsely increased because of interference by HAMAs, as shown by 
an overrecovery of 126%. 
Conclusions: The Nichols Advantage TgR assay is a valuable complementary method to 
overcome the technical problem of interference by TgAbs or HAMAs in TgAb assays. Fur­
ther studies are needed to confirm the potential added value of this TgR assay. 
Serum thyroglobulin (Tg) measurements play a key role in the postsurgical follow-up of 
patients with differentiated thyroid cancer (DTC) (1), but these measurements are severely 
hampered by the presence of Tg antibodies (TgAbs), which can cause under- or overestima­
tion of Tg concentration depending on the Tg assay format (2,3). The National Academy of 
Clinical Biochemistry guideline (4) recommends the use of sensitive TgAb immunoassays 
to detect TgAbs in favor of Tg recovery (TgR) testing because TgR testing fails to differenti­
ate TgAb-positive and -negative sera (5,6). The differences in immuno-reactivity between 
endogenous Tg and Tg added to patient serum, as well as the amount of Tg added and the 
duration of incubation, all appear critical to the TgR result (5,7). However, limitations of 
TgAb testing are also recognized: TgAb concentrations do not correlate with the degree of 
interference (3,8); TgAb positivity does not indicate interference per se; substances other 
than TgAbs can interfere with Tg measurement (9); and TgAb detection is strongly method 
dependent (10). 
A reliable hallmark of TgAb interference is the presence of RIA/immunometric assay 
discordance (4,10), but intermethod comparisons are impractical because few RIAs are 
available (10). Therefore, the technical problem of TgAb interference in Tg measurements 
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has not been overcome. The release of a new TgR assay enabled us to reassess the clinical 
utility of recovery testing in detecting interference in serum Tg measurements by comparing 
the TgR assay with a quantitative TgAb test and the methodological benchmark for TgAb 
interference, RIA/immunometric assay discordance (10), in relation to the clinical status of 
the patient. 
We collected sera from 127 patients with DTC undergoing thyroid hormone suppression 
therapy who visited our outpatient clinic between May and September 2003. No evidence of 
disease was defined as absence of clinical, scintigraphic, or radiologic evidence of recurrent 
or persistent disease, including undetectable Tg with an immunoradiometric assy (IRMA, 
ELSA-hTg, CIS bio international; functional sensitivity (defined as the lowest concentration 
for which the interassay CV did not exceed 20%), 1.5 µg/L) during thyroid hormone suppFes­
sion therapy for at least 1 year (for the clinical characteristics of the patients, see Table 1). 
Table I. Clinical characteristics of the study patients 
All patients 
n=l27 
















MO 1 1 1  
Ml 15  
Mx 1 
Follow-up-yrs b 6 (0-43) 
Disease state d -no 
No evidence of disease 95 
Evidence of disease 32 















Clinical characteristics of all patients and of the subgroup of TgAb-positive patients. 
• TgAb positivity in TgAb-ICMA and/or TgAb-MEIA assay. 
b Median (range). 
c Postoperative TNM classification (14). 
d Disease state at time of sampling. 
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We performed serum Tg measurements with a fully automated 2-step immunochemilumi­
nometric assay (Tg-ICMA) that used 3 monoclonal antibodies (Advantage®, Nichols Insti­
tute Diagnostics). The assay characteristics are reported elsewhere (11). 
In a limited number of samples, we used a Tg-RIA as the comparison method because it 
appeared minimally affected by TgAb (5,10). 
Both the Tg-ICMA and Tg-RIA were calibrated against the CRM-457 reference prepara­
tion, but the Tg-ICMA showed a 1.8-fold higher Tg reading, likely reflecting differences in 
assay specificity for circulating Tg isoforms (11). Tg-ICMA/RIA discordance, as a method­
ologic benchmark for TgAb interference, was defined as being present when there was a dif­
ference between both Tg assays after correction for the 1.8-fold difference and each method's 
reproducibility (CV). 
TgAb measurements were performed either by chemiluminescence immunoassay 
(TgAb-ICMA performed on an Advantage; Nichols Institute Diagnostics) or by microparticle 
enzyme immunoassay (TgAb-MEIA, performed on an AxSYM; Abbot Diagnostics). Interas­
say imprecision profiles, as determined by measuring human DTC serum pools with various 
TgAb concentrations in 20 runs over a 2-week period with 2 different lots of reagents, were 
79%, 19%, and 13% at 0.1, 2 and 75 kilounits/L, respectively, for the TgAb-ICMA and 23%, 
11% and 7% at 31, 155 and 522 kilounits/L, respectively, for the TgAb-MEIA. The cut-off val­
ues used for TgAb positivity, based on the lowest TgAb concentrations in serum for which the 
interassay CV did not exceed 20% (functional sensitivity), were 2 and 45 kilounits/L for the 
TgAb-ICMA and TgAb-MEIA, respectively. These values were slightly higher than the manu­
facturers' cut-off limits of 1 and 34 kilounits/L, respectively. Both TgAb assays are referenced 
to the WHO Tg autoantibodies First International Reference Preparation (WHO 65/93). 
We performed TgR testing with a new recovery assay on the Nichols Advantage plat­
form by adding 10 µg/L of purified human Tg in DTC sera with Tg-ICMA concentrations 
< 80 µg/L. We measured Tg in sera with (Tg2) and without (Tgl) added Tg (aTg) and calcu­
lated the percentage recovery from the formula: [(Tg2-Tgl)/aTg] x 100. 
Tg, TgAb, and TgR results and clinical data for all TgAb-positive patients are summa­
rized in Table 2. 
The prevalence ofTgAbs was 13% (17 of 127) in either one or both TgAb assays. TgAbs were 
detected in 12% (16 of 127) with the TgAb-ICMA and in 10% (13 of 127) with the TgAb­
MEIA, and 9% (12 of 127) showed positivity in both assays. The intermethod variability for 
the detection of TgAbs likely resulted from differences in assay sensitivity and specificity de­
spite standardization against WHO 65/93 (10). The prevalence of TgAbs in our DTC patients 
(10%-12%) seemed to be lower than the prevalences reported by others (20%-30%) (5,12). 
Nevertheless, our results correspond with previous data (9) reporting a TgAb prevalence in 
DTC patients of29% at initial examination, decreasing to < 10% after 3 years follow-up. The 
median follow-up in our study was 4 years. 
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Table 2. Clinical data for TgAb-positive patients and assay results 
TgAb measurable in both TgAb-ICMA and TgAb-MEIAa 
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<0.6 <l 4.4 46.9 68 43/F p T2NlM0 NED 
2 <0.6 4.9 94.6 207.5 25 73/F p T3NlM0 NED 
3 <0.6 NAS 18.6 48.6 63 76/F p T2NlM0 27 NED 
4 <0.6 <l 20 74.8 74 61/F p T3N0M0 2 NED 
5 <0.6 <l 17.6 49.5 56 82/F p T4NOMO 3 NED 
6 <0.6 1.4 89.6 133 64 49/M p TxNlM0 19 NED 
7 <0.6  1.0 119.9 140.6 62 45/F p T4NlM0 4 NED 
8 4.5 2.1 2.1 91.7 89 37/F p T2N0M1 0 ED 
9 <0.6 3.3 34.5 64.0 45 41/F p T2N0M0 11 NED 
10 <0.6 6.5 760.4 >1000 40 39/F p TxNlMl 29 NED 
11 <0.6 <l 44.3 125.4 62 7 7/F p T4N0M0 3 NED 
12 <0.6 3.1 133.7 464.3 34 76/F p T3NlM0 ED 
TgAb only measurable in TgAb-ICMA a 
13 <0.6 <l 5.1 20.7 85 27/F p T2N0M0 11 NED 
14 <0.6 <l 5. 7 23.7 82 25/F p T3NlM0 10 NED 
15 <0.6 <l 3.4 23.8 95 67/F p T2N0M0 2 NED 
16 4167 NA 2. 3 20.7 NDh 70/F H T4N0M1 0 ED 
TgAb only measurable in TgAb-MEIA a 
17 <0.6 <l <2.0 49.1 106 66/F p T4N0M0 27 NED 
• Bold numbers indicate measurable serum Tg, TgAb positivity, or compromised Tg. 
b Cut-off for positivity, 2 kilounits/L. 
c Cut-off for positivity, 45 kilounits/L. 
d Histology: P, papillary; H, hiirthle cell 
' TNM classification based on criteria listed in Ref. (14) 
r Disease state at time of sampling, see text. NED, no evidence of disease; ED, evidence of disease. 
8 NA, not assessed. 
h ND, recovery not determined because of high serum Tg concentration. 
Evidence of disease was present in 3 of 17 (18%) TgAb-positive patients. Two patients (pa-
tient 12 and 16 in Table 2) had extensive metastatic disease. In the third patient (patient 8), 
TgAbs were measured shortly after radioiodine ablation therapy. Tg was detectable by Tg-
ICMA in 2 of these 3 patients (Table 2). 
We determined a reference interval for TgR by performing recovery testing in 96 TgAb-
negative DTC sera. We obtained a nongaussian distribution (P < 0.05, Shapiro-Wilk nor-
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mality test) with a slight left tail, with recoveries of 67%-125% (mean, 96%; 95% confidence 
interval, 70%-120%, see Figure IA). TgR < 80% might reflect some form of interference, e.g. 
by autoantibodies not recognized by the TgAb assay or from substances other than TgAbs. 
To reveal possible interference, we used the Tg-RIA to retest samples from 5 of 7 patients 
with TgR values of 67.5% to 76.4% and a Tg-ICMA result < 0.6 µg/L. The Tg-ICMA and Tg­
RIA results were concordant for 4 of 5 sera, providing no evidence for interference in Tg 
measurements. In 1 TgAb-negative patient with a slightly compromised recovery (67.5%), 
Tg-RIA/ICMA discordance (1.1 µg/L by Tg-RIA versus < 0.6 µg/L by Tg-ICMA) supported 
the recovery result, indicating serum Tg interference. 
130 • 

















0 10 20 










60 70 80 
We suspected overrecovery in 1 sample with a TgR of 126%, a serum Tg-ICMA result of 8.6 
µg/L, and Tg that was undetectable by RIA (< 1 µg/L) and by IRMA (< 1.5 µg/L; ELSA-hTg, 
CIS bio international). In this sample, the Tg-ICMA result was falsely increased as a result 
of interference by heterophilic antibodies (11). We therefore used 70%-120% as the reference 
interval for TgR. 
TgR differed significantly in TgAb-negative (n=96) and TgAb-positive sera (n=17; 
P < 0.0005, Mann-Whitney U test). The TgR was compromised (< 70%) in 91% of samples (10 
of 11) that tested positive for TgAbs in both TgAb assays, whereas the TgR was within the ref­
erence interval (� 70%) for 95% of samples that were negative for TgAbs in the TgAb-ICMA 
(96 of 101) and 97% of samples (98 of 101) that were negative in the TgAb-MEIA (Table 3). 
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Table 3 .  TgR, by Tg assay, in TgAb-positive and -negative patients. 
TgR < 70% TgR ;::: 70% Total 
n n n 
ICMA 
Positive 10  5 15 
Negative 96 97 
Total 1 1  101 1 12 
MEIA 
Posit ive 10  3 13  
Negative 98 99 
Total 11 101 112 
Ten of 12 (83%) sera with positivity for TgAbs in both assays had compromised TgR. Consid­
ering the TgAb assays separately, 67% of the sera positive in the TgAb-ICMA (10 of 15) and 
77% of the sera positive in the TgAb-MEIA (10 of 13) showed TgR < 70% (Table 3). Patients 
with higher TgAb titers showed more compromised recovery (Pearson correlation for TgAb­
MEIA, r = 0.79 (P < 0.0003); for TgAb-ICMA, r = 0.55 (P < 0.03) (see Figure 1B and Figure 
lC). Sera that were positive only in the TgAb-ICMA (n = 3) or the TgAb-MEIA (n = 1) had 









• • • 
l 
• 









Figure lB.  TgR in TgAb-ICMA positive sera. 
TgR in 16 TgAb-ICMA positive sera. 
Cut-off value TgAb-ICMA positivity: 2 kilounits/L. 
• indicates sample with TgAb-positivity in both TgAb-ICMA and TgAb-MEIA. 






























Figure IC. TgR in TgAb-MEIA positive sera. 
TgR in 13 TgAb-MEIA positive sera. 
Cut-off value TgAb-MEIA positivity: 45 kilounits/L. 
• indicates sample with TgAb-positivity in both TgAb-ICMA and TgAb-MEIA. 
D indicates sample with TgAb-positivity in only TgAb-MEIA. 
• 
1000 
Remeasurement of 6 TgAb-positive sera (patients 4,8,13,14,15 and 17 in Table 2) by Tg-RIA 
to determine whether TgR was falsely unaffected showed no RIA/ICMA discordance, thus 
favoring the outcome of the TgR results. The results for patient 8, with TgR within the ref­
erence interval, illustrate that despite TgAb positivity in both TgAb assays, serum Tg was 
measurable by the Tg-ICMA and seemed unaffected on the basis of a comparison with the 
Tg-RIA result (Table 2). Follow-up studies are needed to determine whether low TgAb posi­
tivity in sera with TgR within the reference interval indicates disease activity or represents 
signal noise, a distinction of major concern in clinical practice. The detection of TgAb in a 
patient means the loss of clinical utility of Tg measurements. In addition, the presence of 
supposed TgAb positivity might prompt unnecessary imaging and promote unnecessary 
patient concern. TgR measurements might be helpful in these particular cases. 
We also performed Tg-RIA measurements in 9 of 10 sera that were positive for TgAbs 
in both assays and showed compromised TgR. In 3 cases (patients 1, 5, and 11), intermethod 
comparison provided no further evidence for interference in the serum Tg measurement, 
whereas in 6 cases (patients 2, 6, 7, 9, 10, and 12), RIA/ICMA discordance confirmed Tg in­
terference. Remarkably, only 1 of these patients (patient 12) had known disease activity: the 
other patients with considerably high TgAb titers and compromised TgR had no evidence of 
disease and had been in follow-up for up to 29 years (range, 1-29 years). Several studies have 
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shown that persistence of TgAb positivity during long-term follow-up may be representative 
of persistent disease (5,13), whereas serum TgAb concentrations decrease or disappear in 
disease-free patients. Accordingly, TgAb positivity in conjunction with compromised TgR 
and ICMA/RIA discordance in these patients should alert the clinician. Serial TgAb mea­
surements as surrogate tumor marker (10) and follow-up will show whether these patients 
really have persistent or recurrent disease. 
In this study, we showed that testing for TgR by the Nichols Advantage TgR assay has 
value complementary to that of quantitative TgAb measurement in the detection of inter­
ference in Tg measurements, in particular in sera with low TgAb titers. Furthermore, this 
method can detect interference from TgAbs not detected by direct TgAb measurement 
or from other interfering substances, such as heterophilic antibodies. Further studies are 
needed to confirm the potential added value of this TgR assay. We would like to emphasize 
that the results observed with the Nichols Advantage TgR assay cannot be transposed to 
other TgR assays (5,6). 
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CHAPTER 4 
ABSTRACT 
Background: Sensitivity of thyroglobulin (Tg) measurement in the follow-up of differenti­
ated thyroid carcinoma (DTC) can be optimized by using a sensitive Tg assay and rhTSH 
stimulation. 
We evaluated the diagnostic yield of a sensitive Tg assay and rhTSH stimulated Tg in the 
detection of recurrences in the follow-up of DTC. Additionally the value of imaging tech­
niques for the localization of recurrences was evaluated. 
Methods: We included 121 disease free patients in long-term follow-up for DTC (median 
10 years, range 1-34). Tg during thyroid hormone suppression therapy (Tg-on) and rhTSH 
stimulated Tg were measured with a sensitive Tg assay. Patients with rhTSH stimulated Tg � 
1.0 ng/ml underwent imaging with neck ultrasound, FDG-PET and post therapy I-131 whole 
body scan (WBS). 
Results: Sensitive Tg measurement resulted in 3 patients with Tg-on � 1.0 ng/ml, recurrence 
could be localized in 2 of them. RhTSH stimulation resulted in Tg � 1.0 ng/ml in another 17 
of 118 patients. Recurrence could be localized in only 1 additional patient (1 of 118 patients). 
Recurrence was localized by neck ultrasound in 1 of 3, by FDG-PET in 2 of 3 and by post 
therapy I-131 WBS in 2 of 3 patients. 
Conclusions: In the detection of recurrences in DTC, rhTSH stimulation had very limited 
additional value in comparison to Tg-on measurement with a sensitive Tg assay. We consider 
this too low to justify rhTSH stimulation in all patients during long-term follow-up. Neck 
ultrasound, FDG-PET and post therapy I-131 WBS showed complementary value in local­
ization of disease, but were only positive in a small fracture of all procedures. 
INTRODUCTION 
Although differentiated thyroid cancer (DTC) is characterized by an excellent prognosis 
after thyroidectomy and radioiodine ablation, recurrences occur often even many years after 
this initial therapy (1). Therefore, lifelong follow-up of DTC is recommended. The clinical 
and economical relevance of optimal follow-up with accurate diagnostic testing is crucial 
considering the large population of patients in lifelong follow-up for DTC world-wide. 
Traditionally, the cornerstone of follow-up is serum thyroglobulin (Tg) measurement. 
Optimal sensitivity is reached when Tg is measured during thyrotropin (TSH) stimulation 
because TSH promotes Tg synthesis (2). TSH stimulation can be simply achieved by induction 
of hypothyroidism following thyroid hormone withdrawal. However, externally administered 
recombinant human TSH (rhTSH) has recently been proven to be an effective alternative to 
thyroid hormone withdrawal. It stimulates the release of Tg by thyroid remnants and meta­
static lesions of DTC without inducing the poorly tolerated side effects of hypothyroidism 
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(3,4,5). Besides the availability of rhTSH, also the recent development of more sensitive Tg as­
says may considerably increase the sensitivity of Tg measurement to detect recurrent disease. 
New immunometric assays (IMA) have a functional sensitivity as low as 0.1 ng/ml (6), possibly 
allowing the detection of smaller amounts of thyroid tissue, even when TSH is suppressed (7). 
The current European guidelines for the follow-up of DTC (8) recommend the use of a 
sensitive Tg assay that is standardized on the European reference standard (CRM-457) (9,10) 
with a functional sensitivity < 1.0 ng/ml. Additionally, the use of rhTSH for Tg measurement 
is recommended for the first evaluation 6-12 months after initial therapy to confirm the 
adequacy of thyroidectomy and radioiodine ablation (8,11,12). Although several studies (4,5) 
support the diagnostic accuracy of rhTSH stimulated Tg measurement at the time of this 
first evaluation, the optimal management of DTC patients concerning Tg measurement in 
the long-term follow-up phase is less clear. Some authors consider Tg measurement during 
thyroid hormone suppression therapy (Tg-on) sufficient for the detection of recurrences in 
low-risk patients as long as Tg remains undetectable (7,8,13). Others favour periodic rhTSH 
stimulated Tg measurement, arguing that tumor may exist in patients with an undetectable 
Tg-on (11,12). Prospective data about these issues are lacking. Accordingly, the recently pub­
lished American Thyroid Association (ATA) management guidelines for patients with DTC 
state that the timing or necessity of subsequent rhTSH stimulated Tg testing is uncertain for 
those found to be free of disease (14). 
Recently, Smallridge et al. (6) questioned if a Tg assay with improved sensitivity could 
eliminate the need for rhTSH stimulation when Tg during thyroid hormone suppression 
therapy is < 1.0 ng/ml. This retrospective study showed that when using a sufficiently sensi­
tive Tg assay, these patients rarely have a rhTSH stimulated Tg > 2 ng/ml and only one of 
80 patients had detectable disease. This recurrence was demonstrated by ultrasound despite 
numerous imaging studies. Additionally, the lack of localizable disease in a significant part 
of patients with detectable stimulated Tg, brings up for discussion, whether this stimulation 
is useful. The lack of evidence that the early detection of especially local disease will improve 
prognosis actualizes this question even more (15,16). 
For the detection of recurrent disease several imaging methods are used. Neck ultra­
sound has established a fixed place in the follow-up of DTC, particularly for the detection 
of cervical lymph node metastasis (17). The timing and the method of choice for additional 
imaging is less clear. Applied methods are post therapy I-131 whole body scan (WBS), com­
puted tomography (CT ) of the neck and chest, 18-F Fluorodeoxyglucose Positron Emission 
Tomography (FDG-PET), and magnetic resonance imaging (MRI). 
In this study, we evaluated the introduction of a highly sensitive Tg assay (18) and the 
additional value of rhTSH stimulation, for the detection of recurrences in disease free pa­
tients in long-term follow-up for DTC. Additionally, we evaluated the value of different im­
aging techniques including neck ultrasound, FDG-PET scan and post therapy I-131 WBS in 





All patients who were treated and followed for DTC in the University Medical Centre Gron­
ingen (UMCG) between 1978 and 2003 and were disease free were eligible for participation. 
Disease free was defined as no clinical evidence of recurrent or persistent DTC and unde­
tectable Tg-on for at least 1 year. This Tg level had been routinely measured by an immu­
noradiometric assay (CIS Bio International, Gif-sur-Yvette, France) with a detection limit 
of 1.5 ng/ml for many years. Exclusion-criteria were age under 18 years or above 75 years, 
pregnancy and severe psychiatric illness. Additionally, patients testing positive for Tg anti­
bodies were excluded. 
All patients had undergone initial treatment consisting of total thyroidectomy, followed 
by radioiodine ablation therapy. Additional treatment, such as lymph node dissection and 
additional 1-131 therapy was performed when indicated. Routine follow-up included visits 
at the outpatient clinic every four months in the first two years, and thereafter annually. At 
each visit physical examination of the neck, Tg-on and TSH measurement were performed. 
Patients used a suppressive dose oflevothyroxin. All patients gave written informed consent 
to participate in the study, which was approved by the medical ethical review committee of 
the University Medical Centre Groningen. 
Study design 
At baseline, Tg-on was measured with a new sensitive Tg assay (see "Serum measurements" 
section) in all patients. Subsequently, all patients underwent rhTSH stimulated Tg measure­
ment. Patients with rhTSH stimulated Tg � 1.0 ng/ml underwent additional imaging includ­
ing FDG-PET scanning, neck ultrasound and post therapy 1-131 WBS to detect recurrent 
disease. After 3 months Tg-on and rhTSH stimulated Tg measurement were repeated. 
RhTSH stimulated Tg measurement 
RhTSH (Thyrogen, Genzyme Corporation, Cambridge, MA) was administered intramuscu­
larly (i.m) at a dose of 0.9 mg once a day for two consecutive days, while maintaining thyroid 
hormone suppression therapy. Seventy-two hours after the second rhTSH injection, Tg and 
TSH were measured. 
Imaging studies and radioiodine treatment 
For detection of recurrent disease, patients underwent FDG-PET, ultrasound examination 
of the neck (with fine needle aspiration when indicated) and treatment with 150 mCurie 
1-131 followed by a post therapy 1-131 WBS. 
FDG-PET scan was performed during thyroid hormone withdrawal, using an ECAT 
HR+ camera (Siemens/CTI, Knoxville, TN). Patients fasted overnight before the investiga-
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tion. Ninety minutes after intravenous injection of 5 MBq/kg of FDG, a 2-D whole-body 
image was acquired from top of the skull to the knees. Images were reconstructed using 
iterative methods with attenuation correction. Emission time was 5 minutes and transmis­
sion time was 3 minutes. 
Ultrasound of the neck was performed by an experienced and dedicated radiologist 
using a Siemens machine with a linear 13 MHz transducer, with fine needle aspiration of 
suspicious lymph nodes or masses. Lymph nodes with short axis 2: 10 mm and/or round 
oval shape, unsharp borders, inhomogeneous pattern (in particular calcifications or cystic 
changes), absence of echogenic hilus or hypoechoic pattern (17,19,20) were biopsied with 
percutaneous fine needle aspiration. In case of a hot spot in the neck on the FDG-PET scan, 
this information was passed to the radiologist who tried to puncture this specific node. 
Post therapy 1-131 WBS was performed with a two-headed gammacamera (Multispect 
2, Siemens) with a high-energy collimator. We acquired three to four IO-minute adjacent 
spot views covering the whole body in anterior and posterior views. When necessary, ad­
ditional views were obtained. The post therapy 1-131 WBS was performed 10 days after the 
administration of 150 mCurie 1-131. All these imaging procedures were performed within 
two weeks. 
Additional imaging, including MRI and CT, was performed to confirm positive find­
ings on either post therapy 1-131 WBS or FDG-PET scan. Levothyroxin was stopped six 
weeks before radioiodine treatment and replaced by triiodothyronine until two weeks before 
radioiodine treatment. Levothyroxin was restarted after the treatment. A low iodine diet 
was followed during one week before treatment. Tg and TSH were measured six weeks after 
thyroid hormone withdrawal (Tg-off), on the day of the 1-131 treatment. 
To evaluate the effect of radioiodine treatment, we repeated Tg-on and rhTSH stimu­
lated Tg measurement four months after treatment with 150 mCurie 1-131. 
Evaluation of imaging and final disease status 
All imaging, radiological and nuclear images were evaluated and compared with previous 
scans by an independent expert panel consisting of endocrinologists, nuclear medicine phy­
sicians and a head-neck surgeon, aided by a radiologist when required. Disease status of each 
patient was assessed and categorized as "no recurrence localized,, or "recurrence localized,,. 
"Recurrence localized,, implied one or more abnormal imaging studies strongly suggestive 
of recurrent or metastatic thyroid carcinoma. "No recurrence localized" implied negative 
radiological and nuclear imaging. Subsequently, the expert panel determined the therapeu­
tic consequences of the findings. 
Serum measurements 
Before inclusion in this study, during routine follow-up, Tg was measured by an immu­
noradiometric assay with functional sensitivity of 1.5 ng/ml (Cis Bio International, Gif-
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sur-Yvette, France). During the study, Tg was measured by a more sensitive assay (Nichols 
Advantage® Tg assay, Nichols Institute Diagnostics, San Clement, CA, USA). This is a fully 
automated chemiluminescence sandwich immunoassay with functional sensitivity of 0.6 
ng/ml and calibrated against the CRM-457 reference preparation (18). 
TSH was measured by a time-resolved fluoroimmunoassay using the DELFIA system 
(PerkinElmer Life Sciences, Turku, Finland) with a detection limit of 0.003 mU/1. Tg an­
tibodies (TgAb) were measured by a chemiluminescence immunoassay (Nichols Advan­
tage, Nichols Institute Diagnostics, San Clement, CA, USA) with a cut-off value for TgAb 
positivity of 2 IU/ml (21). All serum measurements were performed in the same institution 
(UMCG). 
Statistical analysis 
Data are expressed as median and range. The differences in Tg and TSH before and after 
radioiodine treatment were analysed using the Wilcoxon test for paired data. For statistical 
reasons, Tg values < 0.6 were considered to be equal to 0.6 ng/ml and TSH values < 0.003 
were considered to be equal to 0.003 mU/L in this test. P-values of less than 0.05 were con­
sidered to indicate statistical significance. Statistical analysis was performed using SPSS ver­
sion 10.0 software (SPSS, Inc., Chicago, IL.). 
RESULTS 
Study patients 
Hundred twenty-one patients with DTC (female 76%, median age 54 years, median follow­
up 10 years (range 1-34) after initial surgery) were studied (Table 1). Patients were divided in 
three groups on the basis of Tg-on result. 
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Table 1. Disease characteristics 
Characteristic All patients Patients with Patients with Patients with 
undetectable Tg-on Tg-on 0.6-1.0 ng/ml Tg-on � 1.0 ng/ml 
N=l21 N=llS N=3 N=3 
Sex -no. (%) 
Female 92 (76) 89 (77) 2 (67) I (67) 
Male 29 (24) 26 (13) I (33) 2 (33) 
Age• (yrs) 54 (43-61) 54 (43-61) 49 (33-51) 56 (31-64) 
Histology -no. (%) 
Papillary 86 (71) BI (70) 3 (100) 2 (67) 
Follicular 29 (24) 29 (25) 0 0 
Hiirthle cell 6 (5) 5 (4) 0 I (33) 
Follow-up• (yrs) IO (6-16) IO (6-16) 8 (5-27)  16 (5-23) 
TNM-classification b -no. (%) 
Tl-T3 100 (82) 96 (84) 3 (100) I (33) 
T4 3 (3) 2 (2) 0 I (33) 
Tx 18 (15) 1 7  (15) 0 I (33) 
NO BS (70) 84 (73) I (33) 0 
NI 32 (27) 27 (24) 2 (67) 3 (100) 
Nx 4 (3) 4 (4) 0 0 
MO 120 (99) 1 14 (99) 3 (100) 3 (100) 
Ml I (1) I (1) 0 0 
TNM-stage b -no. (%) 
<45 years 
stage I 72 (60) 68 (59) 3 (100) I (33) 
stage II  0 0 0 0 
>45 years 
stage I 5 (4) 5 (4) 0 0 
stage II 26 (21) 26 (23) 0 0 
stage III 1 1  (9) 9 (8) 0 2 (67) 
stage IV I (1) I (1) 0 0 
unknown 6 (5) 6 (5) 0 0 
Risk-groupc -no. (%) 
Low-r isk 103 (85) 99 (86) 3 (100) I (33) 
High-risk 12 (10) IO (9) 0 2 (67) 
Unknown 6 (5) 6 (5) 0 0 
• Median w ith interquartile range (25th and 75th centile) in the groups "All patients, n=l21" and "Pat ients w ith un-
detectable Tg-on", N=l lS". Med ian and range in the groups "Pat ients w ith Tg-on 0.6-1.0 ng/ml, N=3"and "Patients 
w ith Tg-on � 1.0, N=3". 
b TNM-classification and staging accord ing to Hermanek & Sobin, 1 992 (34). 
c Low-risk patients are stage I d isease if younger than 45 years or Stage I or II if older than 45 years. 
Group 1: Patients with Tg-on � 1.0 ng/ml 
In three patients Tg-on was � 1 .0 ng/ml ( Table 2). As expected, in these three patients Tg 
after rhTSH was also � 1.0 ng/ml. Imaging resulted in the localization of a recurrence in two 
of them. In patient A (Tg-on 1.1 ng/ml) no recurrence could be identified on FDG-PET scan, 
neck ultrasound, post therapy 1-131 WBS or MRI scan of the neck region (Table 3). In patient 
B (Tg-on 1.3 ng/ml), recurrence was located in the lower jugular region and identified on 
neck ultrasound, MRI and CT scan. There was no I-131 uptake. Selective neck dissection was 
performed and three malignant lymph nodes were removed. Patient C (Tg-on 2 . 8  ng/ml) 
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had an extensive paravertebral/mediastinal recurrence, identified on FDG-PET scan, post 
therapy I-131 WBS, and a subsequent MRI, CT scan and octreotide scintigram. This tumor 
was inoperable and not amenable to radioiodine or octreotide therapy. External radiother­
apy with palliative intention was started. Patient died from respiratory insufficiency due to 
the consequences of metastatic thyroid carcinoma, eleven months after the identification of 
recurrent disease. 
Tg-on measurement (Table 2) was repeated 4 months after radioiodine treatment (before 
neck dissection in patient B and the start of radiotherapy in patient C, patient A refused Tg 
measurement). Tg-on was lower but remained detectable in both patients (Table 3). Only in 
patient B, rhTSH stimulated Tg measurement was repeated after radioiodine therapy (patient 
A refused and patient C was not stimulated because of extensive disease). RhTSH stimulated 
Tg was 6.7 ng/ml before radioiodine therapy and 5.3 ng/ml after radioiodine therapy. 
Group 2: Patients with Tg-on 0.6-1.0 ng!ml 
Three patients (Table 2) had detectable Tg-on levels between 0.6 and 1.0 ng/ml (0.76, 0.81 
and 0.99 ng/ml). After rhTSH stimulation Tg was undetectable in the first patient and rose 
to 1 .3 and 8.6 ng/ml in the two other patients. These two patients were referred for imaging. 
In none of them recurrence was localized (Table 4). 
Four months after radioiodine treatment Tg-on and rhTSH stimulated Tg were mea­
sured again (Table 4). Tg-on after radiodine treatment remained detectable in one of both 
patients (2.6 ng/ml). At the second rhTSH stimulated Tg measurement, Tg remained detect­
able in both patients (0.96 and 10.0 ng/ml). 
Group 3: Patients with undetectable Tg-on (< 0.6 ng!ml) 
Tg-on was undetectable in 1 15 patients. After rhTSH stimulation, Tg became detectable in 
19 patients (Table 2). In 15 patients (13%) rhTSH stimulated Tg was 2:: 1.0 ng/ml (median 1.6 
ng/ml, range 1.0-5.4). Imaging was performed in 14 out of these 15 patients with undetect­
able Tg-on and rhTSH stimulated Tg 2:: 1.0 ng/ml. One patient refused imaging because of 
pregnancy wish. After evaluation of all images, recurrence was localized in one of 14 patients 
(Table 5). Recurrence was localized in patient F and was located in the right supraclavicular 
fossa and identified on FDG-PET scan, post therapy I-131 WBS and MRI scan. The suspi­
cious lesion was resected and histopathological analysis showed a lymph node metastasis of 
papillary thyroid carcinoma. In the remaining 13 patient no recurrence could be localized. 
Four months after radioiodine treatment (and before surgery in patient F), Tg-on and 
rhTSH stimulated Tg were measured again (Table 2). Tg-on had become detectable in 1 of 
14 patients, Tg and TSH levels did not significantly differ (p=0.4 and 0.7) compared to the 
situation before radioiodine treatment. At the second rhTSH stimulated Tg measurement, 
Tg remained detectable in 13 of 14 patients but was significantly lower (p=0.005) than before 
radioiodine treatment while no difference in TSH was found (p=0.084). 
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Table 2. Serum Tg and TSH levels 
Patients with 
Tg-on � 1.0 ng/ml • 
(N=3) 
Tg-on (ng/ml) h 1.3 (1.1-2.8) 
TSH (mU/1) 0.04 (0.004-0.075) 
Tg after rhTSH (ng/ml) 5.3 {4.5-6. 7 )  
TSH (mU/1) 13 (9.2-19) 
Tg-off (ng/mW 8.1 (3.5-10.0) 
TSH (mU/1) 16.0 {21.0-46.0) 
Tg-on (ng/ml), 4 months after 
radioiodine treatment 1.0 (0.84-1.9) 
TSH (mU/1) 0.018 {0.014-0.022) 
Tg after rhTSH (ng/ml), 
4 months after radioiodine 
treatment 5_3d 
TSH (mU/1) 26 
• Median with range. 
b Tg-on: Tg during thyroid hormone suppression therapy. 
' Tg-off: Tg after 6 weeks thyroid hormone withdrawal. 
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Patients with Patients with 
Tg-on 0.6-1.0 ng/ml • Tg-on < 0.6 ng/ml 6 
(N=3) (N=llS) 
0.81 (0. 76-0.99) <0.6  
0.014 (0.003-2.4) 0.048 {0.017- 0.31) 
1.3 (<0.6-8.6) <0. 6  (<0.6-<0.6) 
7.4 {14.0-15.0) 14.0  (9.8-20.0) 
2.6/20.0° 3. 75 {1.65-6. 78) f 
48.0/50.0 46.5 (35.5-53.5) 
<0.6/2.6° <0. 6  {<0.6-<0.6) f 
0.019/0.11 0.03 (0.008-0.46) 
0.96/10.0' 1.35 (0.99-1.95) r 
17/26 14.5 (9. 9-21.5) 
d N = 1: RhT SH stimulated Tg measurement, 4 months after radioiodine treatment was performed in one of three 
patients. One patient refused, the second patient was not stimulated because of extensive disease. 
• N = 2: RhTSH stimulated Tg was � 1.0 ng/ml in 2 patients, these patients were referred for imaging. 
fN = 14: RhTSH stimulated Tg was � 1.0 ng/ml in 15 patients, imaging was performed in 14 patients. In one patient 
imaging was not performed because of pregnancy wish. 
6 Median with interquartile range (25th and 75th centile). 
Diagnostic yield of imaging tests 
Imaging studies were performed in 19 of 20 patients with rhTSH stimulated Tg � 1.0 ng/ml 
(one patient refused because of pregnancy wish). All these patients underwent neck ultra­
sound, FDG-PET scan and post therapy I-131 WBS. Additional imaging including MRI, CT 
and octreotide scanning was performed when better anatomical localization was needed or 
when results were contradicting. Only in three patients recurrence could be localized. 
In patient B (Table 3) recurrence was localized in the neck and was initially detected by 
neck ultrasound. FDG-PET scan and post therapy I-131 WBS were negative. Exact anatomi­
cal localization was achieved by CT and MRI. Patient C (Table 3) had extensive metastatic 
disease, which was visualized by nuclear medicine methods (FDG-PET, radioiodine imag­
ing, octeotride scintigraphy) as well as CT and MRI. Patient F (Table 5) with a supraclavicu­
lar lesion had a negative ultrasound and positive FDG-PET, post therapy I-131 WBS and 
MRI. 
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Table 3.  Patients with Tg-on � 1.0 ng/ml 
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Table 4. Patients with Tg-on 0.6-1.0 ng/ml and rhTSH stimulated Tg � 1 .0 ng/ml 
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Table 5. Patients with undetectable Tg-on and rhTSH stimulated Tg � 1.0 ng/ml 
F 58/M Pap 2 0 0 Low- 12 <0.6  
risk 





1-131 WBS, MRI 
G 55/F Pap 2 1 0 High- 3 <0.6 2.8 6. 7 <0.6 1.6 Negative 
risk 
H 50/M Foll 2 0 0 Low- IO <0.6 3.1 11.0 0.6 2.1 Negative 
risk 
39/M Pap 2 1 0 Low- 4 <0.6  3.0 8.4 <0.6 2.5 Negative 
risk 
55/F Pap 2 0 0 Low- IO <0.6 1.2 2.3 <0.6 1.3 Negative 
risk 
K 43/F Pap 2 0 0 Low- 17 <0.6 1.6 6.0 <0.6 0. 7 9  Negative 
risk 
L 36/F Pap 2 1 0 Low- 16 <0.6 2.2 NPG <0.6 NPB No imag ing 
risk because of 
M 53/F Pap 1 0 0 Low- 3 <0.6  1.0 1.8 <0.6  <0.6 
r isk 
N 60/M Pap 4 1 0 High- 5 <0.6 1.0 1. 7 <0.6 1.0 
risk 
0 68/M Pap 1 1 0 High- 16 <0.6 1.4 1.0 <0.6 1.3 
r isk 
P 55/M Pap 2 1 0 Low- 18 <0.6  1.2 1.5 <0.6 1.2 
risk 
Q 48/F Pap 2 0 0 Low- 15 <0.6 5.4 2. 7 <0.6 4.3 
risk 
R 42/F Pap 2 0 0 Low- 5 <0.6  1.4 5.1 <0.6 1.4 
risk 
S 46/F Pap 4 0 0 Low- 18 <0.6  3.9 7.0 <0.6 1.9 
risk 
T 60/M Fol 1 1 0 Low- 21 <0.6  1.1 0.85 <0.6 0.96 
risk 
Table 3, 4, 5. 
• M:male, F:female. 
b Pap: papillary, Foll: follicular, Hiirthle: Hiirthle cell. 
c TNM classificat ion and r isk group staging (34). 
d Tg during thyro id hormone suppression therapy. 
• All Tg results in ng/ml. 
r Tg after thyro id hormone w ithdrawal. 
8 NP: not performed. 
h Recurrence: recurrence local ized, NRL: no recurrence localized. 
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DISCUSSION 
This prospective study showed that the introduction of a new sensitive Tg assay for clinical 
disease free patients resulted in the localisation of 2 recurrences (1.8%) in a cohort of 121 
patients considered to be in remission. The additional yield of rhTSH stimulation in these 
patients was 1 additional localized recurrence (1 of 118 patients, 0.8%). We consider this too 
low to justify rhTSH stimulation in all patients. These results confirm the retrospective data 
recently presented by Smallridge et al. (6). 
Although the presence of the established risk factors result in a reduced life expectancy 
(22), also initial low-risk patients can die from thyroid cancer (23), illustrating that distinc­
tion between high and low-risk is limited (24). Therefore in this study, we included patients 
irrespective of prognostic factors influencing risk of recurrence. Additionally, most recur­
rences occur within the first decade after initial therapy, but up to one third of recurrences 
occur in the subsequent years. Recurrences are described even more than 40 years after ini­
tial diagnosis (1). Therefore, lifelong follow-up is advised (8). We included patients regardless 
of follow-up duration. By doing so, this study population consisted of a mixture of low-risk 
and high-risk patients and variable follow-up duration, reflecting the variety of patients in 
follow-up for DTC in daily clinical practice (25) and results of this study are applicable to all 
patients with DTC in follow-up for DTC. 
Tg measurement is the cornerstone in the follow-up of DTC but accurate measurement 
of Tg is technically challenging. An important requirement of Tg assays is a functional sen­
sitivity low enough to detect small amounts of thyroid tissue when TSH is suppressed (7). 
The importance and surplus value of a sensitive Tg assay has been shown in this study. Two 
patients with recurrent disease could be identified solely on the basis of Tg-on levels � 1.0 
ng/ml by using a sensitive Tg assay. In 2 of 3 patients, with Tg-on � 1.0 ng/ml recurrent 
disease could be localized so diagnostic yield of imaging was high when using 1.0 ng/ml as 
cut-off. Tg-on in these patients had been undetectable by the conventional assay, so formerly 
rhTSH stimulated Tg measurement would have been needed to identify these patients. These 
patients are illustrative that optimizing sensitivity of Tg assays, may obviate the need for 
rhTSH stimulated Tg measurement in the future follow-up of DTC (26). 
In one patient with undetectable Tg-on, recurrent disease was found. Only in this pa­
tient (1 of 121 patients) rhTSH stimulated Tg measurement had additional diagnostic yield in 
the detection of recurrent disease. Clearly, this very limited result of rhTSH testing does not 
validate the introduction of routine rhTSH stimulated Tg measurement in the follow-up of 
DTC .  Moreover, regular serial Tg-on measurement with a sensitive Tg assay anyhow would 
have identified this solely patient, since the change in Tg over time is more informative than 
a single Tg determination (27) . Tg-on will increase during serial Tg-on measurement (28,29) 
when recurrent disease is actually present. 
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Zanotti-Fregonara et al. (30), also evaluated the utility of rhTSH stimulation. Their re­
sults endorse the limited value of periodic rhTSH stimulation in patients with stage I thyroid 
cancer. In contrast, they recommend rhTSH stimulation in higher-risk patients because of 
positive Tg levels after rhTSH in 4 of 35 high-risk patients (11%). However, two of these pa­
tients already had detectable Tg-on levels. In only one patient, recurrence was localized 10 
months after the last I-131 therapy, and according to our definition this patient could not be 
considered as in remission. Results of our study do not support the use of rhTSH stimulation 
in the long-term follow-up of high-risk patients. Recurrent disease was localized in one low­
risk patient with Tg only detectable after rhTSH stimulation (patient F) and in one low-risk 
and in one high-risk patient with detectable Tg-on (patient B and C respectively). 
Uncertainty exists about the clinical value of low but detectable Tg-on values in sensi­
tive Tg assays. In the present study a small number of patients had Tg-on levels between 0.6 
and 1.0 ng/ml. The rise in Tg after rhTSH to � 1.0 ng/ml in 2 of these 3 patients indicated 
residual thyroid tissue and not an assay artefact (31). Nevertheless, recurrent disease could 
not be localized. This illustrates that the sensitivity of Tg measurement currently exceeds the 
sensitivity of the available imaging techniques and therefore careful watching of the slope 
of Tg-on is recommended. The optimal timing of imaging needs to be ascertained in future 
studies. Extensive imaging when Tg-on in a sensitive assay rises above a certain cut-off level 
will be far more efficient, preventing needless patient burden and medical costs. 
In the present study, imaging including post therapy I-131 WBS, neck ultrasound and 
FDG-PET was performed in all patients suspected of recurrent disease. Neck ultrasound is 
considered the most sensitive method to detect local recurrence, although it is not specific 
and is an operator-dependent procedure (8,32). In contrast, radioiodine scanning has high 
specificity for recurrences of differentiated thyroid cancer but considerably low sensitivity 
(32). Particularly in radioiodine negative differentiated thyroid cancer, FDG-PET is useful 
and has both high sensitivity and specificity (33). Results of this study showed that these 
three imaging methods are complementary in the detection of recurrent disease. Never­
theless, additional imaging including CT and MRI scanning was needed to provide better 
anatomical localization oflesions. This result illustrates that the fusion of anatomy and me­
tabolism by the recently introduced integrated PET/CT systems, is a promising technique 
(32,33). 
Finding a low or undetectable Tg after rhTSH stimulation could be considered as a re­
assurance to patients that truly no disease activity is present. In the present study, Tg was 
< 1.0 ng/ml after rhTSH in the vast majority (87%) of patients. Actually, this result only 
confirmed the already known absence of disease in these patients with undetectable Tg-on. 
In this group of patients, rhTSH stimulation is an expensive, unnecessary diagnostic test. 
Moreover, these data underscore the adequacy of undetectable Tg-on confirming the ab­
sence of disease and contradict the opinion that "an undetectable serum Tg measured dur­
ing thyroid hormone suppression is often misleading in a large proportion of patients with 
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residual DTC" (7). We did not routinely use neck ultrasound during follow-up so we could 
have missed small lymph node metastases in these patients. For it is known that lymph node 
metastases can be detected by neck ultrasound in patients with both undetectable Tg-on and 
undetectable rhTSH stimulated Tg or Tg-off (16,17). This is the reason why the combination 
of Tg measurement and neck ultrasound is now becoming the standard of care, although it is 
still controversial whether the early detection of generally very small lymph node metastases 
will improve prognosis (15,16). 
In conclusion, Tg measurement with a sensitive Tg assay has an additional diagnostic 
yield in the detection of recurrent disease in patients in follow-up for DTC and practically 
obviates the need for rhTSH stimulated Tg measurement. Long-term follow-up of DTC can 
safely be based on serial Tg-on measurement with a sensitive Tg assay and additional diag­
nostic tests should be performed only when Tg-on rises above an established cut-off level. 
This will result in a limited follow-up protocol, warranting the detection of recurrences of 
DTC and reducing patient burden and medical costs. 
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ABSTRACT 
Introduction: Knowledge of the quality of life (QOL) in patients in follow-up for differenti­
ated thyroid cancer (DTC) is limited. Moreover, the impact of recombinant human TSH 
stimulated thyroglobulin (rhTSH-Tg) measurement, a monitoring method in the follow-up 
of DTC, on QOL is unknown. RhTSH-Tg includes the measurement of Tg, a tumor marker 
in the follow-up of DTC, after two consecutive injections of rhTSH. We assessed QOL in 
patient in long-term follow-up for DTC and the impact of rhTSH-Tg measurement and sub­
sequent diagnostic procedures on QOL in these patients. 
Methods: In 121 clinically disease free patients in long-term follow-up for DTC, Tg during 
thyroid hormone suppression therapy (Tg-on) and rhTSH-Tg were measured with a newly 
introduced sensitive assay. Patients with rhTSH -Tg 2:: 1.0 ng/ml (Tg + patients) underwent 
additional imaging . The RAND-36 questionnaire was only completed at baseline. Anxiety 
items of the Hospital Anxiety and Depression scale (HADS), the General Health Question­
naire (GHQ) and Cancer Worries (CW) were completed at baseline and after being informed 
about rhTSH-Tg result. Additionally, Tg + patients and a sex- and age-matched subset of 
Tg - patients (rhTSH-Tg < 1.0 ng/ml) completed these questionnaires after being informed 
about imaging results and subsequent conclusions about their disease status. 
Results: RhTSH-Tg measurement resulted in 101 Tg - and 20 Tg + patients. Imaging showed 
recurrence in 3 of 19 Tg + patients. Two of these three patients could have been identified 
solely by Tg-on. At baseline, DTC patients showed impaired quality of life compared with 
the general population (RAND-36). For Tg + patients, anxiety, psychological distress and 
CW significantly increased after being informed about Tg result. Moreover, CW remained 
increased in Tg + patients after being informed about disease status compared with Tg - pa­
tients, even though additional imaging showed no recurrence in most of them. 
Conclusion: Patients in long-term follow-up for DTC showed reduced QOL. Additionally, 
notification of a positive rhTSH-Tg has a negative effect on QOL. Cancer worries remained 
increased compared with Tg - patients, despite of negative imaging. The low yield of rhTSH 
testing and its negative impact on QOL justifies withholding this test during long-term fol­
low-up. 
INTRODUCTION 
Differentiated thyroid carcinoma (DTC) generally has a good prognosis with 10-year sur­
vival rates as high as 90% (1). In the follow-up of DTC, the aim is the early detection of recur­
rent disease to prevent local incurable disease and mortality. Up to 20% of patients develop 
recurrent disease and late recurrences can occur even after 15-20 years (2-4). Therefore, life-
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long follow-up is recommended. The measurement of thyroglobulin (Tg) as a tumor marker 
is the cornerstone in follow-up. 
Traditionally, primary outcome measures in cancer follow-up are overall survival and 
disease-free survival (5,6). Accordingly, in the follow-up of thyroid cancer the attention is 
mainly focused at developing optimal monitoring methods to detect recurrent disease, and 
improving the sensitivity of the tumor marker (Tg) measurement. However, the effect of dif­
ferent monitoring methods on the psychological health of patients has received only limited 
attention. Especially because follow-up of thyroid cancer is lifelong, recognizing the impact 
of monitoring on psychological health is important. 
After initial therapy, consisting of (near) total thyroidectomy and radioiodine ablation 
therapy, thyroid hormone suppression therapy is initiated to prevent hypothyroidism and 
to diminish the risk of recurrent disease. During follow-up, sometimes thyroid hormone 
withdrawal is needed to optimize sensitivity of diagnostic radioiodine scanning or Tg mea­
surement. The negative impact of thyroid hormone withdrawal on quality of life (QOL) is 
well-documented. The induced hypothyroidism causes a significant deterioration in patients 
QOL (7). The introduction of recombinant human TSH (rhTSH) allows sensitive diagnostic 
testing comparable to thyroid hormone withdrawal (8) without the necessity to stop thyroid 
hormone replacement. The use of rhTSH prevents the dramatic decrease in quality of life 
related to hormone withdrawal (9,10). However, whether this TSH stimulation, either by 
rhTSH or thyroid hormone withdrawal is necessary in the long-term follow-up of DTC is 
unclear (11). Especially with the increasing availability of the high sensitive Tg assays, Tg 
measurement during thyroid hormone suppression therapy (Tg-on) might be sufficient. 
Although the negative influence of thyroid hormone withdrawal on QOL is avoided, 
monitoring with rhTSH stimulated Tg measurement or Tg-on measurement might still in­
fluence QOL, and specifically the psychological dimension of QOL. Every follow-up test 
used, is inevitably hampered by the occurrence of false positive test results. This can lead to 
unnecessary additional testing and physical and psychological harm. In an earlier study, we 
showed that rhTSH stimulated Tg measurement resulted in a significant amount of patients 
with rhTSH-Tg > 1.0 ng/ml, suspect for recurrent disease. However, the diagnostic yield of 
extensive imaging in these patients was very limited (12). The use of rhTSH stimulated Tg 
measurement in 121 patients, resulted in the localization of 1 additional recurrence, com­
pared with Tg-on measurement with a sensitive Tg assay. When using sensitive Tg assays, 
the clinical significance of low detectable Tg levels is unclear and unnecessary testing and 
treatment is likewise a critical issue (13). Data about the impact of a positive (rhTSH stimu­
lated) Tg test and subsequent diagnostic testing on psychological health are lacking. 
Therefore, we examined the quality of life in clinically disease free patients in long­
term follow-up for DTC as well as the impact of rhTSH stimulated Tg measurement and the 




Study population and study procedure 
Clinically disease free patients in follow-up for DTC, were recruited from the outpatient 
clinic of the Department of Endocrinology of the University Medical Centre Groningen 
(UMCG), as earlier described (12) (Table 1). Patients were studied with questionnaires at 
three time points: at baseline after explaining the study procedure (T l), after being reported 
the result of rhTSH stimulated Tg measurement and the diagnostic consequences (T2) and 
after being informed of the results of all imaging and eventual therapeutic consequences 
of the findings (T3). At T l  and T2  all patients were studied. At T3, all Tg positive (19 Tg +) 
patients who received additional testing were studied and compared with a sex- and age­
matched control group of Tg negative patients (36 Tg - patients) who did not receive diag­
nostic testing. 
The study protocol with rhTSH stimulated Tg measurement and subsequent diagnostic 
imaging have been described previously (12). Figure 1 presents the flowchart of this study. 
In short, Tg during thyroid hormone suppression therapy (Tg-on) and rhTSH stimulated 
Tg were measured with a sensitive Tg assay (14). For rhTSH stimulated Tg measurement, 
patients received 0.9 mg rhTSH (Thyrogen, Genzyme Corporation, Cambridge, MA) by in­
tramuscular injection on day 1 and 2, on day 5 thyroglobulin was measured. Patients with 
rhTSH stimulated Tg � 1.0 ng/ml underwent imaging with neck ultrasound, FDG-PET and 
post therapy 1-131 WBS. 
All patients gave informed consent and the study procedures were approved by the med­
ical ethical review committee of the University Medical Centre Groningen. 
All patients: 
Tg-on measurement 













Figure 1. Flow-chart of the study 
Measurements 
Tg + patients: 
Neck US 
FOG-PET scan 
Radio-iodine therapy (150 mC 1 -131) 
.-------, Post-therapy 1-131 whole body scan Additional imaging on indication 
Tg - patients: 
No further diagnostic 
testing 
Tg + patients: 
Report of results of diagnostic imaging 
+ eventual therapeutic consequences 
Health related quality of life (HRQOL), psychological distress, anxiety and cancer worries 
were assessed by the use of questionnaires which were validated in Dutch (15-17). All subse­
quent mentioned questionnaires, except the RAND-36, were used at T l, T2 and T3. 
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HRQOL 
The RAND-36 Health Survey was used at T l  to assess HRQOL (18). This instrument, which 
is comparable to the SF-36 (19) contains eight different subscales: physical functioning (PF), 
social functioning (SF), role limitations due to physical problems (RP), role limitations due 
to emotional problems (RE), mental health (MH), vitality (VT), bodily pain (BP) and general 
health perception (GH) . For each subscale, scores were coded, summed up and transformed 
to a scale from O to 100, with higher scores indicating better functioning . The scores on all 
subscales of the RAND-36 of all study-patients were compared with a sex- and age-matched 
control group consisting of 232 Dutch subjects, who served to validate the Dutch version of 
the RAND-36 in a general population survey (18). 
Pschycological well-being 
Psychological distress 
The General Health Questionnaire (GHQ), was used as an instrument to assess psychologi­
cal distress (20). The total score gives an indication of the severity of distress; the higher the 
score, the more psychological distress is experienced. We made use of the 12-item version in 
which each item is rated on a four-point scale . Scores on the items are summed up to a total 
score on the scale . Baseline scores of the DTC patients were compared with GHQ scores 
from a Dutch general population sample (21) . 
Anxiety 
The Hospital Anxiety and Depression Scale (HADS) (16,22) has proved to be a useful clini­
cal indicator of anxiety and depression (23-25) among patients with somatic illnesses. We 
only used the seven items concerning anxiety in this study. Baseline scores of the DTC pa­
tients were compared with anxiety scores from a general population sample, taken from a 
survey of the general Dutch population (16). 
Cancer Worries 
Lerman et al. (26) developed four Likert-style items to assess breast cancer worries. These 
included the frequency of breast cancer worries, the impact of worries on mood, and the im­
pact on daily functioning . In this study, these items were modified to refer to worries about 
thyroid cancer concerning the past 4 weeks (27). These four items were summed to create a 
thyroid cancer worries scale . 
Statistics 
The Student's t-test for independent variables and Levene's test for equality of variance was 
used for a comparison of scores between the study patients and the control group. Differ­
ences between the scores of Tg positive and Tg negative patients were examined with the 
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Mann-Whitney test. The Wilcoxon two paired sample test was applied to examine scores 
over time. In the Tg positive group, imaging showed recurrent disease in only 3 of 19 pa­
tients. This group was too small to analyze separately. 
RESULTS 
We included 121 clinically disease free patients in long-term follow-up for OTC. After rhTSH 
stimulation, Tg was < 1.0 ng/ml in 101 patients (Tg - patients) and ;::::: 1.0 ng/ ml in 20 patients 
(Tg + patients ). Additional imaging was performed in 19 Tg + patients, one Tg + patient 
refused imaging because of pregnancy wish. Recurrence could be localized in 3 of these 19 
patients. 
One hundred eighteen patients (98%) returned completed questionnaires. Three pa­
tients did not return complete questionnaires (2 Tg - patients and 1 Tg + patient who did not 
receive additional imaging because of pregnancy wish). 
Patient characteristics 
The patient and disease characteristics of the two groups of patients, Tg + and Tg - patients, 
are shown in Table 1. No significant differences between groups were found in terms of age, 
age at initial diagnosis, histology of tumor, tumor stage and risk-group. The groups differed 
significantly in sex distribution, the Tg - group consisted of 81 % females, while the Tg + 
group consisted of 47% females. 
Table 1. Clinical characteristics at baseline 


































b Figures are numbers of patients with percentages in parentheses. 










12 (5 -18) 
P-value 








' Patients are staged at time of ablation, according to TNM classification and risk group staging (37). 
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Questionnaire scores 
Baseline (Tl) 
Patients in follow-up for DTC had significantly worse scores on the RAND-36 for vitality 
(p=0.006) and role limitations due to physical problems (p=0.003), but a better score for role 
limitations due to emotional problems (p=0.014) compared to the sex- and age-matched gen­
eral population control group (Table 2). Compared with the general Dutch population, no 
clear differences in anxiety (HADS) or psychological distress (GHQ) were found (Table 3). 
At baseline, there were no differences between the two groups of DTC patients in 
HRQOL (Rand-36), psychological distress (GHQ), anxiety (HADS) and worries about thy­
roid cancer (Cancer Worries). 
Table 2. RAND-36 scores of DTC patients compared with healthy control group at 
baseline 
RAND-36 Scales• DTC pat ients General populat ion b p-value 
N=118 N=232 
Physical Funct ioning 82.1 ±21. 3 78.5 ±25.3 0.2 
Role-Physical 75.4 ±39.1 87.8 ±29.3 0.003 
Bod ily pa in 83. 7 ±22.8 80.9 ±24.6 0.32 
General health 67.5 ±21.0 69.9 ±21.6 0.33 
Vital ity 62. 7 ±19.2 68.8 ±19.2 0.006 
Social Funct ioning 83. 7 ±21.4 87. 7  ±19. 7 0.09 
Role-Emotional 87.5 ±30. 7 78.2 ±37.0 0.014 
Mental Health 76.8 ±14.2 78.6 ±16.9 0.33 
• All data are means ± SD. 
b Sex- and age- matched control group (21). 
Table 3. Psychological distress (GHQ) and anxiety (HADS) scores of DTC patients 
compared with healthy control group at baseline 
Quest ionna ire• 
Psychological d istress 
(GHQ) 
Anxiety (HADS) 




b N=2425, mean age 67 years, 41% female (21). 
' N=l901, mean age 61.3 years, 51.2% female (16). 
General population 
3.9' 
d NA; not available, data for statistical comparison were not available. 




Tg + patients experienced increased psychological distress (p=0.04), more anxiety (p=0.03) 
and an increased level of cancer worries after being informed about the Tg result (T2) 
(p=0.04), compared with baseline. After all imaging and being informed about disease status 
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(T3), anxiety decreased (p=0.02). No significant change in psychological distress or cancer 
worries was found between T2 and T3. Additionally, no significant change in psychological 
distress, anxiety or cancer worries was found between Tl  and T3 (figure 2A,2B,2C). 
Tg - patients showed a decrease in anxiety (p=0.029) after being informed about the 
rhTSH stimulated Tg value (T2), anxiety level remained stable between T2 and T3, and Tl 
and T3. No other changes were found (figure 2A,2B,2C). 
Between group comparison of Tg + and Tg- patients at T2, showed increased psycho­
logical distress (p=0.009), more anxiety (p=0.021) and more cancer worries (p=0.002) for 
Tg + patients. After finishing all diagnostic tests and being informed about disease status 
(T3), Tg + patients showed a persistent higher level of cancer worries (p=0.030) in compari­






T1 T2 T3 
Time of testing 
Figure 2A. Psychological distress (GHQ) in Tg positive and Tg negative patients 
Black dots are Tg positive patients, white dots are Tg negative patients. 
Median and interquartile ranges are given.  
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Higher scores indicate more psychological distress. 
* = significant difference in test result between Tg positive and Tg negative patients. 
t = significant change in test result for Tg positive patients between Tl and T2. 
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T1 T2 T3 
Time of testing 
Figure 2B. Anxiety (HADS) in Tg positive and Tg negative patients 
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Black dots are Tg positive patients, white dots are Tg negative patients. 
Median and interquartile ranges are given. 
Higher scores indicate more anxiety. 
* = significant difference in test result between Tg positive and Tg negative patients. 
t = significant change in test result for Tg positive patients between Tl and T2. 
:t = significant change in test result for Tg negative patients between Tl and T2. 










Figure 2C. Cancer worries in Tg positive and Tg negative patients 
Black dots are Tg positive patients, white dots are Tg negative patients. 
Median and interquartile ranges are given. 
Higher scores indicate more worries about thyroid cancer. 
* = significant difference in test result between Tg positive and Tg negative patients. 
t = significant change in test result for Tg positive patients between Tl and T2. 
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DISCUSSION 
In this study, we showed that clinically disease free patients in long-term follow-up for dif­
ferentiated thyroid cancer (DTC) have a reduced health related quality oflife (HRQOL) com­
pared to the general population. Additionally, we showed that a positive rhTSH stimulated 
thyroglobulin (Tg) test in the follow-up of differentiated thyroid carcinoma has a significant 
negative impact on psychological health. RhTSH-Tg positive patients (Tg +) showed a tem­
porary increase in psychological distress and anxiety compared to baseline and compared 
to rhTSH stimulated Tg negative (Tg -) patients. Moreover, Tg + patients showed a higher 
level of cancer worries (p=0.030) in comparison to Tg - patients after the Tg result, and these 
worries about thyroid cancer persisted despite receiving negative imaging results, compared 
with Tg negative patients. The majority (84%) of these Tg + patients did not have evidence of 
recurrent disease after diagnostic imaging. 
At baseline, DTC patients showed reduced HRQOL compared with the general popula­
tion, in the RAND-36. This is in line with earlier studies (5,28,29). Although included pa­
tients were clinically disease free and in long-term follow-up (median follow-up ten years), 
they reported lower vitality and more role limitations due to physical functioning. This im­
plies that HRQOL remains permanently impaired after the diagnosis of differentiated thy­
roid cancer, despite of being cured for years. Crevenna et al. showed as well permanently im­
paired vitality score in the RAND-36 in patients in long-term follow-up for DTC, although 
longer duration of cure was associated with better scores on different quality of life items. 
These findings should be addressed by health care providers and patients needing additional 
psychological support should be recognized and supported. There were no clear differences 
between DTC patients and the general population in anxiety and psychological distress. A 
higher level of anxiety might be expected in DTC patients. After cancer treatment concerns 
about recurrence can persist and translate into more general forms of psychological distress 
such as anxiety and depression (30). Since age and gender are associated with QOL (31), the 
absence of a sex- and age-matched control group for these comparisons limit its interpreta­
tion. 
RhTSH stimulated Tg measurement and secondly highly sensitive Tg assays are intro­
duced in the follow-up of DTC to optimize diagnostic yield of Tg measurement. But higher 
sensitivity of these monitoring tests might be at the cost of specificity. Low detectable Tg val­
ues are found in patients (14) who are clinically disease free. Likewise in a significant num­
ber of patients with (low) detectable rhTSH stimulated Tg (1.0-2.0 ng/ml), no recurrence is 
found despite of extensive imaging (12,32). Currently, it is difficult to differentiate those in 
whom recurrence will be identified from others in whom Tg will spontaneously decline over 
time. This uncertainty can lead to unnecessary extensive diagnostic testing and considerable 
patient burden. Indeed, we showed that monitoring patient with rhTSH stimulated Tg mea­
surement in the follow-up has an negative impact on psychological health for Tg + patients. 
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The use of rhTSH stimulated Tg measurement resulted in a considerable number of Tg + 
patients. After patients received this abnormal result, they indicated increased psychologi­
cal distress and experienced more anxiety compared to patients with a favorable Tg negative 
test result. Uncertainty about the result of following, potential frightening diagnostic proce­
dures, including radioiodine therapy, plays an important roll in this situation (7). These Tg + 
patients had to wait to find to out whether they still had cancer and obviously these patients 
also showed more worries about thyroid cancer. 
Although most Tg + patients (84%) could be reassured that no cancer was found (at 
this moment), worries about thyroid cancer remained higher for Tg + compared to Tg - pa­
tients. These results correspond with data from studies concerning the psychological impact 
of false positive findings in cancer screening programs (although indeed a positive Tg test 
without localized recurrence is not per se a false positive finding). Abnormal screening tests 
for breast and cervical cancer (e.g. mammogram and Papanicolaou test) increase anxiety 
and distress, but these effects are generally transient (33,34). General anxiety and distress 
subside when findings in the end proves to be normal (35,36). However, cancer-specific con­
cerns can prevail long-term (up to two years) after testing, although final test results are 
normal (33,36). These prevailing cancer worries in Tg + patients are a serious adverse psy­
chological consequence, even more knowing that after four years follow-up in none of these 
patients recurrence was found. 
In conclusion, we showed that patients in long-term follow-up for DTC have a reduced 
HRQOL. Additionally, a positive rhTSH-Tg test and the subsequent diagnostic tests induce 
anxiety, cancer worries and increased psychological distress, while diagnostic yield is lim­
ited. The low yield of rhTSH testing and its negative impact on QOL justifies withholding 
this test during long-term follow-up. 
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ABSTRACT 
Background: Sensitivity of thyroglobulin (Tg) measurement to detect remnants or recur­
rence of differentiated thyroid cancer (DTC) can be improved by measurement of Tg after 
stimulation with recombinant human TSH (rhTSH-Tg). We compared the cost-effectiveness 
of rhTSH-Tg and Tg measurement during thyroid hormone suppression therapy (Tg-on) in 
the long-term follow-up of DTC. 
Methods and results: In 121 patients in follow-up for DTC, Tg-on and rhTSH-Tg were mea­
sured. Extensive imaging was performed in 19 patients with rhTSH-Tg � 1.0 ng/ml. Only 
in three patients recurrence could be localized. However, two of these three patients had 
detectable Tg-on (� 0.6 ng/ml) and would have been identified without rhTSH. 
Thus, rhTSH-Tg resulted in detection of one extra patient with localized recurrent dis­
ease (primary measure of effect). The cost-effectiveness ratio was €192.961, which means 
that an extra €192.961 had to be invested with the rhTSH protocol to detect one additional 
patient with localized recurrence compared to the Tg-on protocol. 
When cost-effectiveness ratio was recalculated first using higher Tg cut-off values for 
imaging (Tg-on: 1.0 ng/ml, rhTSH-Tg 2.0 ng/ml) and second using higher Tg cut-off val­
ues in combination with only a limited imaging protocol, rhTSH-Tg resulted in respectively 
€160.134 and €151.226 extra costs to detect one extra patient with localized recurrence. 
Conclusions: The use of rhTSH-Tg resulted in very high costs, while additional diagnostic 
yield compared with Tg-on was limited. This unfavourable cost-effectiveness ratio should be 
taken into account in the evaluation of the place of rhTSH-Tg in the follow-up of DTC. 
INTRODUCTION 
Thyroglobulin (Tg) measurement is the primary diagnostic test in the follow-up of patients 
with differentiated thyroid cancer (DTC) and is considered the most sensitive tool for detec­
tion of recurrent disease (1,2). Sensitivity of Tg measurement increases after TSH stimula­
tion, which can be reached by thyroid hormone withdrawal or administration of recombi­
nant human TSH (rhTSH). 
Thyroid hormone withdrawal induces clinical hypothyroidism which will lead to a con­
siderable quality oflife impairment (3). Besides, thyroid hormone withdrawal has a substan­
tial economic impact. A Dutch study (4) showed a mean of 59% lost time at work during the 
withdrawal period, costing an estimated amount of €2.495.791 per year in the Netherlands 
(calculated on the basis of 450 patients). 
RhTSH administration is an alternative approach for preparing patients for serum Tg 
measurement. It is a relatively expensive adjuvant for testing (€1062 excluding the cost of 
injecting the drug) but avoids hypothyroidism and the associated impairment of quality of 
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life (3,5), while it is effective in stimulating Tg production (5,6). Therefore, rhTSH has been 
widely introduced in the clinical routine and has now a prominent place in the follow-up of 
low-risk patients to check for the completeness of thyroidectomy and 1-131 remnant ablation 
(7-9). 
Although rhTSH may have a place in the early follow-up, the value of measurement of 
rhTSH stimulated Tg (rhTSH-Tg) in the long-term follow-up (> 1 year after initial treatment) 
of DTC is unknown. Data about the additional diagnostic yield of rhTSH-Tg compared with 
Tg measurement during thyroid hormone therapy (Tg-on) without TSH stimulation are 
lacking. We evaluated in a prospective study the diagnostic yield of rhTSH-Tg in the detec­
tion of recurrences in clinically disease-free patients in long-term follow-up for DTC (10). 
We observed that rhTSH-Tg had very limited additional diagnostic yield compared with 
Tg-on measurement with a sensitive Tg assay. 
Since follow-up of DTC is lifelong and the prevalence of thyroid cancer worldwide is 
475.200 (11), considerable medical costs are generated. The extensiveness of the follow-up 
regimen and the used diagnostic procedures will largely influence these medical costs. As 
health care systems are limited in their financial resources, assessing the balance between 
costs and effects of a new diagnostic procedure as rhTSH stimulated Tg measurement is 
crucial for medical decision making. 
Unfortunately, data about cost-effectiveness of follow-up protocols in DTC are lacking. 
For this reason, as part of the prospective study, we determined and compared the cost and 
effects of rhTSH-Tg with Tg-on measurement in clinically disease free patients in long-term 
follow-up for DTC. 
METHODS 
Design of the study 
This prospective study evaluated the diagnostic yield of rhTSH-Tg in the detection of recur­
rent disease compared with Tg-on measurement in clinically disease free patients in long­
term follow-up for DTC. The study protocol and main findings of the rhTSH study have been 
reported in detail elsewhere (10). 
In brief, patients with DTC who were clinically disease free for > 1 year were included. 
Clinically disease free was defined as no clinical evidence of recurrent or persistent DTC and 
undetectable Tg-on for at least 1 year. During routine follow-up in our outpatient-clinic, Tg 
was measured with an immunoradiometric assay (Cis Bio International) with a functional 
sensitivity of 1.5 ng/ml. However, in the study, all Tg measurements were performed with 
a more sensitive Tg assay (Nichols Advantage® Tg assay, Nichols Institute Diagnostics, San 
Clement, CA, USA) with a functional sensitivity of 0.6 ng/ml (12). 
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On the basis of Tg result after rhTSH, patients were divided into two groups. Patients 
with rhTSH-Tg < LO ng/ml received no further testing. Patients with rhTSH-Tg � 1.0 ng/ml 
underwent imaging procedures in order to attempt to localize any possible recurrence. In 
all these patients 18-F Fluorodeoxyglucose (FDG) Positron Emission Tomography (PET ), 
ultrasound (US) examination of the neck (with fine needle aspiration when indicated) and 
a posttherapy 1-131 whole body scan (WBS) after treatment with 150 mCurie 1-131 was per­
formed. Additional imaging was performed on indication. An expert panel assessed disease 
status on the basis of all performed imaging and categorised patients as no recurrence lo­
calized or recurrence localized. In addition, therapeutic consequences of these results were 
determined. 
A total of 121 Tg-antibody negative, clinically disease free patients were included. All 
patients had undergone (near) total thyroidectomy followed by radioiodine ablation, and 
used a suppressive dose of levothyroxin. 
Economic evaluation 
The aim of the economic evaluation was to assess the cost-effectiveness of rhTSH-Tg com­
pared with Tg-on measurement. The primary measure of effect in this economic evaluation 
was the number of patients with localized recurrence, detected in the diagnostic tests. The 
costs analysis was performed from a healthcare perspective, where only costs made for the 
benefit of diagnosis were taken into account. The time horizon of the economic evaluation 
varied between patients. Starting point for all patients was the moment the diagnostic cycle 
started by performing Tg-on measurement (Figure 1). Endpoint was the moment Tg-on was 
< 1.0 ng/ml or in case Tg was � 1.0 ng/ml the moment that additional diagnostic testing was 
completed. Since the primary measure of effect was the number of patients with localized 
recurrence, costs for treatment of recurrent disease were not included in the analysis. 
In the economic evaluation, the price level of 2006 was used. Costs of outpatient visits 
and general practitioners visits were valued based on Dutch standard prices (13). Informa­
tion on costs of medication was obtained from the Dutch Health Care Insurance Board 
(CVZ) (14). Laboratory tests and diagnostic imaging were valued according to tariffs of the 
National Health Tariffs Authority (CTG/ZAio) (15). For admission to an isolation room and 
an additional post therapy scan no standard prices were available. For these cost categories 
the costs were based on true resources used and time invested by staff and were calculated 
in one of our previous studies (16). These costs were used after indexing to the price level of 
2006. Since the time horizon was shorter than one year in all patients, costs and effects were 
not discounted. 
All patients were tested following two procedures: Tg-on and rhTSH-Tg. For the eco­
nomic evaluation these two procedures were considered separate as two scenarios to assess 
the costs of both follow-up strategies. In the first scenario, costs and effects of the Tg-on 
measurement and subsequent imaging were established. Costs of the Tg-on measurement 
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were based on true resources used in the total group of 121 patients. Costs of imaging were 
based on the average use of imaging techniques in the group of patients with a detectable 
Tg (� 0.6 ng/ml) based on Tg-on measurement. In the second scenario, costs and effects of 
imaging were based on the average use of imaging techniques in the group of patients with 
rhTSH-Tg � 1.0 ng/ml (n=19). 
To adjust for possible changes in the future in the Tg cut-off value for additional imag­
ing, we compared costs and effects when Tg-on � 1.0 ng/ml and rhTSH-Tg � 2.0 ng/ml were 
used as cut-off levels. Additionally, we calculated costs and effects when using a limited 
imaging protocol for localizing recurrent disease, consisting of only neck ultrasound and 
a posttherapy 1-131 WBS after treatment with 150 mCurie 1-131. In this limited scenario, 
FDG-PET and additional anatomic imaging (MRI, CT) were omitted. 
Tg - on RhTSH measurement 0.9 mg 
i.m 
u u u - - -
Figure 1. Study design 
RESULTS 
RhTSH - Tg 
measurement RhTSH - Tg <l .O ng/ml 





The results of this clinical study have been published in detail elsewhere {10). 
Clinical characteristics of the study-population are presented in Table 1. At baseline, 
Tg-on was detectable (� 0.6 ng/ml) in 6 of the 121 patients. RhTSH-Tg was � 1.0 ng/ml in 
20 patients {17%). In 5 of these 20 patients, Tg-on had also been detectable (� 0.6 ng/ml). In 
one patient Tg-on was detectable but rhTSH-Tg was < 1.0 ng/ml. No imaging was performed 
in this patient, because indication for imaging was based on the rhTSH-Tg result. Further 
calculations are based on these 5 patients with Tg-on � 0.6 ng/ml. 
Imaging was performed in 19 of the 20 eligible patients (one patient refused imaging be­
cause of pregnancy wish). After evaluation of all images, 16 patients showed no localization 
of a recurrence and 3 patients were classified as having recurrent disease. Two of these three 
patients with localized recurrent disease had detectable Tg-on, meaning that these patients 
would have been identified without the procedure of rhTSH stimulation. 
81  
CHAPTER 6 
After 4 years follow-up, none of the 16 Tg positive patients with negative imaging showed 
recurrent disease. Additionally, in the Tg positive patient who refused imaging because of 
pregnancy wish no recurrence has been found. 
Table 1. Clinical characteristics at baseline 
Characterist ic All pat ients n=l21 
Sex- no. (%) 
Female 
Male 
Age " (years) 




Follow-up • (years) 











54 (20-7 3) 












• Data are given as number (percentage) or median with range. 
h TNM-classification (34) 
Economic evaluation and costs 
Costs of Tg measurement procedure 
The mean total costs per patient were €129 for Tg-on measurement in itself and €1232 for 
rhTSH-Tg in itself (Table 2). The use of rhTSH, generated €1103 (€1232-€129) extra costs per 
patient. These higher costs mainly resulted from the costs of the rhTSH injection (€1062). 
Table 2. Costs of initial diagnostics per patient 
Cost category 
Out patient visits 
Laboratory tests 
Medication 
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Table 3. Mean costs of additional diagnostic tests per patient 
Cost category Tg-on protocol (n=S) rhTSH protocol (n=l9) 
Costs (€) Costs (€) 
Diagnostic imaging 2168 1724 
Stay in isolation room 2438 2438 
Outpatient visits 184 230 
Total 4790 4392 
Costs and effects of additional imaging 
Additional imaging was performed in 5 patients according to the Tg-on protocol (Tg-on 
� 0.6 ng/ml) and in 19 patients according to the rhTSH protocol (rhTSH-Tg � 1.0 ng/ml). 
Mean total costs per patient for imaging procedures were €4790 in the Tg-on protocol and 
€4392 in the rhTSH protocol (Table 3). The Tg-on protocol resulted in the detection of two 
patients with localized recurrence, rhTSH-Tg resulted in the detection of three patients with 
localized recurrence. Costs per patient with localized recurrent disease were €19780 in the 
Tg-on protocol and €77.507 in the rhTSH protocol, so the rhTSH protocol generated €57.727 
extra costs per patient with localized recurrence (Figure 2, 3). This difference in costs was 
predominantly caused by the higher number of patients referred for imaging in the rhTSH 
protocol (19 patients versus 5 patients in the conventional protocol). Imaging in these 14 
extra patients resulted in one additional patient with localized recurrent disease. 
1 16 patients: no Tg detectable 
No additional costs 
Tg measurement 
121 patients 
1 2 1  x €  129 = 
€ 1 5.609 
5 patients: Tg detectable 
Additional diagnostic tests 
5 X € 4790 = € 23.950 
2 patients 
Recurrence localized 
Costs per patient with localized 
recurrence 
3 patients 
No recurrence localized 
€ 15609 + € 23.950/2 = € 39.559/2 
€ 19.780 
Figure 2. Costs and effects of the Tg-on protocol (Tg cut-off 0.6 ng/ml) 
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101 patients: no Tg detectable 
No additional costs 
Tg measurement 
121 patients 
121  x €  1232 = 
€ 149.072 
20 patients: Tg detectable 
Additional diagnostic tests 




Recurrence localized No recurrence localized 
Costs per patient with localized 
recurrence 
€149.0702 + € 83.448/3 = € 232.520/3= 
€ 77.507 
Figure 3. Costs and effects of the rhTSH protocol (Tg cut-off 1.0 ng/ml) 
Cost-effectiveness ratio 
The cost-effectiveness ratio (Ll costs/ Ll effect) was €192.961 (€232.520 - €39.559 / 1), meaning 
an extra 192.961 euros have to be invested with the rhTSH protocol to detect one additional 
patient with localized recurrent disease compared to the Tg-on protocol. 
Cost and effects of two scenarios with higher Tg cut-off value 
When Tg-on cut-off value was increased to 1.0 ng/ml, three patients were eligible for ad­
ditional diagnostic testing. This protocol would result in the detection of two patients with 
localized recurrence and costs per patient with localized recurrence would be €16.044 (Table 
4). One patient with disease activity would be missed, who would have been identified with 
the rhTSH protocol. This patient was also missed in the Tg-on protocol when using Tg � 0.6 
ng/ml as cut-off (detection limit of the assay). The cost-effectiveness ratio, comparing with 
the rhTSH protocol (cut-off 1.0 ng/ml), was €200.432 (€232.520 - €32.088 / 1) (Table 4). 
When rhTSH stimulated Tg cut-off value was increased to 2.0 ng/ml, 10 patients were el­
igible for additional diagnostic testing. Yet all three patients with localized recurrence would 
have been detected and costs per patient with localized recurrence would be €64.074. The use 
of rhTSH resulted in €160.134 extra costs (cost-effectiveness ratio: €192.222 - €32.088 / 1) to 
detect one extra patient with recurrent disease, comparing this rhTSH protocol (cut-off 2.0 
ng/ml) with the Tg-on protocol with the adjusted cut-off level of 1.0 ng/ml (Table 4). 
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Cost and effects of two scenarios with higher Tg cut-off value and limited imaging protocol 
The limited imaging protocol consisted of US examination of the neck and a posttherapy 
1-131 WBS. Using the higher Tg cut-off values for additional imaging (Tg-on: 1.0 ng/ml and 
RhTSH-Tg: 2.0 ng/ml) in combination with this limited imaging protocol would result in 
the identification of two recurrences in the Tg-on protocol and three recurrences in the 
rhTSH-Tg protocol. Mean total costs per patient for imaging procedures were €3159 in the 
Tg-on protocol and €2724 in the rhTSH protocol. Costs per patient with localized recurrent 
disease were €12.543 in the Tg-on protocol and €58.771 in the rhTSH protocol. An extra 
€151.226 have to be invested with this adjusted rhTSH protocol to detect one additional pa­
tient with localized recurrent disease compared to the Tg-on protocol (Table 4). 
Table 4. Costs and effects of different protocols 
Tg detectable above cut­
off value and additional 
imaging performed• 






o _ e s  









Costs per patient with 
localized recurrence 
€19. 780 €7 7.507 €16.044 €64.074 €12.543 







(1. 0  ng!ml) 
a Number of patients with Tg above cut-off level who were referred for additional imaging. 
b Number of patients with localized recurrent disease. 
c Extra cost for the detection of one additional patient with localized recurrence. 
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The use of rhTSH stimulated Tg measurement in the long-term follow-up of 121 DTC pa­
tients resulted in the detection of one extra patient with localized recurrent disease com­
pared to Tg measurement during thyroid hormone suppression therapy with a sensitive Tg 
assay, at the cost of an extra 192.961 euros . We highly doubt if these extra costs are worth 
the additional effect . 
The higher costs for the rhTSH stimulated Tg procedure were firstly due to the expensive 
rhTSH injections in itself and secondly due to the large amount of additional diagnostic pro­
cedures required . In 101 patients with rhTSH-Tg < 1.0 ng/ml, the comprehensive procedure 
of Tg measurement with rhTSH injections cost €1103 extra per patient while it only con­
firmed the absence of disease (demonstrated by the Tg-on protocol). Additionally, with the 
use of rhTSH 14 extra patients were suspected of recurrent disease and subsequently under­
went highly costly additional testing, including 1-131 WBS after high dose radioiodine treat­
ment. Imaging was negative in 13 of these 14 extra patients and unnecessary . Consequently, 
the positive predictive value (PPV) of this rhTSH-Tg was very low (3 out of 19 patients recur­
rence localized, PPV 16%). Besides extra costs, imaging caused substantial patient burden 
in terms of concerns about possible recurrence of cancer and extra hospital visits including 
unnecessary radioiodine treatment. In our opinion, the potential reassurance and relief of 
negative imaging do not outweigh this patient burden. 
The clinical significance of elevated rhTSH-Tg values in patients in whom no tumour 
could be identified is insecure. In this study, in none of these patients recurrence was found 
during 4 years follow-up. Either tumour recurrence or a spontaneous decline in Tg can oc­
cur over time, but distinguishing these patients is difficult (17-19). An increase in serially 
determined Tg levels is more informative than the absolute value of Tg in the lower range 
(12,18-20) . Extensive imaging only when Tg rises above a certain cut-off level will largely 
contribute to cost-effective follow-up management . Additionally, with the introduction of 
highly sensitive Tg assays this Tg measurement can be performed during thyroid hormone 
suppression therapy (10,21-23), saving the costs of rhTSH stimulation . 
We included patients irrespective of prognostic factors influencing risk of recurrence 
and follow-up duration. Although the presence of the established risk factors result in a 
reduced life expectancy (24), also initial low-risk patients can die from thyroid cancer (25), 
illustrating that distinction between high and low-risk is not perfect (26). In the present 
study, recurrent disease was found in two low-risk patients (follow-up 5 and 12 years) and 
one high-risk patient (follow-up 16 years), once again demonstrating the limitation of the 
current staging systems (10). Moreover, this study-population reflects the variety of patients 
in follow-up for DTC in daily clinical practice and results of are applicable to all patients in 
follow-up for DTC. 
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Future changes in either the Tg-on or the rhTSH protocol might influence its cost-ef­
fectiveness. In the present study we chose rather stringent Tg cut-off values, influencing the 
number of patients referred for imaging. No consensus exists about the optimal threshold 
for additional imaging, but most authors consider a stimulated Tg > 2.0 ng/ml indicative 
for recurrent disease (27). However, the large between-method variability in Tg assays that 
persists despite CRM-457 standardization can lead to difficulties with comparison of Tg 
results of different assays (28). Additionally, Tg cut-off levels will continue to evolve as new 
Tg assays are introduced (29). In this study, when using adjusted Tg-on cut-off value of 1.0 
ng/ml and rhTSH-Tg cut-off value of 2.0 ng/ml, unnecessary imaging was prevented in re­
spectively two and nine patients, saving costs without influencing effectiveness. Despite of 
these adjustments, rhTSH-Tg still resulted in €160.134 extra costs to detect one extra patient 
with localized recurrence. 
Indeed, the extensive imaging performed in the rhTSH study also influenced the cost­
effectiveness. Firstly, in this study FDG-PET was performed in all patients with detectable 
Tg. Currently, in most clinics FDG-PET is not a first-line tool in Tg positive patients and is 
only used in selected cases, mostly when I-131 WBS is negative (27,30,31). Secondly, we used 
in some cases anatomic imaging (MRI, CT ) for optimal differentiation between normal and 
pathologic imaging and treatment planning. These techniques were not essential for the pri­
mary goal, the localization of recurrence. We composed a limited imaging protocol includ­
ing neck ultrasound and posttherapy WBS, which is the standard of care in most hospitals 
when patients have detectable Tg in follow-up. Using these techniques, in combination with 
the adjusted Tg cut-off value (2.0 ng/ml), all recurrences were identified, but still an extra 
€151.226 had to be invested to detect one additional patient with localized recurrence com­
pared with Tg-on measurement. These adjusted Tg cut-off levels and limited imaging sce­
narios only marginally influenced the cost-effectiveness ratio and confirmed the high costs 
of the use of rhTSH stimulation. 
Other studies analysing the cost-effectiveness of Tg-on and rhTSH-Tg in the follow-up 
of DTC are lacking. Only one abstract reported a cost-utility analysis of four strategies of 
follow-up in thyroid cancer, combining a method of stimulation (rhTSH or thyroid hormone 
withdrawal) and a testing protocol (neck ultrasound + Tg + WBS or neck ultrasound + Tg 
alone) (32). The combination of rhTSH-Tg and neck ultrasound was the most cost-effective 
strategy. However, a strategy with Tg-on measurement was missing in this analysis. There­
fore, the results of this present study are an important contribution in the evaluation of 
rhTSH-Tg and Tg-on in the long-term follow-up of DTC, even more since the need for (rh) 
TSH stimulation in this phase is nowadays more and more challenged (22,23). 
The costs of rhTSH stimulated Tg are extremely high, also when cut-off levels are ad­
justed and limited imaging modalities are used, and in our opinion do not outweigh the 
benefit of the detection of one extra patient with localized recurrence. Moreover, regular 
serial Tg-on measurement with a sensitive Tg assay anyhow would have identified this single 
CHAPTER 6 
patient, since the change in Tg over time is more informative than a single Tg determina­
tion (20). Tg-on will increase during serial Tg-on measurement when recurrent disease is 
actually present. Moreover, differentiated thyroid cancer is a relatively benign disease with 
generally a slow course. There is no evidence to support that earlier intervention in this pa­
tient ultimately will affect mortality (33). 
In conclusion, our study compared costs and effects ofTg-on and rhTSH-Tg in the long­
term follow-up of patients with differentiated thyroid cancer. RhTSH-Tg had a limited ad­
ditional clinical benefit in these patients but costs per detected patient with evidence of dis­
ease were excessively high. This unfavourable cost-effectiveness ratio should be taken into 
account in the evaluation of the place of rhTSH-Tg in the follow-up of DTC. 
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ABSTRACT 
Background: Selective embolization therapy (SET ) has been employed to treat a number 
of malignant tumors, but experience with its use in metastatic differentiated thyroid carci­
noma (DTC) is limited. Here we report our experience with the effect of SET on symptoms 
and serum thyroglobulin (Tg) in patients with bone metastases from DTC. 
Methods: This was a retrospective study of 13 patients with bone metastases from DTC 
who underwent 65 embolizations for bone metastases in 43 sessions. In the treated patients, 
symptoms considered related to bone metastases were compared before and about 4-7 weeks 
after the embolization session. Embolization sessions were excluded for analysis if concomi­
tant therapy had taken place within 4-7 weeks before and/or after the session. Serum Tg 
concentrations were employed as an index of tumor debulking by SET. We attempted to esti­
mate the influence of SET on survival time in patients with disseminated DTC who did, and 
an historical control group of patients with disseminated DTC who did not received SET. 
Results: After exclusion of 12 (of which 3 sessions failed) out of 43 sessions, clinical symp­
toms such as pain and neurological symptoms decreased after 17, increased after 6 and did 
not change after 8 procedures. In 43 sessions, 20 of which were excluded (including the 3 ses­
sions that failed), serum Tg decreased after 14 and increased after 9. The median standard­
ized survival time of the group that received embolization was not significantly different to 
that of the group that did not receive embolization. 
Conclusions: Embolization therapy does not appear to improve life expectancy, but in se­
lected patients can achieve palliation of pain, prevent neurological damage, can reduce tu­
mor burden and give devascularization of the tumor before surgery. 
INTRODUCTION 
Although overall survival in patients with differentiated thyroid carcinoma (DTC) is ex­
cellent, patients with persistent disease have a life expectancy of approximately 60% of the 
normal residual life span (1). The challenge in treating this persistent disease is to improve 
survival and control symptoms such as pain and different neurological symptoms. Standard 
treatment consists of thyroidectomy followed by high-dose radioiodine and lifelong thyroid 
hormone suppression therapy. In cases of persistent disease, surgery and occasionally ad­
ditional external beam therapy, are used. Other treatments, including labeled octreotide, 
have limited results (2). 
Selective embolization therapy (SET ) for the treatment of bone tumors was first de­
scribed by Feldman et al. in 1975 (3). Camille et al. (4) were the first to write about pre-oper­
ative embolization therapy for thyroid carcinoma. They wrote about embolization of metas­
tases from thyroid carcinoma before surgery in four cases with spinal or pelvic metastases. 
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Several case reports with embolization therapy in the treatment of thyroid cancer are 
described {5-10). Few reports, including one report written by our group, deal with embo­
lization therapy for bone metastasis in thyroid cancer (11,12); others concern direct embo­
lization of the primary thyroid tumor {13,14) or the use of embolization as a preoperative 
procedure (15-18). These reports indicated that some patients achieved a rapid reduction in 
pain and tumor burden. Barton et al. (19) showed that embolization is generally an effective 
treatment for bone metastases of different primary tumors. It is known that embolization 
therapy together with antivascular therapy (Marimastat) has no additional effect for clini­
cal symptoms (20). Previous studies have shown that clinical improvement was not always 
concordant with tumor regression on imaging (12). 
We report our experience with the effect of SET on symptoms and serum thyroglobulin 
(Tg) in patients with bone metastasis from DTC, and we investigate if SET has an additional 
value to life expectancy. 
MATERIALS AND METHODS 
The University Medical Center Groningen is the major referral center in the northern part of 
The Netherlands for treatment of patients with DTC. The treatment regimen and follow-up 
were described earlier (21) and consisted of a total thyroidectomy and I-131 therapy, with Tg 
measurement under thyroxine suppression therapy after a negative posttherapeutic whole­
body scan (WBS). 
The patient group consisted of 13 patients with disseminated DTC who received SET for 
their bone metastases to control pain, and/or to achieve tumor debulking, and in specific 
cases to obtain devascularization before surgery. An additional nonrandomized group of 87 
patients with disseminated DTC who did not receive SET (No-SET group) was used to esti­
mate the impact of SET on survival. Between 1996 and 2006 the 13 SET-treated patients un­
derwent 65 embolizations in 43 sessions. Eleven of these patients had persistent disease after 
initial therapy, nine of them presented with only bone metastases. The other two patients 
were in remission after initial treatment, but developed recurrent persistent disease with 
bone metastases. The SET procedures were executed after obtaining informed consent. 
The 87 patients in the No-SET group were part of the large cohort that has been de­
scribed earlier(l). Sixty seven of these patients had persistent disease after their initial surgi­
cal and radioiodine treatment, and 20 patients developed recurrent disease after this initial 
treatment and did not have a second remission after the additional treatment. 
Regarding terminology, an embolization session refers to several embolizations in one 
patient on the same day, and an embolization refers to as one embolization procedure. 
The success of embolization was evaluated by additional angiography after the embo­
lization session. After 3-4 months the success of the embolization was measured by mag-
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netic resonance imaging and computed tomography. Embolizations that were at least 60% 
complete were considered partially successful, and embolizations that were 100% complete 
were considered completely successful. 
Completely and partially successful embolizations were included in the analysis unless 
there was concomitant therapy near the time of the procedure. In 43 embolization sessions 
during which 65 embolizations were administered, 48 embolizations were successful, 13 
embolizations were partially successful and 4 embolizations were not successful. To evaluate 
the effect of therapy (symptoms and Tg levels), no concomitant therapies in a period of 4-7 
weeks before and after the embolization sessions were accepted for evaluation. Therefore, 
nine embolization sessions were excluded because of concomitant surgery (four sessions and 
four embolizations), antivascular therapy (three sessions and eight embolizations), and 1-131 
therapy (two sessions and two embolizations). In eight other embolization sessions no Tg 
levels were available. Of the total 12 and 20 embolization sessions that were excluded, both 
contained the 4 embolizations executed in 3 sessions that failed. In sum, 23 embolization 
sessions were evaluable for Tg levels and 31 sessions for symptoms. 
Persistent disease after initial therapy was defined as clinical evidence of thyroid can­
cer found at any visit after ablation. Recurrent disease was defined as tumor recurrence 
indicated by newly detectable Tg during suppression therapy or clinical evidence of disease 
detected by other technique. The characteristics of the SET and non-SET groups are given in 
Table 1. Both groups were compared for differences in survival. Most of the patients in the 
embolization group have follicular thyroid carcinoma and Ml  tumors. For survival, both 
subgroups of patients were also compared separately with the same subgroup in the control 
group. 
Table 1. Patient characteristics 
Embolization group 
Sex: male/female 
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Laboratory methods 
Serum Tg was measured by a commercially available radioimmunoassay (Cis Bio Interna­
tional, Gif-sur-Yvette, France), with a lower detection limit of 1.5 ng/mL. In cases of an 
undetectable serum Tg, the presence of Tg antibodies was evaluated by recovery of added 
standard Tg. Tg antibodies were considered to be absent if recovery was > 85%. None of our 
patients had Tg antibodies. 
After March 2004 an immunochemiluminometric Tg assay was introduced (Nichols 
Advantage• Tg assay; Nichols Institute Diagnostics, San Clemente, CA), detection limit < 0.6 
ng/ml. For Tg antibody detection the Nichols Advantage • TgAb assay (Nichols Institute 
Diagnostics) with a cut-off value for TgAb positivity of 2 mIU/L was introduced (22). 
Embolization technique 
Before embolization, all the tumor-supplying vessels were visualized by diagnostic angio­
graphy. Embolization was performed during the same session. A no. 6 French (F) sheath was 
placed into the femoral artery, to facilitate catheter exchange. Then a 6 F guiding catheter 
(Boston Scientific, Natick, MA) was inserted proximal in the main tumor-feeding artery. 
With a microcatheter (Excel l 4;Boston Scientific) a superselective microcatheterization of 
the tumor vessels was performed. The tumor was embolized with repetitive small injections 
of polyvinyl alcohol foam particles of 150-250 microns (Contour emboli, Target Therapeu­
tics, Fremont, NE). The treated site of the metastases and the embolized arteries are shown 
in Table 2. With additional angiography, the direct result of the embolization session was 
documented. For the detection of side-effects, including the postembolization syndrome as 
flu-like symptoms or fever (11) and technical complications, all patients in whom emboliza­
tion was performed were clinically observed during 24-48 hours. 
Effect of therapy 
The effect of the therapy was evaluated by clinical complaints such as pain, mobility, insensi­
bility, and Tg levels. These data were collected from the patient charts retrospectively. 
Clinical complaints of the local metastases were categorized as regression, stabilization, 
or progression. The clinical complaints before the embolization session were compared with 
those about 4-7 weeks after the embolization session. 
Tg was measured 3 weeks before (range, 0-136 days) and up to 7 weeks (range, 10-164 
days) after embolization during thyroid stimulating hormone (TSH) suppression. The indi­
vidual standardized survival time was calculated as the ratio between the observed survival 
time of an individual and the median residual life span of the individuals with the same age 




Differences in standardized survival were analyzed by log rank test. Continuous variables 
are given as mean with SD; differences were tested by Mann-Whitney U-test. Differences in 
prevalences were tested by chi-square test. Changes in subjective complaints and Tg concen­
trations were tested by sign-test. P-values less than 0.05 were considered significant. 
RESULTS 
Table 1 shows the characteristics of the SET and No-SET groups. More females were present 
in the embolization group, but age was comparable in both groups. The prevalence of distant 
metastases at diagnosis was significantly higher in the SET group (p < 0.0005) than in the 
No-SET group, and positive regional nodes were not present at diagnosis (p < 0.005). There 
were significantly more (p < 0.0003) follicular thyroid carcinomas in the SET group than in 
the No-SET group. Twelve patients in the SET group had follicular thyroid carcinoma, one 
patient (no.IO) had Hiirthle cell carcinoma. 
Table 3 shows the characteristics of individual patients, the number of embolizations, 
their locations and additional therapies. Eight patients in the SET group were locally treated 
with external beam therapy; five of these patients had this therapy before the embolization 
session. The mean time of external beam therapy before an embolization session was 10.5 
months with a range of 1.5-20.5 months. Of the 13 embolizations that partially succeeded 
and the four embolizations that failed, external beam therapy was not given before embo­
lization. 
Figure 1 shows the angiogram made before the embolization session. In Figure 2A and 
Figure 2B the situation before and after embolization of the left side is visible after finishing 
the right side ofL3. Indications for embolization were tumor debulking before 1-131 therapy 
(42.5%), preventing neurological damage (35%), diminishing complaints of pain (45%) and 
embolization before debulking surgery (10%). In total the percentages are more than 100% 
because some embolization procedures had more indications. 
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Table 2. Arteries treated with embolization therapy 
Site metastases• 
Patient 1 
I .  acetabulum(r)/os ischii/ ramus superius ossis 
pubis 
2. os ischium(r)/ramus ossis pubis(r) 
Embolized artery 
Embolized artery 
internal iliac a.(r) 
internal iliac a.(r) tumor branches/medial circumflex 
of femoral a.(r) 
3. acetabulum(r) not specifically mentioned 
4. relapse proximal and at the same height of known internal iliac a.(r) (tumor branches) 
pelvis metastase(r) os ischium extended to medial 
backside of acetabulum and os pubis(r) 
5. os ischii(r)/sacrum/acetabulum(r)/os pubis 
6. os ilium medial/sacrum/os ischii/upper part 
medial os pubis(r) 
7. os ilium lateral 
8. ramus ossis pubis superior and inferior(!) 
9. pubis ring 
10. os ileum(r) 






1. humerus proximal(!) 
2. os ilium lateral (r) 
3. humerus proximal (1) 
4. os ilium(r) 
Patient 4 
1. 6th rib(l) 
Patient 5 
I. Th6, Th7(r) 
2. Th6, Th7(r) 
3. scapula 
4. Th6, Th7(r) 




1 .  L3, L4(1) 
2. L3, L4(1) 
3. L3, L4(1) 
medial and lateral circumflex of femoral a. 
internal iliac a.(r) 
gluteus maximus a.(r) 
internal iliac a.(l) (tumor branches)/tumor branch 
from retroperitoneal a. from external iliac a.(l) 
separate branches from profunda femoris a. 
separate branches from profunda femoris a. 
separate branches from profunda femoris a. 
Embolized artery 
lumbar spinal a. L3(r) and L4(r,l) 
lumbar spinal a. L3(1,r) (collateral a.) (right side by 
means of microcoil) 
lumbar spinal a.(r) (collateral a.) 
Embolized artery 
lateral upper arm a. (tumor branches incl. coiling and 
separate branch) 
internal iliac a.(r) {3 main branches) 
axillaris a.(l) (tumor branches) 
internal iliac a.(r) (tumor branches) 
Embolized artery 
costal a. 6 and 7(1) (including coiling) 
Embolized artery 
costal a. 7(r) (including coiling) 
costal a. 6 and 8(r) (tumor branches) 
costal a. 6 and 8 (r) (tumor branches) 
costal a. 7(r) (including microcoil) 
costal a. 7(r) (including microcoil) 
lumbar spinal a.(l) 
intercostal a. Th6(r) 
Embolized artery 
lumbar spinal a. L3(1) and L4(1) 
lumbar spinal a. L4(1,r ) (proximal branch) 




1. os il ium(r) w ith infiltrat ion in sacrum(r), 






7. os il ium lateral(r) 
8. sacrum med ial(r) 
9. os pubis med ial/cran ial(r) 
10. os ilium(l) 
11. os il ium(r) medial/cranial 
12. il ical(l) and at the SI jo int(l) 
Pat ient 8 
1. L2(r) (Ll, L3) 
2. L2, L3 
Patient 9 
1. ThlO, Thll (r) 
2. ThlO, Toll  (l) 
3. skull 






6. os ilium(r) 










internal iliac a.(r)/gluteal a. w ith collaterals to 
c ircumflex of femoral a. and the lowest lumbal a.(r) 
internal il iac a.(r)( includ ing microco il)/circumflex of 
femoral a. (tumor branches) 
internal il iac a.(r) (3 branches includ ing co il ing) 
internal il iac a.(r) (collateral tumor branches 
including m icrocoil) 
lateral c ircumflex of femoral a.(tumorbranches)/ 
internal il iac a.(r) (tumor branches) 
internal iliac a.(r) 
' internal il iac a.(r) 
internal il iac a.(r) 
internal il iac a.(r) 
internal il iac a.(l) 
lumbar spinal a. L4(r) 
lumbar spinal a. L4(1) 
Embol ized artery 
lumbar spinal a. L2(r) 
lumbar spinal a. L3(l,r) ( includ ing co il ing) 
Embolized artery 
intercostal a.(r) ( includ ing co il ing) 
intercostal a.(l) 
middle men ingeal a. pre- and midbranch 
(tumor branches) 
Embol ized artery 
lumbar spinal a. L4(l) ( includ ing microcoils) (distal/ 
proximal/tumor branches) 
internal il iac a.(r) ( includ ing microco il) (tumor 
branches) 
lumbar spinal a. L4(l)/lumbal a. 
lumbar spinal a. 12(1)/lumbal is a. (including co il ing) 
lumbar spinal a. 
internal il iac a./proximal branch near internal iliac 
a.(r)/retroperitoneal branches at the transit ion of 
external il iac a. and femoral is communis a. (medial 
branch) 
retroper itoneal iliac c ircumflex a.(tumor branches) / 
internal il iac a.(r) (tumor branches) 
lumbar spinal a. L3(l) 
lumbar spinal a. L3(r) (tumor branches) 
lumbar spinal a. L3(r) (tumor branches) and L4(1) 
lumbar spinal a. L3(r) (tumor branches) 
Embol ized artery 
lumbar spinal a. L3(l,r) ( includ ing co il ing) 
lumbar spinal a. L3(l) 
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Patient l2 Embolized artery 
1. C4 truncus costocervical is(r), coiling bifurcat ion and 
vertebral a.(l) 
Patient 13  Embolized artery 
1 .  CS-C6 truncus thyreocervicalis(l) 
a, artery; r, right; 1, left; Ll-LS, lumbar vertebrae 1-5; Th5-Th7, 1h10, 1h11, thorac ic vertebrae 5-7, 1 0, 1 1; C4-C6, 
cervical vertebrae 4-6. 
Table 3 . Individual data about additional therapies in the embolization group 
u "' � ,&l = 
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Female 60 T2NQMI Follicular 1 1  1-11:  pelv is 750 pelvis: 50 Gy, pelv is 8 Gy 
2 Female 60 TINOMI Foll icular 3 1-3: L4 900 paravertebral and L4: 24 Gy, 
corporectomy L4 
3 Female 68 T3NOMI Follicular 4 1,3: humerus, 750 pelvis: 8 Gy 
2,4:ileum 
4 Female 46 T2NQMI Follicular 1: 61h rib 900 exc ision r ibmetastasis 
5 Female 62 T2NOMI Follicular 7 1: Th6, 2: Th7, 600 Th. 6, 7, 8: 24 Gy, Sac: 
3:shoulder, 24 Gy, ThS:25 Gy 
4: Th6, 5: Th7, 
6: pelvis/sacrum, 
7: ThS 
6 Female 65 T N M  Follicular 3 1-3: L3-4 750 
7 Female 40 T4NOMI Foll icular 12 1: pelv is and part LS, 900 pelvis: 50 Gy, Ll-3:30 Gy 
2-12: pelvis 
8 Female 7 7  T N M  Foll icular 2 1-2: L2 450 Th. 12-14: 30 Gy 
9 Female 54 T2NOMO Follicular 3 1: 1h10, 2: 1h11, 3: 650 Th. 5-12: 30 Gy, skull:30 Gy, 
skull skull:20 Gy 
10 Male 35 TxNOMO Follicular 1 1  1 :  L4, 2: ileum, 3: L2, 640 Ll-LS: 8 Gy 
4: L3, 5: L4, 6: ileum, 
7: ileum, 8: L4, 9: L2, 
1 0: L4, 11 :  L3 
1 1  Female 52 T,NDMI Foll icular 2 1-2: L3 600 corporectomy L3 
12 Female 45 T N M  Follicular 1: C4 450 corporectomy C4 
13  Male 83 T,NDMI Foll icular 1: C5/C6 150 sur�ical CS-C6 
• Age a in it ial diagnosis (from duration of illness). 
T, tumor; N, nodes; M, metastases. 
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Figure I .  Angiogram before the embolization session of patient 11 (anterioposterior projection). Selective 
catheterization of the feeding lumbar artery on the left side shows a blush in the metastase of the 
third lumbar vertebra (L3). 
F igure 2A. A sagittal Tl-weighted image 
noncontrast enhanced of patient 11, 
showing a process in the third lumbar 
vertebra (L3) with destruction of the 
posterior wall of the corpus. 
1--, • J 
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I 
--- � ...... ......-:::: 
F igure 2B. An axial Tl-weighted image noncontrast 
enhanced, showing the same findings. 
Tumor extending into the pedicles 
bilaterally. Widening on the left side. 
Pre- and post-SET symptomology in patients with successful embolizations 
Symptoms of patients comprised pain and neurological symptoms like numbness, tingling, 
or radicular pain. Symptoms decreased during 17 sessions, were unchanged during 8 ses­
sions, and increased during 6 sessions (p < 0.01). The duration of improvement after these 
17 sessions had a mean duration of 8.1 months with a range of 0.2-36 months. The most ef­
fective embolizations were performed at the first session. Most of the patients of whom the 
symptoms were unchanged after the session, did not have complaints before the emboliza­
tion session. 
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Tg levels 
In 23 of the 43 embolization sessions Tg levels were evaluable. Before embolization Tg levels 
ranged from 18 to 18,200 ng/ml and afterward from 13 to 37,400 ng/ml (Table 4). After the 
embolization, serum Tg levels decreased in 14 procedures (mean change, 1015 ng/ml) and 
increased in 9 procedures (mean change, 4932 ng/ml, not significant). The greatest changes 
in serum Tg after embolization were noted in patients with the higher serum Tg concentra­
tions (Table 4). 
Of the 14 patients who had a decrease in Tg level, 8 patients had symptomatic relief, 4 
patients did not feel difference in their complaints, and 2 patients had an increase of symp­
tomatic complaints. Of the nine patients who had an increase in Tg level, four patients had 
symptomatic relief, two patients did not feel difference in their complaints, and three pa­
tients had an increase of symptomatic complaints. 
Table 4. Tg levels before and after embolization session 
Patient Tg level before embolization Tg level after embolization 
(ng/mL) (ng/mL) 




2. 4365 2400 
18 13 
3. 246 102 
67 70 
5. 525 16 
1415 1730 
6. 155 250 
250 827 
7. 1240 379 
489 442 
1110 1098 
8. 97 45 
50 14 
9. 772 276 
214 198 
10. 685 1280 
6910 25,350 
5460 9200 




Survival time in SET and non-SET patients 
The survival expressed as median standardized survival time was not significantly different 
between the SET group, which was 0.43 (95% confidence interval (CI), 0.24-0.63), and the 
non-SET group, which was 0.56 (95% CI, 0.39-0.74). 
Comparison of the patients with follicular thyroid cancer separately showed no sig­
nificant difference, 0.42 (95% CI, 0.04 -0.80), in the survival between the patients with em­
bolization therapy and the patients of the control group. Comparison of the standardized 
survival of the 13 patients from the embolization group with the 23 patients from the control 
group with Ml tumors also showed no difference, 0.42 (95% CI, 0.0-0.95). 
Complications 
During the first five embolization sessions no steroid coverage was added, and several minor 
complications occurred (temporary hypotension, postembolization syndrome, and local 
edema). Afterward, prednisolone was given 30 mg daily during two weeks, and then was ta­
pered in two weeks. No complications were seen in the following 38 embolization sessions. 
DISCUSSION 
Our series illustrated that embolization therapy can achieve palliation of pain and prevent 
neurological damage in a substantial number of patients with bone metastases from dif­
ferentiated thyroid cancer, but in contrast to radical surgical removal of bone metastases 
(23), embolization therapy does not appear to improve survival. Based on serum Tg mea­
surements taken weeks after this therapy, it appears that more than half of treated patients 
achieved a reduction of tumor burden. Life expectancy, however, is probably not influenced 
by embolization therapy. The changes in serum Tg after embolization therapy were highly 
variable, but a decrease was noted more often than an increase. 
When embolization therapy was successful or partially successful, in 61 % there was a 
decrease of the serum Tg level. To minimize a possible long-lasting effect of other treatments, 
we used in our analysis only those embolization sessions for patients who had received no 
additional therapy 28-49 days before and for the same period after their embolization ses­
sions. It should be noted that the half-life ofTg in the circulation is 4 hours to 4 days (24-26). 
Therefore, as serum Tg was measured at least 10 days after embolization therapy, it seems 
unlikely that serum Tg reflected acute necrosis of infarcted tumor tissue. Our data suggest 
that Tg is a weak indicator of tumor necrosis after embolization. Embolization therapy ap­
pears to be beneficial in two ways. First, it appears to improve the quality of life in some 
patients. This is particularly important because the survival of patients with metastatic dif­
ferentiated thyroid cancer (DTC) is relatively long. This conclusion is also supported by the 
study of Eustatia-Rutten et al. (12). They noted that a substantial percentage of patients had 
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improvement in clinical symptoms after embolization therapy, although some of these pa­
tients did not have tumor regression scored by Tg-level and/or imaging. In another study of 
four patients, Smit et al. (9) noted dramatic relief of neurological symptoms after emboliza­
tion therapy of vertebral metastasis from differentiated follicular thyroid carcinoma. In a 
third study of van Toi et al. (1 1), there was improvement of symptoms in patients treated 
with embolization and radioiodine therapy, but this improvement was not significantly dif­
ferent compared to patients treated with radioiodine therapy alone. The present study is a 
larger one than our early preliminary study (11) of five patients with bone metastasis due 
to DTC. In that study, radioiodine therapy alone or radioiodine therapy combined with 
embolization therapy was used, and there was a significantly greater decrease in serum Tg 
in patients when the combination of embolization and radioiodine therapy was employed 
than radioiodine alone. In the current larger series we conclude that embolization therapy 
is beneficial in a substantial number of patients. In our patients, the clinical symptoms were 
evaluable in 31 embolization procedures. A decrease of clinical complaints was found in 
55%. Embolization therapy has been shown to be a safe and effective noninvasive procedure, 
which is in this study is confirmed by the low treatment failure of only four embolizations, 
and can be combined with all other treatment options, and complications are not common 
(11, 12). 
The second advantage of embolization therapy is that it can be used to prepare selected 
patients for surgery of the targeted metastatic lesion. This was done in four of our patients. 
Metastatic thyroid lesions, especially in bones, are hypervascular. By means of preoperative 
embolization, the intraoperative blood loss can be reduced (10), as has been shown in meta­
static renal cell carcinomas (27). 
Irradiated metastases can also be embolized to decrease local tumor progression. Five 
patients in our series had been irradiated before embolization therapy, and this did not make 
the procedure more difficult. 
The present study was not designed to determine the effect of SET on life expectancy 
because there were important clinical differences between SET and non-SET patients. Based 
on a comparison of these groups, however, it seems unlikely that SET has an important 
impact on life expectancy. This is not surprising because, for the most part, SET only tar­
gets a portion of the tumor burden. It is also consistent with other reports regarding SET 
as a treatment for thyroid and other cancers. Wirbel et al. (28) reported that preoperative 
embolization of spinal and pelvic metastases of different primary tumors, mostly renal cell 
carcinoma, had no influence on survival time. In the study of Bernier et al. (29), 34 of 109 
(31 %) patients with DTC received selective arterial embolization therapy as preoperative 
and/or palliative treatment for bone metastases. No improvement in survival was noted. In 
the future, specific systemic treatment modalities for patients with DTC and hematological 
spread disease might possibly be more effective to improve survival. For improvement of 
survival, an aggressive multidisciplinary approach has been advocated (30), but local thera-
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pies for tumor control, like embolization therapy, are very valuable to the preservation of 
quality of life. 
In conclusion, life expectancy in patients with metastatic disease is not improved by em­
bolization therapy, but a significant effect on complaints and reduction of tumor burden was 
found. Embolization therapy can be used for tumor debulking, devascularization of tumor 
before surgery, and pain reduction, and can be combined with other treatment modalities 
such as radiation. 
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CHAPTER 7 
SUMMARY AND GENERAL DISCUSSION 
Generally, differentiated thyroid cancer (DTC), including papillary and follicular thyroid 
cancer, carries an excellent prognosis. Ten-year survival rates range between 83% and 98% 
(1,2). This favorable prognosis results from both the effective initial therapy and the gener­
ally indolent biological behavior of this tumor. Initial therapy consists of total thyroidectomy 
followed by high dose radioiodine therapy to eliminate microscopic residual or metastatic 
disease and subsequent lifelong thyroid hormone suppletion therapy. Despite the favorable 
general prognosis, recurrence rates are high, as up to 20% develop recurrent disease dur­
ing follow-up. Recurrences may become clinically evident even after 20 years following this 
initial therapy. Therefore lifelong follow-up of thyroid cancer patients is recommended (3,4). 
Follow-up strategies should be able to identify patients with recurrent disease. However, a 
proper balance between the diagnostic yield of monitoring tests and the associated patient 
burden and medical costs should be maintained. In the previous chapters we evaluated dif­
ferent aspects of the follow-up of DTC aiming to contribute to the development of an op­
timal follow-up strategy. The results of these studies are summarized and discussed in the 
following sections. 
Thyroglobulin measurement 
In the follow-up, the measurement of serum thyroglobulin plays a central role. Thyroglobu­
lin (Tg) is a very large and heterogeneous glycoprotein, produced by thyroid epithelial cells 
and serves as a physical backbone for thyroid hormone synthesis. Tg can be used as a tumor 
marker because thyroid cells are the only source of Tg in the human body (5). Therefore, 
the presence of Tg after total thyroidectomy and high dose radioiodine therapy indicates 
the presence of residual functional thyroid tissue or recurrent / persistent disease. As a very 
specific biomarker, Tg measurement should be as sensitive, accurate and precise as possible. 
Improving sensitivity is the main point of interest in the development of new Tg assays. 
Highly sensitive Tg assays may be able to measure Tg levels in the lower range, and therefore 
permit the discovery of recurrent disease at an earlier stage. 
In chapter 2 we have illustrated the usefulness of a new highly sensitive Tg assay in the 
follow-up of DTC. Analytic performance of this immunochemiluminometric assay (ICMA) 
was characterized by high sensitivity, full automation and high reproducibility. When we 
introduced this assay in the clinic, we identified measurable Tg levels in 12 of 1 10 patients, 
while our conventional immunoradiometric (IRMA) assay showed no demonstrable Tg. 
Four of these 12 patients had clinical evidence of disease at the time of measurement, en­
dorsing the potential for earlier disease detection with this assay. However, the significance 
of the low detectable Tg concentrations in the remaining eight patients in this study is un­
clear. Improved sensitivity of Tg assays might come at the expense of a decreased specificity 
(6). Accordingly, other studies evaluating new sensitive Tg assays have reported an increas-
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ing number of patients with low but detectable Tg levels without any demonstrable disease 
(6,7). These low Tg levels can be related to residual thyroid tissue or recurrent thyroid cancer 
which is too small to be imaged. The sensitivity of these modern Tg assays might exceed the 
sensitivity of currently available imaging techniques. Low detectable Tg levels can give rise 
to possibly unnecessary concern and even excessive diagnostic testing (8). Moreover, the 
course of serum Tg levels over time is probably more important than one single serum Tg 
value (9) and this pattern should play a crucial role in clinical decision-making. Therefore, 
follow-up data of these patients are needed to interpret the value of these low Tg levels and 
determine accurate Tg cut-off levels which warrant further diagnostic testing (6). 
Another explanation for these elevated Tg levels can be the presence ofheterophilic an­
tibodies (HAMA) or of other, non-specific antibodies. Interference of HAMA's in immuno­
metric assays usually leads to false positive results in the absence of Tg, or if Tg is present to 
a false elevation in the measured Tg level. Rarely, HAMA's can also lead to false negative or 
falsely low results (8). Both interference from HAMA's as well as from Tg antibodies (TgAb) 
are major methodological problems ofTg measurement. In chapter 3, methods to detect this 
interference are studied. 
Interference by thyroglobulin antibodies in thyroglobulin measurement 
The reported prevalence of TgAb in DTC patients ranges from 10%-25% (10,11). TgAb can 
cause under- or overestimation of Tg level depending on the Tg assay format (12,13). There­
fore, all sera sent for Tg measurement require adjunctive Tgab testing (14). Tg is not reliable 
in TgAb positive sera. Available methods for assessing TgAb interference are quantitative 
TgAb measurement by TgAb immunoassays and Tg recovery (TgR) testing. The discordance 
between Tg measurements made by a radioimmunoassay (RIA) versus an immunometric 
assays (IMA) is generally considered the methodological benchmark for interference by 
TgAb. But this is impractical because few RIA's are available (15) and radioimmunoassays 
are time-consuming. 
Data about the clinical utility of methods for detecting Tg interference are presented 
in chapter 3. We used two quantitative TgAb assays (TgAb-ICMA and TgAb-microparticle 
enzyme immunoassay (TgAb-MEIA)) and a new Tg-ICMA with TgR (Nichols Advantage•) 
in 127 patients who were followed for DTC. Tg-RIA was used in a limited number of sam­
ples. We provided evidence that TgR testing has value complementary to that of quantitative 
TgAb measurement in the detection of interference in Tg measurement. Particularly in sera 
with low TgAb titers, TgR showed to be helpful. Normal TgR can mean the preservation of 
Tg as tumor marker in the follow-up of these patients. Additionally, in one patient overre­
covery indicated the presence of falsely increased Tg level by HAMA. This was confirmed by 
undetectable Tg by RIA and IRMA (immunoradiometric assay). 
Our results are in contrast with earlier studies, reporting that TgR testing failed to differ­
entiate TgAb-positive and - negative sera and is consequently unreliable (11,16). Therefore, 
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our favorable results observed with the Nichols Advantage TgR assay cannot be transposed 
to other TgR assays. Further studies are needed to confirm the potential added value of TgR 
assays. Unfortunately, discontinuation of Nichols Institute Diagnostics impedes further re­
search to confirm the potential added value of this specific TgR assay. 
From a methodological point of view, the recovery method is an elegant method to as­
sess the extent to which detection of endogenous Tg is blocked by interfering TgAb. In the 
presence of TgAb measured by a quantitative TgAb assay, the recovery result can indicate if 
Tg measurement interference is actually present. Benefit of a quantitative TgAb immunoas­
say is the possibility to use serial TgAb measurement as surrogate tumor marker. Several 
studies have shown that persistently elevated TgAb level may indicate the presence of recur­
rent disease (10,17,18,). Therefore, TgR and quantitative TgAb measurement can be consid­
ered as complementary diagnostic tests. 
RhTSH stimulated Tg measurement in the long-term follow-up of DTC 
Apart from the application of a highly sensitive Tg assay (chapter 2), another method to 
achieve higher sensitivity is measuring Tg during TSH stimulation. TSH promotes Tg syn­
thesis in thyroid cells. TSH stimulation can be achieved by inducing hypothyroidism by 
stopping thyroid hormone suppletion. However, thyroid hormone withdrawal induces sev­
eral complaints like fatigue, cold intolerance, dry skin and weight gain, and results in a 
significant decline in quality oflife (19,20). In 1998, recombinant human TSH (rhTSH) was 
introduced as a practical tool during follow-up to achieve TSH stimulation for Tg measure­
ment and radioiodine scanning without thyroid hormone withdrawal (21-23). A rhTSH 
procedure consists of an intramuscular rhTSH injection on day 1 and day 2. Tg levels are 
subsequently measured on day 5. 
Diagnostic value of a sensitive Tg assay and RhTSH stimulated Tg measurement 
Recommended strategies in the follow-up of DTC patients have been presented in interna­
tional guidelines (24,25). The first evaluation will take place 6-12 months after thyroidectomy 
and radioiodine ablation in low-risk patients, and should consist of (rh)TSH stimulated Tg 
measurement and ultrasound of the neck (US). During the long-term follow-up, Tg is tra­
ditionally measured during thyroid hormone suppression therapy (Tg-on). The timing or 
necessity of subsequent (rh)TSH stimulated Tg measurement was uncertain (24,25); Tg-on 
measurement may fail to identify patients with relative small amounts of residual tumor. 
It was especially questioned whether the recently developed highly sensitive Tg assays 
could eliminate the need for rhTSH stimulation (26,27). In chapter 4 we demonstrate that 
the use of a sensitive Tg assay has additional diagnostic yield over a conventional assay in 
the detection of recurrent disease in long-term follow-up for DTC and practically obviates 
the need for testing after rhTSH stimulation. In this prospective study, 121 clinically disease 
free patients were included. Sensitive Tg measurement in patients on suppression therapy 
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resulted in three patients with Tg � 1.0 ng/ml and recurrence could be localized in two of 
them (neck lesion and mediastinal/paravertebral lesion). RhTSH stimulated Tg measure­
ment resulted in an additional 17 of 118 patients with a Tg concentration above our estab­
lished cut-off level of � 1.0 ng/ml, and therefore were suspected for having recurrent disease. 
However, in only one patient subsequent imaging resulted in the localization of recurrent 
disease (supraclavicular lesion). We have followed the other 16 patients for four additional 
years, but no recurrence was found. In conclusion, the additional yield of rhTSH stimulated 
Tg measurement was one additional patient found to have a localized recurrence. We con­
sider this too low to justify rhTSH stimulation in all patients during long-term follow-up, 
even more because it is conceivable that this patient anyhow would have been identified with 
regular serial Tg-on measurement with a sensitive Tg assay. Meanwhile, other studies, which 
were mainly retrospective evaluations, have confirmed the limited value of periodic rhTSH 
stimulated Tg measurement in long-term follow-up (28-30). 
Follow-up strategies for DTC are determined according to the initially assessed risk of 
recurrence. It has been suggested that rhTSH stimulated Tg measurement is unnecessary in 
low-risk patients but might be useful in high-risk patients (30). This discussion is compli­
cated because multiple schemes for risk stratification are in use with different definitions of 
low and high-risk. Moreover the established risk factors and staging systems often fail in 
predicting who will develop a recurrence or die of tumor, and still also patients in the lowest 
risk group die of thyroid cancer (31,32). Part of this failure is explained by the absence of "the 
response to initial therapy" as a prognostic factor in staging systems (33,34), which seems 
contra-intuitive and confirms the limitations of staging systems. In our study we therefore 
disregarded classification into low- and high-risk subgroups and included patients regard­
less of risk of recurrence or follow-up duration. By doing so, this study population consisted 
of a mixture of low- and high-risk patients, reflecting the variety of patients in follow-up 
for DTC in daily clinical practice. Recurrence was found by using the sensitive Tg assay in 
one low- and one high-risk patient (35), one additional recurrence in a low-risk patient was 
found by using rhTSH stimulated Tg measurement. Consequently, we conclude that for both 
low- and high- risk patients the added diagnostic value of rhTSH stimulated Tg measure­
ment is minimal and long-term follow-up should be based on serial Tg-on measurement 
with a sensitive Tg assay. Currently, most authors (30,36,37) conclude that periodic Tg test­
ing after TSH stimulation is needed in high-risk patients, although the evidence supporting 
this recommendation is very limited and well-conducted prospective studies are lacking. 
There is an urgent need for more research to develop true evidence-based follow-up guide­
lines, tailored according to the risk at recurrence. 
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Impact of the use of rhTSH stimulated Tg measurement on quality of life. 
Traditionally, primary outcome measures in cancer care are survival and disease free sur­
vival. Consequently in the follow-up of cancer, the sensitivity and specificity of monitoring 
methods for detection of recurrent disease are considered of central importance. 
But there has been growing recognition that patient-reported outcome measures, in 
particular measures of quality of life (QOL) convey important additional information in 
cancer care. Since patient with DTC are submitted to lifelong follow-up, careful consider­
ation of the impact of monitoring methods on QOL is essential. Unfortunately, very little 
is known about the influence of follow-up testing on quality of life of DTC patients. New 
monitoring methods are often introduced without evaluating the associated patient burden 
when using these tests. 
Therefore, we examined the impact of the rhTSH stimulation procedure and the subse­
quent additional diagnostic tests on psychological distress, anxiety and cancer worries. The 
results have been presented in chapter 5, and clearly demonstrate that the rhTSH stimulation 
procedure has a significant negative impact on psychological health in those patients who 
turn out to have an increased Tg level, and will undergo additional diagnostic investiga­
tions. As expected, these patients showed a temporary increase in psychological distress and 
higher level of anxiety compared to baseline and Tg negative patients. Moreover, worries 
about thyroid cancer increased after the procedure. These cancer worries remained higher 
compared with Tg negative patients after being informed about imaging results, although 
the majority of these Tg positive patients (85%) had favorable imaging results and no recur­
rence could be localized. 
Since the use of rhTSH resulted in a positive rhTSH-Tg test but no localized recurrence 
in 13% of all participants, prevailing cancer worries will be an important adverse psycho­
logical consequence in a substantial amount of patients. This is even more serious, knowing 
that after four years follow-up in none of these patients clinical evidence for recurrence was 
found. 
This is the first study evaluating the influence of the rhTSH procedure on QOL in the 
follow-up of DTC. The demonstrated unfavorable effect on psychological health should be 
an important issue in the evaluation of the use of rhTSH. Moreover, with the ongoing de­
velopment of laboratory measurements and imaging techniques as monitoring methods for 
DTC, increasing awareness is needed for the impact of their use on QOL. 
Cost-effectiveness of rhTSH stimulated Tg measurement 
As the follow-up of DTC is lifelong and the estimated prevalence of DTC worldwide is 
475.200, considerable medical costs are generated (38). With restricted health care resources, 
evaluating costs and effects of a monitoring method in this follow-up is crucial. In chapter 6, 
the cost-effectiveness of the rhTSH procedure and of Tg measurement during thyroid hor­
mone suppression therapy (Tg-on) are compared. As mentioned earlier, the extra procedure 
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resulted in the detection of one additional patient with localized recurrent disease. The cost­
effectiveness ratio was €192.961, which means that an extra €192.961 had to be invested with 
the rhTSH protocol to detect one additional patient with localized recurrence compared to 
the Tg-on protocol. These high costs were due to the expensive injection in itself (€1232) and 
secondly due to the large amount of additional diagnostic procedures which were required 
to establish the location of the recurrence and treat it with radioactive iodine. In the study 
protocol (see chapter 4), the Tg cut-off value (LO ng/ml) for addition imaging was stringent 
and extensive imaging (neck ultrasound, 150 mCurie radioionine treatment + posttherapy 
I-131 whole body scan, FDG-PET, on indication: CT/MRI/ octrotide scan) was performed. 
Even if we increased our Tg cut-off value (2.0 ng/ml) and used limited imaging (neck 
ultrasound, 150 mCurie radioionine treatment + posttherapy 1-131 whole body scan), the 
costs to detect one additional patient by using rhTSH were still very high (€151.226). The 
unfavorable cost-effectiveness ratio, in addition to the limited diagnostic yield (chapter 4) 
and negative influence on QOL (chapter 5) precludes the use of rhTSH stimulated Tg mea­
surement in the long-term follow-up ofDTC. 
Embolization of bone metastases from differentiated thyroid cancer 
As previously mentioned, generally differentiated thyroid cancer, carries an excellent prog­
nosis. However, patients with persistent disease have a life expectancy of approximately 60% 
of the residual life span (2). In these patients, therapy is aimed at the improvement of survival 
and quality of life. In DTC patients with bone metastases, selective embolization therapy is 
one of the treatment options. In chapter 7, we evaluated the effect of selective embolization 
therapy on life expectancy, symptoms and serum thyroglobulin level in 13 DTC patients (31 
embolization sessions) . Embolization therapy could achieve palliation of pain, reduction 
of neurological symptoms and reduction of tumor burden (based on decreasing Tg levels). 
Survival time was not influenced by embolization therapy. Considering the relatively long 
survival of patients with metastatic DTC, this achieved improvement of quality of life is an 
important result. 
FUTURE PERSPECTIVES 
Differentiated thyroid carcinoma is a relatively rare disease with a prolonged course, conse­
quently prospective randomized clinical trials of treatment and follow-up methods of DTC 
are lacking (3). However, the excellent prognosis in most patients and lifelong follow-up 
implies a large number of patients in follow-up for DTC worldwide. Therefore, any changes 
in follow-up schedules and procedures may have a major human and economic impact . A 
lot of effort is put in the development of diagnostic methods for earlier identification of 
patients with recurrent DTC. However, DTC is a relatively benign disease with generally 
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a slow course and there is no evidence to support that earlier identification and interven­
tion in these patients ultimately will affect mortality (39). This is important to realize, since 
monitoring patients is not always harmless. As presented in this thesis, rhTSH stimulated 
Tg measurement seriously affected the psychological well-being in a significant amount of 
Tg positive patients in whom ultimately no recurrence was found. Likewise, this is a poten­
tial drawback of the new highly sensitive Tg assays. We might uncover minimal disease in 
patients who will never develop clinically significant disease. Appropriate use of monitoring 
methods, on the right moment, in the right patients is essential. The focus in the follow-up 
of DTC should not be on finding occult disease but on identifying patients in whom DTC 
likely shorten their lives (40). The advent of the previously mentioned highly sensitive Tg 
assays is one of the major developments in the follow-up care of DTC patients. As shown 
in chapter 4, the introduction of a sensitive chemiluminiscence immunoassay can result in 
the earlier detection of patients with recurrence, who were not yet identified using a con­
ventional Tg assay. The current drawback of these assays is the detection of low levels of Tg 
in a substantial amount of patients, who have no demonstrable disease activity by imaging. 
Follow-up studies of these assays are needed to determine the significance of these low Tg 
levels. Subsequently, Tg cut-off levels for diagnostic testing should be established to avoid 
unnecessary diagnostic testing and treatment. Moreover, in cases of only slightly elevated 
Tg, the strongest indication for recurrence is still an increasing serum Tg level within the 
same patient rather than a single value (41). Therefore, the slope of serum Tg levels should 
play in important role in clinical decision making. This will warrant the appropriate use of 
these highly sensitive assays, attributing to an optimal follow-up of DTC patients. 
Despite the introduction of the CRM-457 reference preparation (42,43), the variability 
of results using differing Tg assays remains substantially and can differ by a factor three to 
four (44). Future development of harmonization samples is needed to reduce this interassay 
variability (44). Moreover, wide interassay variation limits the applicability of absolute Tg 
cut-off levels mentioned in guidelines for the follow-up of DTC (25,36,45). Therefore, insti­
tutional Tg cut-off values should be defined (44,46). 
TgAb interference is another important methodological problem of Tg measurement. 
Unfortunately, the new Tg assays are still hampered by TgAb interference, rendering Tg 
measurement unreliable for follow-up in patients with TgAb. Presumably, Tg assays with­
out any TgAb interference will not be available in the near future. Therefore, the attention 
should be focused on the development of reliable methods to detect TgAb interference. In 
the future, simultaneously use of Tg recovery testing and quantitative TgAb measurement 
might be the best approach for the accurate detection of interference in Tg measurement. 
Unfortunately, the TgR assay evaluated in this thesis is not available anymore and few new 
TgR methods are developed. In view of the presented favorable results, the value of TgR 
should be reconsidered. Development of accurate TgR assays will simplify the follow-up 
management of TgAb positive patients. Additionally, the value of TgAb levels as surrogate 
1 18 
SUMMARY, GENERAL DISCUSSION AND FUTURE PERSPECTIVES 
marker of disease activity in TgAb positive patients should be explored in depth. An increas­
ing level of TgAb might reflect enhanced presentation of thyroid tumor antigens to the im­
mune system (11). Long-term prospective follow-up studies evaluating the use of serial TgAb 
measurement in DTC patients are needed to confirm this hypothesis. 
Considering the described complexity of the measurement of Tg and TgAb interference, 
centralization of these analyses to centers with the necessary expertise is preferable. Cen­
tralization oflaboratory testing will make it possible to establish Tg cut-off values, generally 
applicable to all DTC patients treated in the affiliated hospitals. 
Recombinant human TSH (rhTSH) was introduced as a practical tool in the follow­
up of DTC to enhance TSH stimulation for Tg measurement and diagnostic radioiodine 
whole body scans (dWBS) without the need for thyroid hormone withdrawal. Nevertheless, 
the need for rhTSH stimulated Tg measurement in the long-term follow-up can be ques­
tioned, as demonstrated in this thesis and by other studies (28-30). Additionally, the sen­
sitivity of dWBS has shown to be low and is nowadays often omitted in follow-up (47,48). 
Consequently, the value of rhTSH for Tg measurement in long-term follow-up and diagnos­
tic radioiodine whole body scans is limited. However, promising applications of rhTSH are 
rhTSH aided FDG-PET and radioiodine ablation therapy. RhTSH is definitely valuable in 
preserving quality of life as opposed to thyroid hormone withdrawal, so potential indica­
tions deserve careful exploration. 
Follow-up strategies for low-risk DTC patients (70-85% of the DTC patients) are well­
defined. It is generally accepted that high-risk patients need more intensive follow-up but 
clear evidence based follow-up strategies for these patients are lacking. Moreover, current 
staging systems are not always correctly predicting outcome. Restaging of patients on the 
basis of the response to initial therapy, referred to as ongoing risk assessment, will result in 
a more correct prediction of the risk of recurrence (34). Additionally, molecular character­
ization may be useful in risk stratification. In the last decades there has been a significant 
improvement in the knowledge of molecular alterations involved in DTC. Molecular char­
acterization of aggressive versus non-aggressive DTC may be a valuable tool to individualize 
treatment and follow-up. In the future, ongoing risk assessment and molecular characteriza­
tion of DTC should be used for the development of more accurate risk staging systems. This 
will result in follow-up protocols tailored to the individual risk at recurrence. 
A minority of patients experience progressive life threatening growth and metastatic 
spread of DTC. Local treatment options, as embolization of bone metastases, are valuable 
in reducing symptoms. Unfortunately, systemic treatment options for advanced radioiodine 
resistant DTC to improve survival are limited. Results of chemotherapy are disappointing 
until now. However, recent advances in molecular oncology have led to the development of 
promising agents targeting growth factors, intracellular receptor kinases and downstream 
mediators of cell signaling. Some of these novel agents, for example Axitinib and Sorafenib, 
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both tyrosine kinase inhibitors, have yet shown clinically relevant antitumor activity in pa­
tients with metastatic thyroid carcinoma in phase II trials (49,50). 
In conclusion, the follow-up and treatment of differentiated thyroid carcinoma is an 
evolving field. At a time of increased sensitivity of monitoring tests in the follow-up ofDTC, 
identifying patients for whom these tests are clinically beneficial is essential to limit patient 
burden and medical costs. Genotypical characterization might have the potential to tailor 
therapy and follow-up to the individual patient. The results of ongoing clinical trials to as­
sess the clinical value of genetic mutation testing for prognostic stratification and the long­
term efficacy of new therapies, are eagerly awaited. 
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SAMENVATTING EN DISCUSSIE 
Gedifferentieerd schildkliercarcinoom, dat bestaat uit papillair en folliculair schildklier­
carcinoom, heeft over het algemeen een uitstekende prognose. De 10-jaars overleving va­
rieert van 83% tot 98% (1,2). Deze gunstige prognose is een gevolg van de effectieve initiele 
therapie en het, over het algemeen, indolente biologische gedrag van deze tumor. De initiele 
therapie bestaat uit totale thyreoidectomie gevolgd door een behandeling met een hoge dosis 
radioactief jodium om microscopische residuele ziekte dan wel metastasen te elimineren. 
Vervolgens wordt levenslang schildklierhormoon substitutietherapie gegeven. Ondanks 
deze gunstige prognose is het aantal recidieven hoog, tot 20% van de patienten ontwikkelt 
een recidief in de follow-up. Deze recidieven kunnen zelfs 20 jaar na initiele therapie ont­
dekt worden. Daarom wordt levenslange follow-up van patienten met schildkliercarcinoom 
geadviseerd (3,4). 
De follow-up strategie moet in staat zijn patienten met een recidief van gedifferentieerd 
schildkliercarcinoom te identificeren. Hierbij moet echter wel een juiste balans zijn tussen 
de diagnostische opbrengst van de onderzoeksmethoden, de belasting voor de patient en de 
medische kosten. In de voorgaande hoofdstukken zijn verschillende aspecten betreffende de 
follow-up van gedifferentieerd schildkliercarcinoom onderzocht, om hiermee een bijdrage 
te leveren aan de ontwikkeling van een optimale follow-up strategie. De resultaten van deze 
studies worden samengevat en besproken in de volgende paragrafen. 
Thyreoglobuline meting 
Het bepalen van het thyreoglobuline (Tg) speelt een centrale rol in de follow-up van ge­
differentieerd schildkliercarcinoom. Tg is een groot en heterogeen glycoprote:ine en wordt 
geproduceerd door epitheliale cellen in de schildklier en client als een matrixeiwit voor de 
schildklierhormoonsynthese. Tg kan als een tumormerkstof worden gebruikt omdat schild­
kliercellen de enige bron van Tg in het menselijk lichaam zijn (5). Hierdoor wijst de aan­
wezigheid van Tg, na thyreoidectomie en hoge dosis radioactief jodium therapie, op ach­
tergebleven functionerend schildklierweefsel dan wel recidief / persisterende ziekte. De Tg 
bepaling moet sensitief, accuraat en precies zijn. Het optimaliseren van de sensitiviteit is een 
van de belangrijke aandachtspunten in de ontwikkeling van nieuwe Tg methodes. Ultra­
sensitieve Tg bepalingen kunnen lagere Tg concentraties meten en hierdoor een recidief in 
een vroeger stadium aantonen. 
In hoofdstuk 2 beschrijven we de waarde van een nieuwe ultrasensitieve Tg meting in de 
follow-up van gedifferentieerd schildkliercarcinoom. Analytische eigenschappen van deze 
immunochemiluminometrische meetmethode (ICMA) zijn de hoge sensitiviteit, de volauto­
matische werking en de hoge reproduceerbaarheid. Bij de introductie van deze meetmethode 
in de kliniek, bleek er sprake van een aantoonbaar Tg in 12 van 110 patienten die tevoren een 
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niet aantoonbaar Tg hadden met een conventionele immunoradiometrische meetmethode 
(IRMA). 
Vier van deze 12 patienten hadden klinische aanwijzingen voor een recidief op het 
moment van Tg meting. Deze bevinding ondersteunt de mogelijkheid om met deze meet­
methode eerder een recidief te detecteren. Echter, de betekenis van de lage aantoonbare Tg 
concentraties in de resterende acht patienten in deze studie is nog niet duidelijk. De verbe­
terde sensitiviteit van Tg bepalingen zou ten koste kunnen gaan van de specificiteit (6). In 
overeenkomst met deze studie, rapporteerden ook andere studies die nieuwe sensitieve Tg 
meetmethoden evalueerden een groot aantal patienten met lage Tg concentraties zonder 
aantoonbare ziekte (6,7). Deze lage Tg concentraties kunnen duiden op resterend schild­
klierweefsel of een recidief schildkliercarcinoom dat te klein is om afgebeeld te kunnen 
worden. De sensitiviteit van de moderne Tg meetmethodes lijkt de sensitiviteit van de op 
<lit moment beschikbare afbeeldende technieken te overtreffen. Deze lage Tg concentraties 
kunnen aanleiding zijn voor onnodige onrust en overmatige diagnostiek bij deze patienten 
(8). Bovendien is het beloop van de serum Tg waarde in de tijd belangrijker dan een indivi­
duele Tg waarde en moet dit een cruciale rol spelen in klinische beslissingen. Follow-up data 
van de patienten met lage Tg concentraties zonder klinische aanwijzingen voor een recidief 
zijn nodig om de waarde van deze lage Tg concentraties te bepalen en om een accurate Tg 
afkapwaarde vast te stellen waarboven aanvullend onderzoek zinvol is ( 6). 
De aanwezigheid van heterofiele antilichamen (HAMA) of andere niet-specifieke anti­
lichamen kan ook een verklaring zijn voor een aantoonbaar Tg. Interferentie van HAMA's 
in immunometrische meetmethodes leidt over het algemeen tot foutpositieve resultaten als 
er geen Tg aanwezig is, of een foutieve verhoging van de gemeten Tg concentratie als er Tg 
aanwezig is. In zeldzame gevallen kunnen HAMA's ook leiden tot foutnegatieve of foutief 
verlaagde resultaten (8). De interferentie van HAMA's en ook aanwezigheid van Tg antistof­
fen (TgAb) zijn belangrijke methodologische problemen bij Tg metingen. In hoofdstuk 3 
worden methodes om deze interferentie te detecteren beschreven. 
Interferentie door thyreoglobuline antilichamen in de thyreoglobuline meting 
De prevalentie van thyreoglobuline antistoffen (TgAb) varieert tussen de 10% en 25% (10,11). 
Deze TgAb kunnen onder- of overschatting van de Tg concentratie veroorzaken, afhanke­
lijk van de gebruikte Tg methode (12,13). Elke Tg meting moet dan ook gepaard gaan met 
een TgAb meting (14) aangezien een Tg uitslag bij een patient met TgAb onbetrouwbaar 
is. Beschikbare methodes voor het bepalen van TgAb interferentie zijn kwantitatieve TgAb 
metingen met behulp van TgAb immunoassays en Tg recovery (TgR) metingen. Bij de Tg 
recovery (Tg terugvindingsmethode) wordt een monster verrijkt met exogeen Tg. Na meting 
van het basale en verrijkte monster kan berekend worden wat het percentage teruggevonden 
Tg (recovery) is. Discordantie tussen een Tg meting met een radioimmunoassay (RIA) en Tg 
meting met een immunometrische assay (IMA) wordt beschouwd als de gouden standaard 
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voor TgAb interferentie. Echter, Tg RIA's zijn tijdrovend en beperkt beschikbaar (15) en 
daarom niet praktisch in gebruik. 
In hoofdstuk 3 worden data over de klinische toepasbaarheid van verschillende metho­
des voor detectie van TgAb interferentie besproken. Twee kwantitatieve TgAb bepalingen 
(TgAb-ICMA en TgAb-microparticle enzyme immunoassay (TgAb-MEIA)) en een nieuwe 
Tg-ICMA bepaling met TgR (Nichols Advantage•) werden gebruikt bij 127 patienten in fol­
low-up voor gedifferentieerd schildkliercarcinoom. De Tg-RIA bepaling werd in een beperkt 
aantal monsters gebruikt omdat deze methode niet bei:nvloed lijkt te worden door TgAb. 
De TgR meting bleek aanvullende waarde te hebben naast kwantitatieve TgAb meting bij 
de detectie van interferentie in de Tg meting. De TgR meting was voornamelijk bijdragend 
in sera met lage TgAb titers. Indien de TgR normaal is, blijft de Tg concentratie bruikbaar 
als tumormerkstof in de follow-up van deze patienten. Een sterk verhoogde recovery uitslag 
wees op een vals verhoogde Tg concentratie door HAMA's. Een onmeetbaar Tg in de RIA en 
IRMA (immunoradiometric assay) bevestigde dit vermoeden. 
Deze resultaten komen niet overeen met eerdere studies, waarin TgR bepalingen TgAb 
positieve en TgAb negatieve sera niet konden onderscheiden en daarom als onbetrouwbaar 
werden beschouwd (11,16). De gunstige resultaten met de Nichols Advantage TgR assay kun­
nen dan ook niet geextrapoleerd worden naar andere TgR bepalingen en verder onderzoek is 
nodig om de toegevoegde waarde van TgR meting te bevestigen. 
Vanuit een methodologisch oogpunt, is de recovery bepaling een elegante methode om 
interferentie in de Tg meting door TgAb te bepalen. Indien een kwantitatieve TgAb bepaling 
TgAb heeft aangetoond, kan de TgR assay aangeven of er daadwerkelijk sprake is van inter­
ferentie in de Tg meting. Het voordeel van een kwantitatieve TgAb bepaling is de mogelijk­
heid om seriele TgAb metingen te gebruiken als een surrogaat tumormerkstof. Meerdere 
studies hebben aangetoond dat persisterend verhoogde TgAb concentraties kunnen duiden 
op de aanwezigheid van een recidief (10,17,18). TgR en kwantitatieve TgAb metingen dienen 
daarom als beschouwd te worden als complementaire diagnostische testen 
RhTSH gestimuleerde Tg meting in de lange termijn follow-up van gedifferen­
tieerd schildkliercarcinoom 
Naast het gebruik van een ultrasensitieve Tg assay (hoofdstuk 2), kan een Tg meting tijdens 
TSH stimulatie een hogere sensitiviteit geven. TSH stimuleert de synthese van Tg in schild­
kliercellen. TSH stimulatie kan worden bereikt door het induceren van hypothyreoi:die door 
het staken van de schildklierhormoonsuppletie. Echter, hypothyreoi:die geeft klachten van 
vermoeidheid, koude intolerantie, een droge huid, gewichtstoename en een significante da­
ling van de kwaliteit van leven (19,20). In 1998 werd recombinant humaan TSH (rhTSH) 
gei:ntroduceerd als middel om TSH stimulatie te verkrijgen voor Tg metingen en radioac­
tief jodium scans zonder het staken van schildklierhormoon (21-23). De procedure van een 
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rhTSH gestimuleerde Tg meting bestaat uit een intramusculaire rhTSH injectie op dag 1 en 
dag 2, en vervolgens een bepaling van de Tg concentratie op dag 5. 
Diagnostische waarde van een sensitieve Tg assay en rhTSH gestimuleerde Tg 
meting 
In verschillende internationale richtlijnen wordt de follow-up van patienten met gediffe­
rentieerd schildkliercarcinoom beschreven (24,25). De eerste evaluatie vindt bij laag-risico 
patienten 6-12 maanden na thyreoidectomie en ablatie met radioactief jodium plaats en be­
staat uit (rh)TSH gestimuleerd Tg meting en een echografie van de hals. In de lange termijn 
follow-up wordt Tg over het algemeen tijdens schildklierhormoon substitutietherapie (Tg­
on) gemeten. Het moment en de noodzaak van (rh)TSH gestimuleerde Tg metingen in deze 
fase was echter onzeker (24,25); Tg-on meting zou mogelijk patienten met een klein volume 
residuele tumor niet kunnen identificeren. Het was onduidelijk of de recent ontwikkelde 
ultrasensitieve Tg bepalingen het gebruik van rhTSH stimulatie overbodig zouden maken. 
De data gepresenteerd in hoofdstuk 4 tonen de toegevoegde waarde van een ultrasensi­
tieve Tg assay in vergelijking met een conventionele Tg assay, voor de detectie van patienten 
met een recidief in de lange termijn follow-up van gedifferentieerd schildkliercarcinoom. 
Hierbij bleek rhTSH gestimuleerde Tg meting overbodig. In deze prospectieve studie werden 
121 patienten ge:includeerd zonder klinisch aanwijzing voor een recidief. Een sensitieve Tg 
meting tijdens suppressietherapie resulteerde in het aantonen van een Tg � 1.0 ng/ml bij drie 
patienten, bij twee van deze patienten kon een recidief schildkliercarcinoom worden gelo­
kaliseerd ( tumor recidieven in de hals en mediastinaal/paravertebraal). De rhTSH gestimu­
leerde Tg meting in de overige 118 patienten gaf bij 17 extra patienten een Tg � 1.0 ng/ml, 
mogelijk wijzend op een recidief schildkliercarcinoom. Echter, slechts in een een patient 
werd bij aanvullend beeldvormend onderzoek een recidief gelokaliseerd (supraclaviculair). 
De overige 16 patienten zijn inmiddels 4 jaar vervolgd. Bij geen van hen is een recidief ge­
lokaliseerd. Concluderend was de toegevoegde waarde van rhTSH gestimuleerde Tg meting 
de opsporing van een extra patient met een gelokaliseerd recidief. Naar onze mening is deze 
opbrengst te beperkt om rhTSH stimulatie in de gehele groep patienten in follow-up voor ge­
differentieerd schildkliercarcinoom te rechtvaardigen. Zeker aangezien het te verwachten is 
dat een seriele Tg-on meting met een sensitieve Tg assay ook zou hebben geleid tot het vast­
stellen van dit recidief. Intussen hebben andere, voornamelijk retrospectieve studies, even­
eens de beperkte waarde van rhTSH gestimuleerde Tg meting in de lange termijn follow-up 
van gedifferentieerd schildkliercarcinoom laten zien (28-30). 
Bij de plaatsbepaling van rhTSH in de follow-up speelt de initiele risico stratificatie een 
belangrijke rol. De waarde van een rhTSH gestimuleerde Tg meting zou vooral zinvol kun­
nen zijn in bepaalde categorieen hoog-risico patienten (30). Echter het gebruik van multi­
pele risicostratificatie systemen waarin laag-risico en hoog-risico verschillend gedefinieerd 
wordt, maakt deze discussie en de daaraan gekoppelde plaats voor rhTSH in de follow-up 
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zeer gecompliceerd. Bovendien zijn de risicostratificatie systemen die nu gebruikt worden 
slechts beperkt in staat te voorspellen wie een recidief zal ontwikkelen en overlijden ook 
patienten in de laag-risico groep aan schildkliercarcinoom (31,32). Dit wordt deels verklaard 
door de afwezigheid van de «respons op initiele therapie" als prognostische factor in de 
stadiering (33,34). Gezien bovenstaande onduidelijkheden werden in onze studie patienten 
ongeacht hun stadiering of follow-up duur gefocludeerd. Hierdoor bestond de studiepopu­
latie uit zowel laag en hoog-risico patienten, representatief voor de varieteit van patienten in 
follow-up voor gedifferentieerd schildkliercarcinoom in de dagelijkse praktijk. Het gebruik 
van de sensitieve Tg assay resulteerde in de lokalisatie van een recidief in een hoog-risico en 
een laag-risico patient (35), een extra recidief bij een laag-risico patient werd gelokaliseerd 
met behulp van rhTSH. Hieruit kunnen we concluderen dat voor zowel laag als hoog-risico 
patienten de aanvullende waarde van rhTSH gestimuleerde Tg meting minimaal is. De lange 
termijn follow-up zou dan ook gebaseerd moeten zijn op seriele Tg-on meting met een sen­
sitieve Tg bepaling. Echter, op dit moment wordt door meerdere auteurs (30,36,37) TSH 
gestimuleerde Tg meting nodig geacht in hoog-risico patienten. De bewijsvoering hiervoor 
is beperkt en goede prospectieve studies onderbreken. Er is dan ook een dringende behoefte 
aan nieuwe studies om te komen tot wetenschappelijk onderbouwde follow-up richtlijnen 
toegespitst op het recidief risico van de individuele patient. 
Invloed van het gebruik van rhTSH gestimuleerde Tg meting op de kwaliteit 
van leven 
De traditionele primaire uitkomstmaten in de zorg voor patienten met kanker zijn over­
leving en ziektevrije overleving. De sensitiviteit en specificiteit van diagnostische testen voor 
de detectie van een recidief worden dan ook essentieel geacht. Kwaliteit van leven wordt 
echter steeds meer gezien als een belangrijke uitkomstmaat in de oncologische zorg. Aan­
gezien patienten met schildkliercarcinoom levenslang in follow-up blijven is aandacht voor 
de impact van gebruikte diagnostische testen in de follow-up op de kwaliteit van leven van 
groot belang. Helaas is hier weinig over bekend. Nieuwe testen in de follow-up worden vaak 
ge:introduceerd zonder evaluatie van de belasting voor de patient. 
Wij onderzochten de invloed van een rhTSH stimulatie procedure en de hieruit vol­
gende verdere diagnostiek op psychologische distress (psychologische reacties die gepaard 
gaan met negatieve gevoelens als angst en somberheid), angst en zorgen over kanker. De 
resultaten van deze studie, beschreven in hoofdstuk 5, laten een duidelijke negatieve invloed 
zien van de rhTSH stimulatie procedure op de kwaliteit van leven van patienten met een 
aantoonbaar Tg die aanvullend onderzoek moesten ondergaan. Bij deze patienten werd een 
tijdelijke stijging van psychologische distress, angst en zorgen over kanker waargenomen in 
vergelijking met controle groep van patienten die na rhTSH stimulatie geen aantoonbaar Tg 
hadden ( Tg negatieve patienten). Tg positieve patienten hielden na de uitslag van de aanvul­
lende diagnostiek meer zorgen over kanker vergeleken met Tg negatieve patienten, ondanks 
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dat de meerderheid van deze Tg positieve patienten (85%) een gunstige uitslag had en geen 
recidief kon worden aangetoond. 
Het gebruik van rhTSH resulteerde in een positieve rhTSH-Tg test zonder gelokaliseerde 
tumor activiteit bij 13% van de gehele studiepopulatie. Persisterende zorgen over kanker zijn 
dan ook een belangrijk negatief effect. Zeker, wanner na vier follow-up nog steeds bij geen 
van deze patienten klinische aanwijzingen voor een recidief zijn gevonden. 
Dit is de eerste studie waarin de invloed van de rhTSH procedure op de kwaliteit van 
leven van patienten in de follow-up voor gedifferentieerd schildkliercarcinoom is onder­
zocht. De ongunstige invloed op psychische distress, angst en zorgen over kanker dient een 
belangrijke rol te spelen in de evaluatie van het gebruik van rhTSH. De verdere ontwikke­
lingen van laboratorium bepalingen en beeldvormende technieken maken het noodzakelijk 
ook het effect hiervan op de kwaliteit van leven te evalueren. 
Kosteneffectiviteit van rhTSH gestimuleerde Tg meting 
De levenslange follow-up en het grote aantal patienten wereldwijd met gedifferentieerd 
schildkliercarcinoom (geschatte prevalentie 475.200) leiden tot aanzienlijke medische kos­
ten (38). Gezien de sterk stijgende kosten van de gezondheidszorg, is evaluatie van de kos­
teneffectiviteit van diagnostische testen cruciaal. In hoofdstuk 6 wordt de kosteneffectiviteit 
van de Tg meting na rhTSH stimulatie vergeleken met de Tg meting tijdens het gebruik van 
schildklierhormoon substitutietherapie (Tg-on). Zoals beschreven in hoofdstuk 4 heeft het 
gebruik van rhTSH een beperkt resultaat (het leidde slechts tot de opsporing van een extra 
patient met een gelokaliseerd recidief). De kosteneffectiviteitratio was €192.961, dit betekent 
dat met het gebruik van rhTSH €192.961 extra moet worden ge:investeerd om bij een extra 
patient een gelokaliseerd recidief vast te stellen, vergeleken met de Tg-on meting. Deze hoge 
kosten worden verklaard door enerzijds de prijs van de rhTSH injectie (€1232) en anderzijds 
het grote aantal aanvullende onderzoeken (inclusief een behandeling met hoge dosis radio­
actief jodium) dat nodig was om de locatie van het recidief vast te stellen. 
In het studieprotocol (zie hoofdstuk 4) werd een relatieflage Tg afkapwaarde (LO ng/ml) 
voor aanvullend onderzoek gebruikt. Daarnaast was het aanvullend onderzoek uitgebreid, 
bestaande uit een echografie van de hals, behandeling met 150 mCurie radioactief jodium 
gevolgd door een diagnostische posttherapie scan, FDG-PET en op indicatie CT, MRI of een 
octreotide scan. Echter, wanneer een hogere Tg afkapwaarde (2.0 ng/ml) zou worden gebruikt, 
gecombineerd met beperkt aanvullend onderzoek slechts bestaand uit een echografie van de 
hals en een behandeling met 150 mCurie radioactief jodium gevolgd door een diagnostische 
posttherapie scan, dan bleven de kosten nodig om een extra patient met een recidief te vinden 
nog steeds erg hoog (€151.226). De ongunstige kosteneffectiviteitratio, de beperkte diagnos­
tische opbrengst (hoofdstuk 4) en de negatieve invloed op de kwaliteit van leven (hoofdstuk 
5) maken dat er geen plaats is voor routinematig rhTSH gestimuleerde Tg meting in de lange 
termijn follow-up van patienten met gedifferentieerd schildkliercarcinoom. 
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Embolisatie van botmetastasen van gedifferentieerd schildkliercarcinoom 
Zoals eerder genoemd heeft gedifferentieerd schildkliercarcinoom over het algemeen een 
uitstekende prognose. De levensverwachting van patienten met persisterende ziekte is echter 
60% van de oorspronkelijke levensverwachting (2). Behandeling van deze patienten is dan 
ook gericht op verlenging van overleving en kwaliteit van leven. Bij patienten met botmeta­
stasen van gedifferentieerd schildkliercarcinoom behoort selectieve embolisatie van de voe­
dende bloedvaten van een metastase tot de behandelmogelijkheden. In hoofdstuk 7 evalue­
ren we de effecten van selectieve embolisatie therapie op de levensverwachting, symptomen 
en de Tg concentratie van 13 patienten met gedifferentieerd schildkliercarcinoom bij wie 
in totaal 31 embolisatieprocedures werden verricht. De levensverwachting werd vergeleken 
met een historische controle groep patienten met persisterende ziekte dan wel terugkeer van 
schildkliercarcinoom na de initiele behandeling. Embolisatie leidde tot een afname van pijn 
en neurologische symptomen en afname van tumormassa (gebaseerd op een daling van de 
Tg concentratie) maar had geen invloed op de overleving. Gezien de relatieflange overleving 
van patienten met gemetastaseerd gedifferentieerd schildkliercarcinoom is vooral de verbe­
tering van kwaliteit van leven een belangrijk resultaat. 
VOORUITBLIK 
Gedifferentieerd schildkliercarcinoom is een relatief zeldzame aandoening met een langdu­
rig beloop waardoor prospectieve gerandomiseerde klinische onderzoeken gericht op de be­
handeling en follow-up ontbreken (3). Echter, door de over het algemeen uitstekende prog­
nose en de levenslange follow-up zijn er wereldwijd een groot aantal patienten in follow-up 
voor gedifferentieerd schildkliercarcinoom. Een verandering in de follow-up strategie heeft 
dan ook een grote (economische) impact. Er wordt veel energie gestoken in de ontwikkeling 
van diagnostische methoden om patienten met een recidief van gedifferentieerd schildklier­
carcinoom eerder te ontdekken. Echter, gedifferentieerd schildkliercarcinoom heeft over het 
algemeen een traag beloop en er is geen overtuigend bewijs <lat eerdere ontdekking en be­
handeling van een recidief uiteindelijk invloed heeft op de mortaliteit (39). Dit is belangrijk 
om te realiseren omdat intensieve diagnostiek naar een recidief ook negatieve effecten kan 
hebben. Zoals beschreven in dit proefschrift, had het gebruik van een rhTSH gestimuleerde 
Tg meting een negatieve invloed op de kwaliteit van leven van een aanzienlijk aantal Tg po­
sitieve patienten bij wie uiteindelijk geen recidief kon worden gelokaliseerd. Dit is ook een 
potentieel nadeel van de nieuwe ultrasensitieve Tg bepalingen. Het is mogelijk dat met deze 
bepalingen patienten worden gei:dentificeerd met minimale ziekteactiviteit die uiteindelijk 
nooit klinisch manifeste ziekte zullen ontwikkelen. Daarom is het essentieel de beschikbare 
diagnostische middelen op het juiste moment bij de juiste patient te gebruiken. Tijdens de 
follow-up van patienten met een gedifferentieerd schildkliercarcinoom zou de nadruk niet 
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moeten liggen op het vaststellen van occulte ziekte bij patienten, maar op het identificeren 
van die patienten bij wie het gedifferentieerd schildkliercarcinoom zeer waarschijnlijk hun 
levensduur zal bekorten (40). 
De introductie van ultrasensitieve Tg bepalingen is een belangrijke ontwikkeling in de 
follow-up van patienten met gedifferentieerd schildkliercarcinoom. Zoals is beschreven in 
hoofdstuk 4, kan de introductie van een sensitieve chemiluminiscente immunoassay een 
eerdere ontdekking van een recidief tot gevolg hebben, die niet zou zijn gevonden met een 
conventionele Tg bepaling. De beperking van deze ultrasensitieve bepalingen is het aan­
tonen van lage Tg concentraties bij een relatief grote groep patienten bij wie geen recidief 
kan worden gelokaliseerd bij aanvullend onderzoek. Studies waarin patienten met een net 
aantoonbaar Tg met een ultrasensitieve Tg bepaling langdurig worden vervolgd zijn nodig 
om de betekenis van deze lage Tg concentraties te kunnen vaststellen. Ook zullen nieuwe Tg 
afkapwaardes voor aanvullende diagnostiek moeten worden vastgesteld om daarmee over­
bodige diagnostiek te voorkomen. Een stijgende Tg concentratie is een veel sterkere aanwij­
zing voor een recidief, dan een (licht) verhoogde Tg concentratie die bij een enkele meting 
wordt vastgesteld. Het beloop van de Tg concentratie in de tijd dient dan ook een belangrijke 
rol te spelen bij klinische beslissingen. Alleen met deze voorwaarden kunnen ultrasensitieve 
Tg bepalingen bijdragen aan een optimale follow-up van patienten met een gedifferentieerd 
schildkliercarcinoom. 
Ondanks de introductie van het CRM-457 standaard preparaat (42,43) blijft er een aan­
zienlijke variatie bestaan in Tg waarden van verschillende Tg bepalingen tot wel een factor 
drie tot vier (44). Een verdere ontwikkeling van een harmonisatiemonster is nodig om deze 
interassay variabiliteit te beperken (44). Door de grote interassay variabiliteit is de bruik­
baarheid van absolute Tg afkapwaardes die genoemd worden in richtlijnen voor de follow-up 
van gedifferentieerd schildkliercarcinoom beperkt en zal ieder instituut eigen Tg afkapwaar­
des moeten definieren (44,46). 
TgAb interferentie is een ander belangrijk methodologisch probleem bij de meting van 
Tg. Ook de nieuwe Tg bepalingen worden helaas gehinderd door TgAb interferentie waar­
door Tg metingen onbetrouwbaar zijn indien TgAb aanwezig zijn. Het is onwaarschijnlijk 
dat in de nabije toekomst Tg bepalingen beschikbaar komen die geen interferentie van TgAb 
ondervinden. Daarom moet de aandacht vooral worden gericht op de ontwikkeling van 
methodes die accuraat TgAb interferentie kunnen detecteren. In de toekomst is mogelijk ge­
lijktijdig gebruik van Tg recovery en kwantitatieve TgAb meting hiervoor de beste methode. 
Helaas is de in dit proefschrift onderzochte TgR bepaling niet meer beschikbaar en worden 
er weinig nieuwe TgR methodes ontwikkeld. Maar gezien de getoonde gunstige resultaten 
in dit proefschrift verdient de TgR bepaling hernieuwde aandacht. De ontwikkeling van 
accurate TgR bepalingen zal de follow-up van TgAb positieve patienten vereenvoudigen. 
Daarnaast zal de waarde van TgAb concentraties als surrogaat maat voor ziekteactiviteit bij 
TgAb positieve patienten verder onderzocht moeten worden. Een stijgende TgAb concentra-
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tie zou kunnen wijzen op een toegenomen presentatie van schildkliertumor antigenen aan 
het immuunsysteem (11). Om deze hypothese te bevestigen zijn langdurige follow-up stu­
dies nodig waarin het gebruik van seriele TgAb metingen in patienten met gedifferentieerd 
schildkliercarcinoom wordt geevalueerd. 
Gezien de complexiteit van de meting van Tg en TgAb interferentie is centralisatie van 
deze bepalingen in centra met de noodzakelijke expertise aan te bevelen. Een centralisatie 
maakt het eveneens mogelijk om Tg afkapwaardes vast te stellen voor alle patienten met ge­
differentieerd schildkliercarcinoom die vervolgd worden in de geaffilieerde ziekenhuizen. 
RhTSH is gei:ntroduceerd als praktisch hulpmiddel in de follow-up om TSH stimulatie 
te bereiken zonder het onttrekken van schildklierhormoon, voor Tg metingen en diagnosti­
sche radioactief jodiumscans. Echter, zoals aangetoond in dit proefschrift en ook in andere 
studies (28-30), is de rhTSH gestimuleerde Tg meting in de lange termijn follow-up niet 
bijdragend. Daarnaast is de sensitiviteit van de diagnostische jodiumscans laag en worden 
deze tegenwoordig steeds minder gebruikt tijdens de follow-up (47,48). Dit betekent dan 
ook dat de waarde van rhTSH voor de Tg bepaling en diagnostische jodiumscan in de lange 
termijn follow-up beperkt is. Echter, veelbelovende toepassingen van rhTSH zijn het gebruik 
bij de FDG-PET scan en de ablatietherapie met radioactief jodium. Omdat rhTSH in verge­
lijking met het onttrekken van schildklierhormoon gunstig is voor de kwaliteit van leven 
van schildkliercarcinoompatienten, verdienen deze potentiele toepassingen een zorgvuldige 
beoordeling. 
De follow-up van laag-risico schildkliercarcinoompatienten (70-85% van de gehele groep 
schildkliercarcinoompatienten) is goed gedefinieerd. Algemeen wordt aangenomen dat 
hoog-risico patienten intensiever vervolgd moeten worden, maar een wetenschappelijk on­
derbouwd follow-up protocol voor deze patientengroep ontbreekt. Bovendien voorspellen 
de huidige risicostratificatiesystemen niet altijd juist de uiteindelijke uitkomst. Het hersta­
dieren van patienten op basis van de respons op initiele therapie zou kunnen bijdragen aan 
een betere voorspelling van de kans op een recidief en overlijden (34). Daarnaast kan het 
karakteriseren van schildkliertumoren met nieuwe moleculaire technieken een belangrijke 
bijdrage leveren aan risicostratificatie. In de laatste decennia is er een enorme vooruitgang 
geboekt in de kennis op het gebied van moleculaire veranderingen betrokken bij het ontstaan 
van gedifferentieerd schildkliercarcinoom. Het vaststellen van moleculaire eigenschappen 
van agressieve en niet-agressieve gedifferentieerde schildkliercarcinomen zal in de toekomst 
dan ook gebruikt kunnen worden voor een meer accurate risicostratificatie. Daarmee kan 
het follow-up protocol aangepast worden op de individuele patient met betrekking tot het 
risico op een recidief. 
Een kleine groep patienten heeft een progressief gedifferentieerd schildkliercarcinoom 
dat tot de dood leidt. Lokale behandelmogelijkheden, zoals embolisatie van botmetasta­
sen, zijn van belang voor het verminderen van klachten. Helaas zijn systemische behandel­
mogelijkheden voor patienten met een gemetastaseerd schildkliercarcinoom dat geen ra-
136 
SAMENVATTING, DISCUSSIE EN VOORUITBLIK 
dioactief jodium opneemt beperkt. De resultaten van chemotherapie zijn op dit moment 
teleurstellend. Recente ontwikkelingen in de moleculaire oncologie hebben echter geleid tot 
de ontwikkeling van veelbelovende middelen gericht op groeifactoren, intracellulaire re­
ceptor kinasen en "downstream" mediatoren van celsignalering. Enkele van deze nieuwe 
middelen, bijvoorbeeld Axitinib en Sorafenib, allebei tyrosine kinase remmers, hebben in 
fase II onderzoeken klinisch relevante antitumor activiteit bij patienten met gemetastaseerd 
schildkliercarcinoom (49,50). 
Concluderend is de follow-up en behandeling van gedifferentieerd schildkliercarcinoom 
sterk in ontwikkeling. De sterk verbeterde sensitiviteit van de diagnostiek in de follow-up 
van patienten met een gedifferentieerd schildkliercarcinoom maakt het noodzakelijk om die 
groep patienten te identificeren voor wie de toepassing van deze diagnostiek daadwerkelijk 
klinisch belang heeft, om zo de belasting voor patienten en de kosten te beperken. Er wordt 
uitgezien naar nieuwe ontwikkelingen op het gebied van de moleculaire biologie die een 
bijdrage kunnen leveren aan zowel de risicostratificatie als nieuwe behandelmogelijkheden. 
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kritische houding waarmee je een grote bijdrage aan dit proefschrift hebt geleverd. Dank dat 
je me altijd het gevoel hebt gegeven dat het goed kwam. 
Mijn andere onmisbare copromotor, Dr. W.J. Sluiter. Beste Wim, bij methodologische of 
statistische obstakels deed een bezoek aan jou altijd weer wonderen. Dank voor deze on­
dersteuning maar meer nog voor je nuchtere en verhelderende kijk op de wetenschap en het 
leven. 
Dr. J.M.W. van den Ouweland. Beste Jody, je bent de motor geweest achter twee belangrijke 
artikelen in dit proefschrift. Veel dank dat je als toegewijde en deskundige klinisch chemi­
cus een onmisbare schakel in dit proefschrift hebt willen zijn. "De aanhouder wint,, was een 
terugkerend motto binnen onze samenwerking en heeft uiteindelijk tot mooie resultaten 
geleid. Samenwerken met jou was een genot. 
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De medewerking van zeer veel mensen is essentieel geweest voor het slagen van de "rhTSH­
studie". Grote dank gaat allereerst uit naar alle patienten die hebben deelgenomen aan deze 
studie. Zonder hen was dit proefschrift nooit tot stand gekomen. 
Voor een goede organisatie van de studie en registratie van studieresultaten kreeg ik voor­
treffelijke steun van Baukje Fokkens en Inge Pop. Met grote zorgvuldigheid hebben jullie 
monnikenwerk verricht, tevens brachten jullie veel gezelligheid in de Triadekamer. Dank je 
wel! Ook het secretariaat en de poli endocrinologie wil ik bedanken voor hun ondersteuning 
bij de studies en al die andere soms kleine dingen die een groot verschil maken. 
Rita van Slooten heeft tevens met grote zorg en toewijding gewerkt aan de onderzoeks­
registratie, helaas hebben wij veel te vroeg afscheid van haar moeten nemen. 
De afdeling Nucleaire geneeskunde, waarbij ik Ha Phan en Adrienne Brouwers in het bijzon­
der wil noemen, dank ik voor hun grote inzet voor de nucleaire beeldvorming en de zeer ple­
zierige samenwerking. Ook dank aan het PET-centrum, de afdeling Radiologie (echografie) 
en Joost Gravendeel voor hun bijdrage aan het slagen van de beeldvormende diagnostiek in 
deze studie. John Plukker bedank ik voor zijn bijdrage vanuit de chirurgie. 
Zorg voor de kwaliteit van leven van patienten houdt mij dagelijks bezig, maar een kwa­
liteit van leven-studie uitvoeren is niet altijd eenvoudig voor een medicus. Prof. dr. A.V. Ran­
chor (N oordelijk Centrum voor Gezondheidsvraagstukken) en dr. Keers, beste A deli ta en 
Joost, dank voor het geven van jullie waardevolle visie vanuit de psychologie op de resultaten 
van deze studie. 
Veel dank hen ik ook verschuldigd aan dr. H. Groen (Afdeling Epidemiologie) voor zijn 
hulp bij het opzetten van de kosteneffectiviteitsanalyse en dr. K.M. Vermeulen (Afdeling Epi­
demiologie). Beste Karin, je hebt me elke keer weer verbaasd hoe verbluffend snel je onze 
studieresultaten doorzag. Dank voor de zeer prettige samenwerking. 
Alle stafleden van de afdeling Endocrinologie wil ik hartelijk bedanken voor hun inte­
resse, hulp en de goede werksfeer. 
Margriet de Vries, jouw enthousiasme en doorzettingsvermogen hebben geleid tot een mooi 
artikel. Dank daarvoor. Juergen Wilde, Eduard Heine en Jan Koerts wil ik bedanken voor 
hun (praktische) bijdrage aan de evaluatie van de thyreoglobuline assay. 
De leden van de beoordelingscommissie Prof. dr. LP. Kema, Prof. dr. J.W.A. Smit en Prof. dr. 
E.G.E. de Vries wil ik hartelijk bedanken voor hun bereidheid dit proefschrift te beoordelen. 
Op de Triadekamer heb ik vele vermakelijke uren doorgebracht met Helen Lutgers, Martine 
v.d. Hem, Rindert de Vries, Susan Borggreve en Udo Mulder. Dank je wel voor deze fantasti­
sche tijd samen. Susan, Rindert en Udo waren de mede-onderzoekers van het eerste uur. 
WOORD VAN DANK 
Susan, jouw eigenheid is je grote kracht en maakte onze tijd samen op de Triadekamer 
tot een kleurrijke periode. 
Rindert, ik vind het een eer om aan je zijde te mogen staan als paranimf. Het is een 
kroon op een goede vriendschap. 
Udo, na onze onderzoekstijd ben ik je in het Martini ziekenhuis alleen nog maar meer 
gaan waarderen. Als poli-maatjes liepen we de deur bij elkaar plat voor goede raad, een mooi 
verhaal over een 'spot-diagnose', en koffie. Laten we <lat nog lang blijven doen. 
Tegelijkertijd met het schrijven van deze laatste woorden in <lit proefschrift, komt ook een 
einde aan mijn opleiding in het Martini ziekenhuis. Ik sluit een mooie tijd af, waarin een 
stevig fundament is gelegd voor de toekomst. Alle internisten (opleider dr. W.M.T. Jans­
sen, voormalig opleider dr. R.S. de Jong) wil ik bedanken voor hun persoonlijke inzet voor 
een goed opleidingsklimaat. Op deze plaats wil ik ook dr. K.M. van Tol bedanken. Beste 
Karin, ik heb dankbaar gebruik gemaakt van het door jou verzamelde cohort schildklier­
carcinoompatienten. Fijn dat ik ook in het Martini ziekenhuis veel van je heb mogen leren. 
Tevens wil ik de collega-assistenten, intensivisten, cardiologen, longartsen en maag-darm­
leverartsen bedanken voor de prettige en leerzame tijd. Een nieuwe uitdaging in het UMCG 
ligt voor me (opleider Prof. dr. R.O.B. Gans). 
Mijn paranimfen Suzanne Klene en Liesbeth Simmelink, wij zijn vriendinnen sinds onze 
eerste uurtjes in de collegebanken. 
Lieve Suus, met jou heb ik heel wat (Afrikaanse) stormen doorstaan, dus dit kunnen we 
ook wel aan. "Happiness' is ons toverwoord, ik hoop dat we samen nog heel veel happiness 
mogen beleven. 
Lieve Liesbeth, ik word altijd weer blij van jouw enthousiasme, oprechte interesse en 
trouw. Dat is me heel dierbaar. Die St. Pietersberg gaan we met zijn drieen halen, ook al zul­
len we met ons huidige tempo dan waarschijnlijk omaatjes van 80 jaar zijn! 
Mijn vrienden en vriendinnen, dank voor alles wat we samen delen en het leven zo mooi 
maakt. 
Altijd kan ik rekenen op de onvoorwaardelijke steun van familie. Mijn lieve schoonfamilie: 
ik heb het met jullie getroffen! Lieve Middendorpjes, van kleins af aan doen we alles samen, 
eigenlijk heb ik 4 broers en twee zusjes. Fijn dat we bij elkaar horen. 
Lieve pap, mam, Gerald, Laurens en Bettie, jullie zijn de bron van alles waar ik nu voor sta. 
Dank je wel dat thuiskomen altijd weer zo goed is. 
Lieve Bastiaan, ik geloof in jou en mij. 
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